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Abstract 
Bone defects caused by trauma, revision surgery, inflammation, tumour 
surgery and developmental deformity remain a major challenge for 
orthopaedic surgeons. There are several different treatment methods 
available, but no consensus guidelines exist and the treatment of such 
defects differs greatly. In recent years, bone grafts have advanced as the 
“gold standard” treatment to augment or accelerate bone regeneration. There 
are however, significant drawbacks associated with this approach. Therefore, 
several clinicians and researchers are investigating novel tissue engineering 
concepts to treat large bone defects.  
The use of mesenchymal progenitor cells in cell-based strategies has 
emerged as a promising alternative in regenerative medicine. In the past, 
bone marrow mesenchymal progenitor cells (MPC), osteoblasts isolated from 
the axial skeleton (tOB) and osteoblasts isolated from orofacial bones (mOB) 
have been suggested for the enhancement of bone repair.  
In this study, the osteogenic potential of different cell types and different cell 
applications in combination with a novel, medical grade composite scaffold 
were compared in a clinically relevant critical-sized tibial bone defect in a 
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Chapter I - Introduction 
 
1.1. Clinical background 
In most cases, bone possesses a good healing capacity and the vast majority 
of bone defects, when stimulated by well-balanced biological and micro-
environmental conditions, heal spontaneously. Refinements in surgical 
techniques, implant design and peri-operative management have significantly 
improved the treatment of complex fractures and other skeletal defects 
caused by high energy trauma, disease, developmental deformity, revision 
surgery and tumour resection1,2,3. However, an unfavourable wound 
environment, sub-optimal surgical technique or biomechanical instability can 
lead to formation of large defects with limited intrinsic regenerative potential4. 
Such defects pose a major surgical, socio-economical and research 
challenge and can highly influence the patient’s quality of life due to limb 
length discrepancy and prolonged, postoperative treatment courses5,6. There 
are different therapeutic options for bone non-unions and bone defects in 
current clinical use, including both operative and non-operative treatments. 
So far, there is no consensus in the guidelines and the treatment of such 
defects differs, depending on the skills of the surgeon7, the options available 
within the hospital, the individual patient and the standard of health care 
systems8. The orthopaedic literature has several references regarding non-
operative treatment methods for bone non-unions. In most cases they are 
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based on the therapeutic application of different forms of electricity9-19, on 
extracorporeal shock wave therapy (ESWT)20-28, and on ultrasound29-32.  
 
Present clinical therapeutic approaches for the operative treatment of bone 
defects include bone grafts, bone transport methods (Ilizarov technique)33, 
implants of different biomaterials or cell transplantation, but none of these 
techniques have proven to be fully satisfactory. The Ilizarov technique is 
based on the intrinsic regenerative potential of bone by doing an osteotomy 
followed by bone distraction33. This technique aims to avoid problems with 
graft integration, but it is a lengthy procedure, highly inconvenient for the 
patient with recurrent pin track infections as a frequent complication34,35. The 
most common method in clinical use for bone non-unions is autologous bone 
grafting4,36-38.  
 
Bone grafts are harvested from the patient’s iliac crest and implanted into the 
defect. In principle these bone grafts contain all the essential components 
required for bone repair, such as growth factors for osteoinduction and 
vascularisation, cells with osteogenic potential and they provide an 
osteoconductive scaffold. There are, however, significant drawbacks 
associated with this approach. In many cases, insufficient grafts are obtained 
and the access to donor sites is limited39,40,41. Donor site morbidity can occur 
and the donor bone is predisposed to fail42. Graft failures usually result from 
incomplete transplant integration, particularly in large defect sites43. In 
addition, graft devitalisation and the subsequent resorption process can lead 
to decreased mechanical stability44. Other treatment options are vascularised 
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autografts45, which are surgically challenging, or the use of allogenic or 
xenogenic bone, which carry the risk of rejection46,47 and transmission of 
infectious disease48-50. The dense nature of cortical bone allografts impedes 
revascularization and cellular invasion from the host even after several 
months or years after implantation41. The limited ability to revascularize and 
remodel is believed to be the main reason for a failure rate of 25% and a 30-
60% complication rate associated with allografts41.  
In order to avoid the limitations associated with the current standard 
treatment modalities for segmental bone defects, many biomedical engineers 
and clinical scientists have focused their research on bone tissue 
engineering. For the clinical application of different novel treatment 
strategies, including the tissue engineering approach, an effective clinical 
outcome with recovery of nearly normal limb function is most important for 
the patient. So far, there have been no randomised clinical studies showing 
that a tissue engineered construct (TEC) enhances the treatment of large 
segmental bone defects without further application of either vascularised 
autografts, non-vascularised autografts, and/or allografts. In human beings, 
after trauma, non-union, tumour resection or chronic osteomyelitis, no 
standardised critical sized defects can be found that would allow a direct 
comparison of different reconstruction methods for bone regeneration 
purposes. Moreover, soft tissue conditions and therefore vascularisation 
issues vary from case to case.  
Therefore, it is necessary to use a large preclinical animal model to have a 
controlled and standardised defect to evaluate the different strategies before 
translation into a clinical application.  
  4 
1.2. Animal Models for segmental defect research 
To translate research findings in the area of cell biology and biomaterials into 
clinical applications for bone regeneration, the use of adequate in vivo animal 
models is necessary. The first step after in vitro experiments is the use of 
small animal models in vivo. Advantages of experiments in small animal 
models are the possibility of using a large number of experimental groups 
due to the low costs of small animals. The application and systematic 
evaluation of new concepts in animal models is an essential step in the 
process of assessing newly developed bone grafts prior to clinical use in 
humans.  
Several animal models have been developed over the years to verify the 
practicability of research approaches and stimulate clinical situations more 
closely. The identification and validation of an in vivo model is difficult as 
there are various differences regarding animal species (dog51, sheep52, pig53, 
minipig54, rat55, mouse56) and treated bone (femur57, tibia58, ulna59, skull60, 
mandible61). When selecting a specific animal species as a model system, a 
number of factors need to be considered. In comparison to humans, the 
chosen animal model should clearly demonstrate significant physiological 
and pathophysiological analogies in respect to the scientific question under 
investigation. Moreover, it must be manageable to operate and observe a 
multiplicity of study objects post-surgery over a relatively short period of 
time62,63,64. While in the 20th century the dog model was mainly used for 
orthopaedic research, over the last decade the use of the sheep model 
increased significantly. Adult sheep offer the advantage of having a more 
similar body weight to humans and long bone dimensions suitable for the use 
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of human implants and prostheses, which is not possible in smaller species 
such as rabbits or smaller breeds of dogs65. In order to ascertain whether 
newly developed bone graft substitutes or tissue-engineered constructs 
comply with the requirements of biocompatibility, mechanical stability and 
safety, the material must be subject to rigorous testing both in vitro and in 
vivo. To simulate biomechanical human in vivo conditions as closely as 
possible, and to assess the effects of implanted bone grafts and tissue-
engineered constructs on segmental long bone defect regeneration, it is 
important that an experimental osseous injury inflicted to study bone repair 
mechanisms should be of the dimension to preclude spontaneous healing66. 
The non-regenerative threshold of bone has been determined in research 
animal models inducing so-called critical-sized defects. Critical-sized defects 
are defined as “the smallest size intraosseous wound in a particular bone and 
species of animal that will not heal spontaneously during the lifetime of the 
animal67” or as a defect which shows less than 10 percent bony regeneration 
during the lifetime of the animal68. Although the minimum size that renders a 
defect “critical” is not well understood, it has been defined as a segmental 
bone deficiency of a length exceeding 2-2.5 times the diameter of the 
affected bone69. 
 
Analysing the literature on the topic of this PhD work, the published papers 
dealing with bone defects demonstrate inconsistencies relating to defect size, 
defect fixation, postoperative treatment, as well as breed, gender, age and 
weight of the animals37,70-75. Many of the published studies have to be 
considered short term studies where no complete bone remodelling can be 
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expected during the experimental period. Moreover, the modification of 
commercially available internal fixation devices occurred as a reaction to 
implant failures early after surgery. These experimental settings do not reflect 
real clinical conditions. One of the most important elements in the study of 
segmental defect healing is the establishment of standardized methods to 
create reproducible test results. In previous work, the research group of Prof. 
Hutmacher developed and established a critical-sized tibial defect model in 
sheep tibiae to evaluate different tissue engineering based treatment 
concepts76-78.  
 
1.3. Cellular biology 
Different approaches in regenerative medicine include cell-based and 
scaffold-based strategies, delivery of osteoinductive growth factors, and 
genetic engineering.  
 
1.3.1 Cell source 
The nature of regenerative medicine will be profoundly influenced by whether 
the cells used are universal (allogeneic) or patient-specific (autologous). It is 
unlikely to be wholly one or the other that will dominate the field, however, at 
this early stage it is worth examining the both cells types from a scientific and 
translational point of view79. 
 
Mesenchymal stem cells (MSCs) and osteoblast cells (OB) have been 
studied in cell based strategies and the former is used most frequently. 
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Mesenchymal stem cells are multipotent progenitor cells, which have the 
potential to differentiate into a variety of mesenchymal tissues such as bone, 
cartilage, tendon, ligaments, muscle, fat and dermis80,81,82,83.  
These cells have shown their therapeutic capacity in several in vitro as well 
as in vivo studies for the regeneration of bone defects and non-unions.  
 
1.3.2 Extracellular Microenvironment 
Growth factors influence chemotaxis, differentiation, proliferation and 
synthetic activity of bone cells, thereby regulating physiological remodelling 
and fracture healing. Numerous growth factors, such as bone morphogenetic 
proteins (BMP), platelet-derived growth factor (PDGF), transforming growth 
factor-ß (TGF-β), and insulin-like growth factors (IGF) have a stimulating 
effect on bone defect healing by inducing chemotaxis, proliferation, and 
differentiation of osteoblasts and their precursors84,85. BMP-7 has already 
been tested successfully in clinical studies on tibial nonunions and fibular 
defects86,87. However, little is known about suitable combinations, 
concentrations, and different time points of delivery of growth factors during 
bone defect healing.  
 
An easy and more physiological way of applying growth factors to bone 
defects is via the use of platelet rich plasma (PRP), a thrombocyte 
concentrate made of autologous blood. PRP is a source of autologous 
cytokines, chemokines and growth factors which, in the case of injury, 
manage and control the process of wound healing and tissue repair. The 
most prominent growth factors in PRP are platelet-derived growth factor 
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(PDGF), transforming growth factor (TGF)-1 and TGF-2, epidermal growth 
factor, insulin-like growth factor, basic fibroblast growth factor and vascular 
endothelial growth factor, which influence cell proliferation and 
differentiation88-90. Several previous investigations demonstrated a positive 
effect of PRP on wound healing91,92. A vast number of studies have been 
performed to investigate the effect of PRP on bone defect regeneration89,93-
96. However, the results are ambiguous regarding the benefit of PRP to bone 
healing. As it is also rich in autologous fibrinogen, PRP in the liquid state can 
convert into fibrin clots in the solid state when activated by thrombin, similar 
to commercial fibrinogen. This indicates that PRP has similar functions to 
other hydrogels in delivering cells into 3D scaffolds97. 
 
1.4. Biomaterials 
The limitations of current approaches necessitate the development of 
alternative bone repair techniques and have driven the development of 
scaffold-based bone engineering strategies. A suitable scaffold will possess a 
porous interconnected pore network (pores & pore interconnections should 
be at least 400 microns to allow vascularization) with surface properties 
which are optimized for the attachment, migration, proliferation and 
differentiation of cell types of interest (depending on the targeted tissue) and 
enable flow transport of nutrients and metabolic waste, and be biocompatible 
and biodegradable with a controllable rate to compliment cell/tissue growth 
and maturation98. The design of these scaffolds also needs to consider 
physico-chemical properties, morphology and degradation kinetics. External 
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size and shape of the construct are of importance, particularly if the construct 
is customized for an individual patient. Scaffold design and fabrication via 
additive manufacturing has advanced tremendously over the past few 
years99. The ability to create scaffolds in a layer by layer manner enables a 
computer animated design to be directly translated from a clinical scan (i.e. a 
patient CT scan) to produce customised scaffolds to fit an anatomical defect 
site. On implantation of a scaffold into a bone defect site, continuous cell and 
tissue remodelling is important for achieving stable biomechanical conditions 
and vascularization within the host site100. Importantly, TECs should stimulate 
and support both the onset and the continuation of bone in-growth as well as 
subsequent remodelling and maturation by providing optimal stiffness and 
external and internal geometric shapes101. Scaffolds must provide sufficient 
initial mechanical strength and stiffness to substitute for the loss of 
mechanical function of the diseased, damaged or missing tissue and in 
addition must degrade at a rate which is compatible with new tissue in-growth 
and maturation102,103.  
 
It cannot be emphasized enough how essential it is to understand and control 
this scaffold degradation process, for successful tissue formation, 
remodelling, and maturation at the defect site. In the early days of tissue 
engineering, it was believed that scaffolds should degrade and vanish as the 
tissue is growing104. Yet, tissue in-growth and maturation differs temporally 
from tissue to tissue and, furthermore, tissue in-growth does not equate to 
tissue maturation and remodelling. In other words a defect filled with 
immature tissue should not be considered “regenerated”. Hence, many 
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scaffold-based strategies have failed in the past as the scaffold degradation 
was more rapid than tissue remodelling and/or maturation105. 
 
The Hutmacher laboratory has spent the last decade translating a concept of 
bone tissue engineering based on slow biodegradable composite scaffolds 
comprising medical grade polycaprolactone (mPCL) and calcium phosphates 
(hydroxyapatite (HA),tricalcium phosphate (TCP)), from the bench to the 
bedside106-115. After a large series of in vitro experiments the group 
consequently performed small animal studies using mice, rat and rabbit 
models which demonstrated the ability of composite scaffolds in combination 
with BMP’s or cells to promote bone regeneration within ectopic sites or 
critically sized cranial defects102. 
The scaffolds received regulatory approval from the Food and Drug 
Administration (USA) in 2007 and have been studied in a clinical setting in 
oral and maxillofacial applications (low-load bearing) for many years116; 
however at the start of the conception of the PhD thesis, scaffold-cell based 
concepts for orthopedic applications have been studied only in small animal 
models. Before translating new treatment concepts based on bone tissue 
engineering principles into a clinical application in orthopaedic and trauma 
surgery, rigorous evaluation is a condition sine qua non in adequate 
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1.5. Thesis Outline 
The treatment of long bone defects and non-unions are still a major clinical 
as well as socio-economic problem around the globe. Beside the non-
operative therapeutic options, like the application of different forms of 
electrical stimulation, the extracorporeal shock wave therapy, and ultrasound 
therapy, which are still in clinical use, several different operative treatment 
methods are available. There is no consensus as to the guidelines and the 
treatment of such defects differs a lot. Chapter II provides a review of the 
literature regarding clinical studies for the treatment of large bone defects 
and non-unions and the different treatment methods.   
 
A number of clinicians and researchers investigate ways to treat large bone 
defects based on tissue engineering principles. Tissue engineering strategies 
for bone regeneration have great potential in regenerative medicine. But in 
vitro as well as in vivo studies in small and large animal models are 
necessary, to translate research findings into clinical use. Although, several 
researchers around the world have conducted different animal studies, the 
literature still lacks controlled studies that compare different clinical treatment 
strategies currently in use. The group of Prof. Hutmacher developed a 
standardised large animal model for the treatment of large bone defects. In 
Chapter III the osteogenic potential of autologous and allogenic 
mesenchymal progenitor cells for the reconstruction of large bone defects 
was analysed. 
Beside mesenchymal progenitor cells (MPCs) differentiated cells 
(Osteoblasts) have been used in cell based tissue engineering strategies. In 
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previous in vitro and in vivo studies in small animal models, the differentiated 
cells showed a higher osteogenic potential compared to mesenchymal 
progenitor cells. In Chapter IV the osteogenic potential of differentiated cells 
were analysed for the reconstruction of critically sized large bone defects. 
Based on the results of the previous experiments described in Chapter III and 
IV the experimental setup for further experiments was changed.  
In Chapter V the application method for allogenic mesenchymal progenitor 
cells and the scaffold design was changed and the osteogenic potential for 
bone regeneration was analysed.  
However, based on results so far obtained in different animal models, bone 
tissue engineering approaches, although successful in most cases, need 
further validation in more clinically relevant animal models as well as in 
clinical pilot studies to translate bone tissue engineering approaches into 
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1.6 . Hypothesis 
The limitations in solving the increasing, and somewhat difficult, orthopaedic 
surgery problems facing society, and the final clinical outcome for patients, 
may be approached from the perspective of the nature of the graft material 
with which the surgeon works. Current clinically established therapeutic 
approaches focus on the implantation of autografts and allografts, metal 
devices, and ceramic-based implants to assist repair of bone defects; all with 
inherent disadvantages. These constraints have triggered a need for new 
therapeutic concepts to design and engineer unparalleled structural and 
functioning bone grafts to replace current treatments. It is within this context 
that the PhD project has emerged, through the integration of engineering, life 
sciences, molecular and cell biology, stem cell biology, and surgery.  Hence, 
the hypothesis of the PhD project is articulated as the following: 
 
A validated large preclinical segmental bone defect model allows the 
qualitative and quantitative comparison of different scaffold-cell-based 
therapy concepts; it is hypothesised that osteoblasts (differentiated cells) 
show a higher osteogenic potential than mesenchymal progenitor cells in a 
scaffold based bone tissue engineering concept for regeneration of a critically 
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Chapter II - Treatment of long bone defects and 
non-unions: from research to clinical practice 
 
2.1. Introduction 
The therapy of large bone defects and non-unions caused by trauma, 
revision surgery, inflammation, tumour surgery, and developmental deformity 
remains a major challenge for orthopaedic surgeons. There are different 
therapeutic options for bone non-unions and bone defects in clinical use, 
containing operative and non-operative treatment. The orthopaedic literature 
attended several references regarding non-operative treatment methods for 
bone non-unions. In most cases they are based on the therapeutic 
application of different forms of electricity, on extracorporeal shock wave 
therapy (ESWT) and on ultrasound25,29,30,117. They led to bony consolidation 
even in cases of non-union after numerous failures with surgery. So far, there 
are no consensus guidelines and the treatment of such defects differs, 
depending on the surgical skills of the surgeon7, the options of the hospital, 
the individual patient, and standard of health care systems8. Therefore, a lot 
of clinicians and researchers investigate ways to treat large bone defects 
based on tissue engineering approaches. Tissue engineering strategies for 
bone regeneration present a promising option in modern regenerative 
medicine. The requirements for successful bone repair include an 
osteoinductive scaffold, growth factors to facilitate osteoinduction and 
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vascularisation of the graft, and cells with osteogenic potential. To translate 
research findings in the area of cell biology and biomaterials into clinical 
applications for bone regeneration, the use of adequate in vivo animal 
models is necessary. Several animal models have been developed over the 
years to verify the practicability of research approaches and stimulate clinical 
situations more closely. The identification and validation of an in vivo model 
is difficult, as there are various differences regarding animal species (dog51, 
sheep52, pig53, minipig54, rat55, mouse56), treated bone (femur57, tibia58, 
ulna59, skull60, mandible61), biomaterials under investigation 
(tricalciumphosphat118 (TCP), titanium mesh cages69, hydroxyapatite119 (HA), 
gelatine sponge120, poly-lactide-glycolide acid121), applied cells (autologous 
cells122, allogenic cells123, xenogenic cells124,autologous bone grafts125) and 
bioactive agents like bone morphogenetic proteins126 (BMP), platelet rich 
plasma127 (PRP), bone marrow aspirates128, growth hormons129 (GH).  
 
Two most recent reviews by Hutmacher’s group summarizes and compares 
available, clinically relevant animal models to guide researchers to choose 
the most appropriate model76,130. From this review, it can be concluded, that 
the literature lacks controlled studies that compare different clinical treatment 
strategies currently in use. Present clinical therapeutic approaches for the 
treatment of bone defects include bone grafts, bone transport methods 
(Ilizarov technique), implants of different biomaterials or cell transplantation, 
but none of these techniques has proven to be fully satisfactory. The Ilizarov 
technique is based on the bones intrinsic regeneration potential by doing an 
osteotomy followed by bone distraction33. This technique aims at avoiding 
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problems with graft integration, but it is a long-lasting procedure, highly 
inconvenient for the patient with current pin track infections as a frequent 
complication34,35. The most common method in clinical use for bone non-
unions is autogenous bone grafting4,36-38. Bone grafts are harvested from the 
patient’s iliac crest and implanted into the defect. In principle these bone 
grafts enclose all the essentials required for bone repair, such as growth 
factors for osteoinduction and vascularisation, cells with osteogenic potential 
and they provide an osteoconductive scaffold, but this procedure is limited by 
the amount of bone that can be taken from the donor site and donor site 
morbidity39,40,41. Other options are vascularised autografts45, which are 
surgically challenging, or to use either allogenic bone or xenogenic bone, 
which carry the risk of rejection46,47 and transmission of infectious disease48-
50. These limitations have lead scientists and clinicians to focus their 
research on tissue engineering aspects of bone reconstruction and 
developing scaffolds to support bone regeneration131.  
 
A wide number of different biomaterials has been developed and are subject 
to current research. There are two major engineering approaches to develop 
novel treatment concepts involving biomaterials: cell-based and cell-free. In 
both cases, materials are engineered to provide optimal function for specific 
applications. In other words, scaffolds for cell-based therapies are intended 
to provide a compatible carrier for viable cells for enhanced histogenesis, 
function and integration within the recipient’s tissue bed. Scaffolds for cell-
free repair are designed to stimulate neo-histogenesis, often by mimicking 
signals for anabolic processes. In the past, different scaffolds have been 
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shown to be useful supports for the reconstruction of bone, however only a 
handful brought fully satisfactory results132.  
For integration within the host site, solid scaffolds need to be resorbable or 
should have a porosity or woven form of favourable texture. Coatings and 
absorption or activation with bioactive molecules can also improve 
integration. These principles have been applied with varying success to 
musculoskeletal repair and reconstruction, but opportunities exist for novel 
procedures. When developing bone engineering strategies for the treatment 
of segmental bone defects, scaffolds used must be able to bear or share 
substantial loads immediately after implantation132. 
Over the last years, the application of bone morphogenetic proteins (BMPs), 
especially BMP-2 and BMP-7, has become more important in the treatments 
of bone defects. These proteins belong to the Transforming Growth Factor-ß 
(TGF-ß) super family and induce osteogenic cell differentiation in vitro133,134, 
in vivo135 as well as bone defect healing at the bedsite86,136. The aim of this 
review is to summarize different operative treatment concepts for long bone 
non-unions and large bone defects that are currently in clinical use and to 
analyse and compare the different clinical studies. 
  
 
2.2. Autologous bone graft 
Bone grafts can be vascularised or non-vascularised. Non-vascularised bone 
grafts can be used alone, or in combination with internal or external fixation. 
Autologous bone grafts unite all the key elements, which are necessary for 
bone repair, such as cells with osteogenic potential, growth factors, and a 
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scaffold. But they are of limited supply and associated with donor site 
morbidity137. The application of autologous bone grafts has advanced as the 
gold standard in the treatment of bone non-unions138-141. The clinical 
application of bone grafts appears in the literature for the first time at the 
beginning of the 20th century142. In 1918 Chutro described a revolutionary 
grafting technique, which bears a remarkable similarity to today’s cancellous 
strip grafting, except that the strips of bone were harvested from the surface 
of the tibia143. Over the next years, a lot of reports were published on the 
biological behaviour of different types of bone graft. In 1931 Gallie published 
his early work showing the superiority of cancellous over cortical bone144. 
Mowlem reached a similar conclusion in a review of 75 cases in which 
cancellous bone had been used to treat bone defects of the skull, the 
mandible and in long bones145. Higgs treated 60 cases of non-union of long 
bones with cortical grafts in 20 cases and with cancellous bone chips in 40 
cases146. All achieved bone union, but the time to union was less, when 
cancellous chips compared to cortical bone were used. In a review of 100 
cases of non-unions of Sakaellarides et al.147 in 1964, autologous bone grafts 
were used to treat bone non-unions. In 56 cases, uninfected non-unions were 
treated by autologous bone-grafting from the iliac crest (35 cases) or a 
cortical onlay graft (21 cases) and achieved bone union in 46 cases (82%). 
Seven cases required revision surgery and only three did not achieve bone 
union (3.5%). The authors came to the conclusion that if there is some 
stability, the transplantation of cancellous iliac bone seems to be one of the 
best methods of treatment. In 1969, Souter published his experiences of 102 
cases of delayed union and non-union of long bones148. Cancellous strip 
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grafting from the iliac crest alone were used in 68 cases and 34 of them 
needed additionally an excision of the fibrous tissue, correction of 
misalignment and internal fixation of the fragments with a plate. The average 
time to bone union varied from 10-16 weeks. Only four grafts out of 102 
cases failed to consolidate within 16 weeks. Reckling and Waters treated 44 
cases of tibial non-unions with cancellous bone grafts from the iliac crest149. 
Bone union was obtained in 97,7%, whereas three patients weeded two 
bone-grafting procedures. Similarly results where described by Gershuni and 
Pinsker, who treated 40 tibial non-unions with autologous bone grafts and 
achieved union in 85% after 20 weeks150.  
 
Open intramedullary nailing and bone grafting with either autologous 
cancellous bone grafts from the iliac crest or cortical reamings of bone from 
the intramedullary canal were compared by Johnson and Marder in 22 tibial 
non unions151. All cases went to union (100%). Compared with closed 
techniques, the authors identified a reduction of time to healing. Another 
important difference between these methods is the ability to augment the site 
of non-union with bone grafts and the ability to remove the scar tissue, to 
obtain anatomical correction of the fragments. Sledge et al. retrospectively 
analysed the records of 51 patients who were treated with intramedullary 
nailing and reaming for non-union of the tibia152. In 10 cases autologous bone 
grafts from the iliac crest were used. In 49 (96%) of the 51 patients, tibial 
union occurred at an average of seven months postoperatively. No 
statistically significant difference was found between open or closed 
intramedullary nailing techniques and the use of autologous bone grafts from 
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the iliac crest for enhancement. This study demonstrated that nailing with 
reaming is a good treatment with acceptable rates of union also predicated 
from other recent reports on the use of nailing with reaming for non-
union151,153,154. There were certain clinical situations in which intramedullary 
nailing techniques have been problematically, because the non-union is 
associated with a number of external skeletal fixations152,155,156, remote 
infections157-160, or deformity161-163. Helfet et al. treated 33 patients who had a 
tibial non-union with limited open exposure, indirect reduction with a femoral 
distracter, tension band plating, lag screw fixation, and autologous bone 
grafting164. All the non-unions healed at an average of four months. In terms 
of complications, four superficial skin breakdowns, one deep infection, and 
one fracture of the plate were reported. The authors came to the conclusion, 
that this plating technique is an acceptable alternative for the treatment of 
aseptic non-unions of the tibial diaphysis, for which standard locked 
intramedullary nailing is contraindicated. Wiss et al. published in 1992 a 
prospective non-randomised study of 39 cases of tibial non-unions, treated 
with autologous bone grafting165. After 7 months postoperatively, union rates 
of 96% have been achieved on average. A retrospective comparative 
analysis of different biological enhancement options for persisting tibial non-
unions was published in 1995 by Brighton et al.166. The authors compared a 
large number of difficult cases of non-unions with direct currents or bone graft 
surgery. They had a number of 171 aseptic non-unions, of which 33 were 
treated with capacity coupling (20 microampere of constant direct current), 
114 with electric currents (60-kilo-hertz, 5-volt peak-to-peak symmetrical sine 
wave signal) and 24 with autologous bone graft from the iliac crest. Of the 
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cases treated with bone grafting, only 58.3% healed. Thus, especially in 
difficult cases where previous grafting had failed, the failure rate of a 
secondary bone grafting was much higher. The tibia is the long bone with the 
highest incidence of non-union because of its poor soft tissue coverage and it 
is also the most common long bone to sustain a fracture. In a review article 
on tibial non-union treatment options, Wiss et al. commented that autologous 
cancellous grafts remains the gold standard in the treatment of tibial non-
union and can be used to augment segments up to 6cm in space with a 
successful outcome in 88% to 95% of all cases.  
 
In 2001, Friedlaender et al.86 reported their experiences with 124 tibial non-
unions in a multi-centre clinical trial. They treated 61 cases of non-unions 
with autologous bone grafts and showed clinical success with full weight 
bearing in 85%. After 12 months, 13% of these patients still had persistent 
pain at the donor site. The use of autologous bone grafts for non-union is 
also described in several other long bones. In the series of Devnani 25 non-
unions were treated with compression plate fixation and autologous bone 
grafts167. The non-unions involved seven femora, eight humerus and ten 
tibiae. All non-unions healed on average within 18 weeks. One femoral plate 
broke after twelve weeks, which required replating. The author came to the 
conclusion, that plate fixation is a useful and effective means in the 
management of non-unions and comparable with other methods. Ring et al. 
described the use of autologous bone grafts in 35 patients with forearm non-
unions168. All of the non-unions healed within six months without the need for 
subsequent procedures. Barbieri et al. reported their experiences on twelve 
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patients with forearm non-unions treated with iliac crest bone block 
grafting169. Healing was achieved in 83.3% without additional procedures. In 
another retrospective study, Hierholzer et al. reported their results of the 
treatment of 45 aseptic non-unions of the humerus170. After an average of 18 
weeks, 100% achieved bony union. Hsu et al. performed a retrospective 
review of 105 humeral non-unions171. The treatment included open reduction, 
plate fixation and the application of autologous bone grafts. All cases 
achieved union after an average of 16 weeks. Lin et al. reviewed 
retrospectively 86 patients with aseptic non-unions of the humeral shaft172. All 
non-unions were treated with removal of the previous implant, open 
reduction, and internal fixation supplemented by cancellous bone grafts. All 
of the non-unions united within an average time of 18 weeks. The femur has 
one of the best healing rates in the body. Therefore, reports on femoral non-
unions are rare and often involve only small sample sizes. Chapman and 
Finkemeier reported a retrospective analyse of 18 cases of femoral non-
unions, all treated with internal fixation and autologous bone grafting173. The 
same authors reviewed a series of 39 patients with femoral non-unions, 
treated with reamed intramedullary nailing174. They had bony unions after an 
average of 19 months in all cases. They recommended reamed exchange 
nailing for the treatment of femoral non-unions prior to bone grafting 
reserving autologous bone grafting as a second line procedure.  
 
Most recently, the Reamer-Irrigator-Aspirator (RIA) was developed as an 
alternative method for long bone canal reaming in the process of 
intramedullary nailing to reduce the incidence of fat embolism and thermal 
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necrosis. Particles aspirated by the RIA are caught in a coarse filter, from 
which they can be recovered and used as a source of autologous bone 
grafts. It has been shown, that the bony reaming debris as well as the 
irrigation fluid is a rich source of growth factors175 and a source of 
mesenchymal stem cells176, which are able to grow, proliferate and 
differentiate into the osteogenic pathway in vitro.  Large volumes of graft can 
be obtained, with up to 90ml harvest being reported in different clinical 
studies and case series (Fig. 1). Belthur et al. showed that using RIA derived 
grafts (37 of 41 cases) compared well with an iliac crest bone graft control 
group (32 of 40 cases). Miller et al. reported a series of 13 patients treated 
with RIA bone grafting enhanced with Dexamethasone. All patients displayed 
at least partial union at most recent follow up, but only six patients went on to 
complete union. All patients treated had persisting non-union or significant 
bone defects that failed to heal with standard procedures. The obvious 
limitation of several studies is that it is really a collection of case reports or 


























Figure 1: Collection of autologous osseous particles mixed with bone 
marrow (B), by using the reamer-irrigator-aspirator (RIA) system (A). The drill 
head of the system applies irrigation and aspiration to the medullary canal. 
An open distal femur fracture of an 32-year old male patient after an motor 
bike accident was stabilized using a LISS-plate (D). The radiographic images 
after surgery showed a remaining bone defect, which were treated in a 
second operation with autologous bone particles and bone marrow obtained 
via intramedullary reaming by using the RIA system (E). The follow up 
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Higgs146 1945	   60	   Tibia	   ABG/CBG	   -­‐-­‐	   100%	  
Sakellarids et 
al.147 
1964	   56	   Tibia	   ABG/CBG	   34,8/48,4	   89%/71%	  
Souter et al.148 1969	   102	   Tibia/Forearm/Humerus/Femur	   ABG	   16	   96,6%	  
Reckling and 
Waters149 
1980	   44	   Tibia	   ABG	   30	   97,7%	  
Gershuni and 
Pinsker150 
1982	   40	   Tibia	   ABG	   20	   85%	  
Johnson and 
Marder151 
1987	   22	   Tibia	   ABG/RBP	   12,5	   100%	  
Sledge et al.152 1989	   51	   Tibia	   RBP/ABG	   28	   96%	  
Simon et al.177 1990	   30	   Tibia	   ABG	   -­‐-­‐	   97%	  
Wiss et al.165 1992	   39	   Tibia	   ABG	   28	   96%	  
Helfet et al.164  1992	   33	   Tibia	   ABG	   16	   100%	  
Brighton et 
al.166 
1995	   24	   Tibia	   ABG	   40	   58,3%	  
Barbieri et al.169 1997	   12	   Forearm	   ABG	   -­‐-­‐	   83,3%	  
Chapman and 
Finkemeier173 
1999	   18	   Femur	   ABG	   -­‐-­‐	   100%	  
Devnani167  2001	   25	   Tibia/Humerus/Femur	   ABG	   18	   100%	  
Friedlaender et 
al.86 
2001	   61	   Tibia	   ABG	   36	   85%	  
Finkemeier and 
Chapman174 
2002	   39	   Femur	   RBP	   76	   100%	  
Ring et al.168 2004	   35	   Forearm	   ABG	   24	   100%	  
Hsu et al.171 2005	   105	   Humerus	   ABG	   16	   100%	  
Hierholzer et 
al.170 
2006	   45	   Humerus	   ABG	   18	   100%	  
Belthur et al.178 2008	   81	   Humerus,	  Femur,	  Tibia,	  Ankle	   ABG	  (40x)	  
RIA	  (41x)	  
-­‐-­‐	   80%	  (ABG)	  
90%	  (RIA)	  
Lin et al.172 2009	   86	   Humerus	   ABG	   18	   100%	  
Miller et al. 2010	   13	   Humerus,	  Femur,	  Tibia	   RIA	   -­‐-­‐	   46%	  
Table 1: Clinical application and outcomes of the treatment of non-unions 
with autologous bone grafts (ABG), reamer-irrigator   aspirator method (RIA), 
cortical bone grafts (CBG) or reamed intramedullary nailing (RBP).  
 
2.3. Distraction osteogenesis and vascularised bone grafts 
Vascularised bone grafts have been proposed to have significant advantages 
over conventional non-vascularised grafts179. These vascularised bone grafts 
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can be taken from various bones, such as the fibula180-182, in varying 
compositions, including skin, fascia or muscle183, as a vascularised solid iliac 
crest bone graft184-186, the lateral border of the scapula187-189, or vascularised 
rib grafts190-192. The disadvantages of these vascularised grafts are the need 
for microsurgical skills193,194, the possibility of total transplant necrosis due to 
anastomotic complications195, and donor site morbidity196. Distraction 
osteogenesis, which was established by Ilizarov197-200 in the middle of the last 
century, is another approach to repair large segmental bone defects. It is 
therefore often described as the “Ilizarov technique”. The advantages are the 
possibility to correct deformities201, small areas of soft tissue defects, and 
immediate mobilization. Its disadvantages are the long duration of external 
osteosynthesis materials, frequency of pin tract infection, and pain 
accompanying the transport202. Several surgeons reported their experiences 
with the Ilizarov technique and free vascularised grafts in a series of case 
reports, but comparative studies between the different treatment strategies 
are rare. Free vascularised fibular grafts were first described in the late 
1970’s by Taylor et al., who used this technique in two cases with extensive 
bone and skin loss48. The technique was developed to salvage two legs, 
which would otherwise have been amputated. A few years later, Weiland et 
al. described their experiences with this technique in 32 cases179. They 
performed 22 free vascularised fibular grafts in the lower extremity and ten 
cases in an upper extremity. The defects were caused either by trauma or 
tumour surgery. The average length of bone defects was 14.9 cm in the 
tumour cases and 16.2 cm for trauma cases. In 12.5% the operation was 
unsuccessful, resulting in amputation.  
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In 1989, Paley et al. published their results of 25 patients, treated with the 
Ilizarov method203. The tibial bone defects had an average size of 6.2 cm. 
Bone union was achieved in all cases within an average time of 54.4 weeks. 
Golyakhovsky and Frankel treated eleven patients with large tibial (9), 
femoral (1), and humeral (1) bone defects with the Ilizarov method204. They 
achieved bone union in all cases with excellent results in eight cases. Green 
compared the non-vascularised bone graft technique with the segmental 
bone transport technique for the treatment of skeletal defects205. Fifteen 
patients with skeletal defects were treated with non-vascularised bone grafts 
and 17 patients with callus distraction. Bone union was achieved in 86.6% of 
the bone graft group and 94.1% in the callus distraction group. Surprisingly, 
the treatment time compared to the defect size was identical in both groups: 
1.9 months per centimetre of defect. The authors came to the conclusion, 
that short defects (up to 5 cm) could be treated with either segmental bone 
transport or cancellous bone grafts, depending on the surgeon’s preferences. 
Whereas large gaps in bone tissue require a more complex reconstructive 
technique, either bone transport or a free vascularised bone graft. Suger et 
al. treated 20 patients with bone and soft tissue defects by open segmental 
bone transport according to Ilizarov206. In 19 cases the bone defect could be 
filled by callus distraction only, while one patient needed additional 
cancellous bone transplantation. Polyzois et al. had experiences with the 
Ilizarov technique in tibial and femoral bone loss in 28 infected and 14 
aseptic cases207. These 42 patients with diaphyseal bone defects (25 tibial 
and 17 femoral) were treated by radical debridement and bone transport. The 
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average defect size was 6 cm. Union was achieved in 38 patients after an 
average treatment period of 40 weeks. Oztürkmen et al. treated 46 patients 
with pseudarthrosis of the femur (n=8) and the tibia (n=38) with the Ilizarov 
method208. The mean defect size was 5.2 cm. Union occurred in 42 (92%) 
cases. The mean time for the fixator appliance was 208 days. Pin tract 
infections occurred in 28 cases. Kocaoglu et al. used the callus distraction 
over an intramedullary nail combined with an external fixator for the treatment 
of 13 patients with an average bone defect size of 10 cm209. Seven patients 
had a segmental tibial defect and six patients a segmental femoral defect. In 
two patients a free non-vascularised fibular graft was added to the distraction 
site for augmentation of a femoral defect at the time of external fixator 
removal. Eleven patients showed excellent results after a mean follow-up of 
47 months, in two cases the nail had to be removed because of an infection. 
The patients underwent revision with an Ilizarov fixator and the non-unions 
healed. The main time for the use of an external fixator was 19.3 weeks. This 
combined method allowed an earlier removal of the external fixator 
associated with an increased patient comfort, a decreased complication rate, 
and a convenient and rapid rehabilitation. Yokoyama et al. treated four 
patients with tibial bone defects with free vascularised fibular grafts and 
another four patients with distraction osteogenesis210. The mean defect 
length in the vascularised bone graft group was 7.3 cm and in the callus 
distraction group 4.6 cm. The union rate of the callus distraction group was 
100%, whereas the vascularised graft group showed a union rate of 75%. 
The authors assessed to the costs associated with both treatments. No clear 
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differences could be determined between the two treatment groups, 
regarding costs and functional outcomes.  
Morasiewicz et al. reported their experiences with the Ilizarov method in 16 
cases of femur non-unions211. In a first operation the authors tried to reach 
bone union by femur shortening. In the second and the third operation the 
authors tried to correct the femoral axis and to re-establish the length of the 
affected bone. In 93.75% bone union was achieved, just one case resulted in 
pseudarthrosis. Zarek and Macias used the Ilizarov method for the treatment 
of pseudarthrosis of the humerus in 20 cases212. The mean time of treatment 
with the external fixator was 29 weeks and the main complication during 
treatment was superficial pin-tract infection (in 40%). Bone union was 
achieved in 19 cases (95%). In all clinical studies, the authors came to 
conclusion, that the Ilizarov method is a simple and safe method for 
successful treatment of diaphyseal bone defects. The main disadvantage of 
the Ilizarov method is the long external fixation time and pin-tract infections. If 
a large soft tissue defect needs also to be treated, the free vascularised bone 
graft with muscle and skin tissue might have advantages.  
To overcome the problems with pin-tract infections and the discomfort for the 
patient by using an external fixateur, motorised, fully implantable, solid 












No.  of  
patient
s 




Size of Defect 
(average in cm) 
Rate of 
union 
Weiland et al.179 198
3	  
32	   Tibia/Humerus	   FVFG	   -­‐-­‐	   15.8	   87.5%	  
Paley et al.203 198
9	  





11	   Tibia/Femur/	  
Humerus	  
CD	   48	   4-­‐16	   100%	  
Green205 199
4	  




ABG	  4/CD	  5	   ABG	  86.6%	  
CD	  94.1%	  
Suger et al.206 199
5	  
20	   Skeletal	  defect	   CD	   -­‐-­‐	   -­‐-­‐	   95%	  
Polyzois et al.207 199
7	  





8	   Tibia	   4	  CD/4	  FVFG	   CD	  37.3/	  
FVFG	  25.1	  












46	   Tibia/Femur	   CD	   29.7	   5.2	   92%	  
Kocaoglu et al.209 200
6	  





16	   Femur	   CD	   -­‐-­‐	   -­‐-­‐	   93.75%	  
Table 2: Clinical application and outcomes of the treatment of bone defects 
and bone non-unions with callus distraction “Ilizarov technique“ (CD), free 
vascularised fibular grafts (FVFG), intramedullary nailing (IMN), and 
autologous bone graft (ABG). 
 
2.4. Tissue Engineering 
According to Langer and Vacanti, tissue engineering is “an interdisciplinary 
field that applies the principles of engineering and life science towards the 
development of biological substitutes that restore, maintain, or improve tissue 
function”215. Over the last two decades, a small group of researchers have 
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focused on approaches for the reconstruction of segmental bone defects or 
bone non-unions. Many research groups around the world aim to find 
suitable combinations of biomaterials, cells with osteogenic potential and 
growth factors for the therapy of bone defects or bone non-unions that allow 
an functional tissue engineering approach.  
 
2.4.1. Growth factor delivery 
Growth factors, especially BMPs, seem to play an import role in osteogenic 
differentiation. In 1965, Urist’s216 discovery of the osteoinductive capacity of 
demineralised bone matrix brought attention to the role of growth factors 
found within. In later years, more than 15 osteogenic proteins or bone 
morphogenetic proteins (BMP) were discovered. Each of these proteins play 
a specific agonistic and/or antagonistic action in the progressive stages of 
bone callus formation217,218. Their osteoinductive potential was shown in 
several in vitro and in vivo studies219-222. Based on these in vitro and in vivo 
findings, bone morphogenetic proteins (BMP-7 and BMP-2) were produced 
by recombinant DNA technology for clinical application223. Friedlaender et al. 
started a randomized multicenter study in 1992, including 122 patients with 
124 tibial non-unions, that was published in 200186. The fixation method for 
all patients was intramedullary nailing in combination with the local 
application of rhBMP-7 (recombinant human bone morphogenetic protein-7 
or OP-1) in a type I collagen carrier (3.5 mg of rhOP-1 mixed with 1g of type I 
bovine bone-derived collagen) in 63 non-unions or the application of 
autologous bone grafts in 61 non-unions. At nine months following the 
surgical procedure, 81% of the OP-1 treated non-unions and 85% of those 
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receiving autogenous bone were assessed by clinical criteria to have been 
treated successfully. By radiographic criteria, at the same point, 75% of those 
in the OP-1 treated group and 84% of the autograft treated group showed 
bony unions. Overall, the OP-1 administration was safe and proved to be 
statistically comparable to the gold standard biologic enhancement of 
autograft. This randomized trial of Friedlaender et al.86 have established 
BMP’s as a bone graft option. The efficacy of recombinant human bone 
morphogenetic protein-2 (rhBMP-2), as an adjunct to the standard care of the 
primary treatment of open tibial fractures, has been investigated in the BMP-
2 Evaluation in Surgery for Tibial Trauma (BESTT) study136. In total, 450 
patients with open tibial fractures were randomized to receive the standard of 
care (intramedullary nail fixation and routine soft-tissue management), the 
standard of care and an implant containing 0,75 mg/ml of rhBMP-2 (total 
dose of 6 mg, solved in 8 ml of sterile water), or the standard of care and an 
implant containing 1.50 mg/ml of rhBMP-2 (total dose of 12 mg, solved in 8 
ml of sterile water). The rhBMP-2 implant was placed over the fracture at the 
time of definitive wound closure. A significant reduction in the risk of 
secondary intervention was observed in the 1.50 mg/ml rhBMP-2 group 
compared with the standard of care alone group. These results suggested 
that rhBMP-2 is an alternative to the standard of care alone in patients with 
acute open tibial fractures. Whereas Aro et al.224 showed no differences in 
the treatment of open fractures with BMP-2. Both groups were treated with 
reamed nails. There was no difference in healing between standard of care 
and BMP, but an increased infection rate in the BMP-2 group. Another 
research group identified the presence of endogenous BMP, their receptors 
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and mediators in a non-union microenvironment217. In their 
immunhistochemical analysis of samples from 17 non-unions and four 
delayed unions they proved the presence of these molecules in 81% of the 
samples, probably at suboptimal levels225 relative to those necessary for 
adequate osteogenesis and bone union.  
 
In the 80’s, Johnson et al. treated six patients with traumatic segmental tibial 
bone defects with autogenous cancellous bone grafts combined with human 
BMP and other insoluble noncollagenous proteins (hBMP/iNCP)226. The 
authors did not describe the type of BMP and the exact concentration. The 
tibial defects ranged from 3-17 cm. The hBMP/iNCP was suspended in a 
chloroform solution of polylactic acid/polyglycolic acid copolymer and poured 
into a Teflon mold 0.2 x 2.0 x 13 cm in length. This strip was placed around 
the defect, whereas the autologous bone grafts filled the intercalary defect. 
Five of the six defects healed without further surgical treatment. From 1989 
to 1998 the same author treated 30 patients with femoral non-unions with an 
allogenic autolysed antigen-free allograft (AAA) and 100 mg of partially 
purified human Bone Morphogenetic Protein (hBMP) lyophilized into the 
implant227. The fixation was achieved with a 95° fixed angel plate in 25 
cases, intramedullary nailing in three cases, and in two cases with a condylar 
buttress plate. Thirteen of 30 patients received additional autogenous bone 
grafts to the intercalary segmental defect. Twenty-four (80%) of the femoral 
non-unions healed, whereas six patients had fatigue failure of the plate 
implant. Dimitriou et al. evaluated the efficacy and safety of rhBMP-7 (OP-1) 
as a bone-stimulating agent in the treatment in of 25 patients with 26 non-
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unions228. There were 10 tibial non-unions, eight femoral, three humeral, 
three ulna, one patella, and one clavicle non-union. In 17 cases the 
application was combined with autologous bone grafting. In 24 cases (92.3%) 
clinical and radiological union occurred within a mean time of 4.2 months. 
One case was a complicated fracture with an infected non-union and with 
multiple previous limb salvation procedures and underwent a below knee 
amputation. Ronga et al. reported in an observational, retrospective, non-
randomized study the use of BMP-7 for the treatment of non-union’s in 
various anatomic sites229. The work was performed by the BMP-7 Italian 
Observational Study (BIOS) Group. The clinical series included 105 patients. 
Additional grafts were used based on the surgeon’s decision. Radiographic 
and clinical assessments were carried out at progressive time intervals on 
two main groups: BMP-7 + autograft (n=50) or BMP-7 (n=38). The authors 
did not describe the exact concentration of BMP. In eleven cases they 
implanted BMP-7 with an osteoconductive agent and in six cases with a 
composite graft (bone marrow, autologous growth factors, allograft, 
hydroxyapatite, fibrin glue). The mean follow-up was 29.2 months. The cases 
treated with a composite graft were excluded, because they were not 
comparable due to the complexity of the treatment. At nine months there was 
an overlapping between the unions recorded in the two main groups with 
healing rates of 86.0% and 85.7%, respectively. The authors came to the 
conclusion, that this is an observational study that illustrates the efficacy of 
BMP-7 with and without bone grafting for the treatment of long bone non-
unions. In 2008, Kanakaris et al.230 published their multicenter study focused 
on the application of BMP-7/OP-1 for the treatment of aseptic tibia non-
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union’s. Sixty-eight patients fulfilled the inclusion criteria for this observational 
study, with a minimum follow-up of twelve months. In 41% the application of 
BMP-7 was combined with revision of the fixation at the non-union site. In 25 
cases the BMP-7 implantation was augmented by autologous bone grafts. 
Non-union healing was verified in 61 (89.7%) within a median period of 6.5 
months (range 3–15 months). No adverse events or complications were 
associated with BMP-7 application. The safety and efficacy of BMP-7 was 
verified in this case series, and was comparable to previously published 
study results. Giannoudis et al. explored the synergistic effect of autografts 
and BMP-7 in the treatment of atrophic non-unions231. In total, 45 patients 
with seven humeral, 19 femoral, and 19 tibial non-unions were included in 
this study. All non-unions were atrophic and seven had bone defects of a 
median length of 2.5 cm (2-4 cm). All of the 45 patients progressed to non-
union healing (100%). Moghaddam et al. published their experiences with 54 
patients who had atrophic non-unions of long bone fractures232. The 
localization of the non-unions included 21 in the femur, 26 in the tibia, three 
in the humerus and seven in the forearm. In 36 cases, BMP 7 was used in 
combination with osteosynthesis revision and bone grafting; in 9 additional 
patients, BMP-7 was used with bone grafting alone. In twelve patients, BMP-
7 was applied as a single procedure without any bone grafting or any change 
in osteosynthesis. Three patients with a non-union in two different long bones 
received one unit of BMP-7 at each bone site (3.5 mg). Forty-seven of the 57 
(82%) implantations were successful, with bony healing confirmed by clinical 
and radiological evaluations. Alt et al. performed a study to analyse the cost 
savings from a societal perspective for the use of BMP-2 in the treatment of 
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open tibial fractures (grade III A and III B) in the UK, Germany, and France8.  
Health care system costs (direct health care costs) and costs for productivity 
losses (indirect health care costs) were calculated using the raw data from 
the Bone Morphogenetic Protein Evaluation Group in Surgery for Tibial 
Trauma ‘‘BESTT study’’. Overall treatment costs per patient and year after 
the initial surgery of the control vs. the rhBMP-2 group were compared. In 
summary, despite the apparent high direct costs of rhBMP-2 in the treatment 
of grade III A and B open tibial fractures, indirect net cost savings were 
calculated for all three countries.  
 
Most of the mentioned studies have limitations, as no randomisation was 
performed, no control groups were used or the number of patients included 
was too small. Nevertheless, the clinical application of the commercially 
available BMP-2 and BMP-7 seems to be a safe procedure for the patient 
without any major complications in any of the mentioned studies. But long-
term effects are still not explored. The clinical application of BMP showed a 
very good healing rate (80-100%), even in cases with several unsuccessful 
previous operations, but even in some cases, BMP cannot lead to a 
successful treatment (Fig. 2). Because of the outcome of the BMP treatment, 
even in therapy resistant non-unions, BMP should be perceived as a 
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(average in cm) 
Rate of union 
Johnson et al.226 1983	   6	   Tibia	   BMP-­‐7	  +	  ABG	   8.3	   83.3%	  
Johnson and 
Urist227 
2000	   30	   Femur	   hBMP/AAA	  
13x	  add.	  ABG	  
2.7	   80%	  
Friedlaender et al.86 2001	   122	   Tibia	   OP-­‐1	   63,	   ABG	  
61	  
-­‐-­‐	   OP-­‐1	   81%,	   ABG	  
85%	  
Dimitriou et al.228 2005	   26	   Tibia,	   Femur,	   Ulna,	  
Clavicle	  
BMP-­‐7	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
17x	  add.	  ABG	  
-­‐-­‐	   92.3%	  
Ronga et al.229 2006	   105	   Tibia,	   Femur,	   Forearm	  
Humerus,	  Clavicle	  
38xonly	  BMP-­‐7	  -­‐-­‐-­‐
11xwith	  add.	  OA	  
-­‐-­‐	   BMP	  86,8%	  
BMP+ABG	  86%	  	  	  
 	   	   	   -­‐50xwith	  add.	  	  	  
	  	  ABG	  
-­‐	  6xwith	  CG	  
	   BMP+OA	  85,7%	  
Kanakaris et al. 230 2008	   68	   Tibia	   43xBMP-­‐7	  
25xBMP+ABG	  
-­‐-­‐	   89.7%	  
Giannoudis et al.231 2009	   45	   Tibia,	  Femur,	  Humerus	   BMP-­‐7+ABG	   2.5	  (n=7)	   100%	  
Maghaddam et 
al.232 





<1,5	   82%	  
Table 3: Clinical application and outcomes of the treatment of bone defects 
and bone non-unions with revision osteosynthesis (intramedullary nailing 
(IMN), plate osteosynthesis (PO) and external fixation (EF)) in combination 
with biological enhancement such as bone morphogenetic protein 7 (BMP-7 
or rhOP-1), autologous bone grafts (ABG), composite grafts (CG, as bone 
marrow, autologous growth factors, allograft, hydroxyapatite, fibrin glue), 










































Fig. 2: A femur non-union of a 79-year old patient after plate osteosynthesis. 
The patient had a sarcoma of the thigh with radiation as a treatment. 
Afterwards, he fell at home and broke his femur. The femur non-union was 
treated with an cortical bone chip, fixed with two additional screws (A). After 6 
months, no healing occurred, and application of cancellous bone in 
combination with growth factors (BMP-7) was performed (B). After another 4 
months, implant failure occurred without any progress in the bone 
regeneration (C). Therefore, the final decision was made to implant a 
prosthesis (D), which was still in place with a good limb function of the patient 
after 1 year (E). 
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2.4.2. Cell based strategies 
Other approaches in regenerative medicine are cell-based strategies for the 
reconstruction of bone defects. Mesenchymal stem cells, periosteal cells and 
osteoblasts have been employed in these cell-based strategies. Among 
these cells, mesenchymal stem cells are used most frequently, and seem to 
be a potential cell source for regeneration of mesenchymal tissues such as 
bone. They are multipotent progenitor cells, which have the potential to 
differentiate into a variety of mesenchymal tissues such as bone, cartilage, 
tendon, ligaments, muscle, fat and dermis80,81,82,83. The cells can be isolated 
from a variety of tissues233,234,235, such as bone, bone marrow, fat and 
periost, using different separation techniques and may be differentiated into 
the appropriate phenotype under defined culture conditions and the influence 
of specific growth factors or cytokines236. Their advantages are unlimited 
supply and easy accessibility by bone marrow aspiration, the possibility of in 
vitro expansion of the cells and a high osteogenic potential, which has been 
extensively studied. In contrast to the little knowledge about the use of 
mesenchymal stem cells for the repair of skeletal lesions in humans, they 
have been studied extensively in several in vitro studies237-240, as well as in 
vivo studies in different animal models241-244 and have demonstrated their 
bone-forming capacity and usefulness in treating critical size bone defects. 
Although strong efforts have been made over the last decade to introduce 
stem cell and tissue engineering treatment strategies to the field of 
orthopaedics, only a few clinical applications are currently available. 
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Based on results of experiments regarding the reconstruction of large bone 
defects in large animal models245, Quarto et al. were the first to report the 
repair of extensive bone defects (4-7cm) in humans by means of implantation 
of a porous ceramic scaffold seeded with in vitro expanded bone marrow 
derived autologous mesenchymal stem cells246. Three patients were selected 
for this cell-based tissue engineering approach after failure of alternative 
surgical therapies. For each patient, osteoprogenitor cells were isolated from 
bone marrow and expanded ex vivo. These cells were placed on 
macroporous hydroxyapatite scaffolds, the size and shape of which reflected 
the particular bone defect in each patient, and implanted at the lesion sites. 
External fixation was provided initially for mechanical stability and was 
subsequently removed (6.5 months after surgery in Patient 1, 6 months after 
surgery in Patient 2, and 13 months after surgery in Patient 3). In all three 
patients, radiographs and computed tomography scans revealed abundant 
callus formation along the implants and good integration at the interfaces with 
the host bones by the second month after surgery. All three patient recovered 
limb function within six to twelve months. Later they included one more 
patient in their study and made a follow up after six to seven years247. In all 
patients a good integration of the implants was maintained. Vacanti et al. 
reported the case of a man who had a traumatic avulsion of the distal 
phalanx of the thumb248. The bone was replaced with in vitro expanded 
autologous periosteal cells that had been expanded and seeded onto a 
porous coral implant. Twenty-eight monthss after the implantation, the patient 
had a thumb of normal length and strength. Kitoh et al. reported the clinical 
results of distraction osteogenesis with transplantation of bone marrow-
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derived mesenchymal stem cells (BMSCs) and platelet-rich plasma (PRP) in 
24 bones (12 femora and 12 tibiae) of 20 patients with achondroplasia and 
hypochondroplasia249. BMSCs derived from the iliac crest were cultured with 
osteogenic supplements and differentiated into osteoblast-like cells. Culture-
expanded osteoblast-like cells and autologous PRP were injected into the 
distracted callus with a thrombin–calcium mixture so that the PRP gel might 
develop within the injected site. Transplantation of BMSCs and PRP was 
done at the lengthening and in 5 patients additionally at the consolidation 
period. The target lengths were obtained in every leg without major 
complications. Surprisingly, the average healing index of the BMC-PRP 
group (27.1 +/- 6.89 d/cm) was significantly lower than that of the control 
group (36.2 T 10.4 d/cm),(p = 0.0005). But the femoral lengthening showed 
significantly faster healing than did the tibial lengthening in the BMC-PRP 
group (p = 0.0092). However, the contribution of the injected cells to the bone 
formation is difficult to evaluate due to the inconsistent number of cells 
injected and the different ways of the cell application. Furthermore, the 
author’s conclusion that the transplantation of cells with PRP shortened the 
treatment period of the distraction osteogenesis cannot be accepted and 
comprehended. Morishita et al. reported the treatment of bone defects 
caused by bone tumours in three patients using tissue-engineered 
implants250. The number of mesenchymal stem cells (MSCs) obtained from 
each patient’s bone marrow cells was first increased and the MSCs were 
forced to differentiate into osteoblasts followed by bone matrix formation on 
hydroxyapatite (HA) ceramics. The tissue-engineered HA was used to fill the 
patient’s bone cavity after tumour curettage. The authors describe, that an 
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immediate healing potential was found by serial plain radiographs and 
computed tomography images, and no adverse reactions were noted in these 
patients. These results indicate that tissue-engineered osteogenic ceramics 
might be an alternative to autologous bone grafts. The percutaneous use of 
autologous bone-marrow cells for the treatment of non-unions was performed 
by Hernigou et al251. The purpose of his study was to evaluate the number 
and concentration of progenitor cells that were transplanted for the treatment 
of non-union, the callus volume obtained after the transplantation, and the 
clinical healing rate. Bone-marrow was aspirated from both anterior iliac 
crests, concentrated on a cell separator, and then injected into 60 non-
infected atrophic non-unions of the tibia. Each non-union received a relatively 
constant volume of 20 cm3 of concentrated bone marrow. An average total of 
51 x 103 fibroblast colony-forming units were injected into each non-union. 
Bone union was obtained in 53 patients, and the bone marrow that had been 
injected into the non-unions of those patients contained >1500 
progenitors/cm3 and an average total of 54,962 ± 17,431 progenitors. The 
concentration (634 ± 187 progenitors/cm3) and the total number (19,324 ± 
6843) of progenitors injected into the non-union sites of the seven patients in 
whom bone union was not obtained were both significantly lower (p = 0.001 
and p < 0.01, respectively) than those in the patients who obtained bone 
union. The efficacy of percutaneously autologous bone-marrow grafting 
seems to be an effective and safe method for the treatment of bone non-
unions. Jäger et al. used bone marrow concentrate (BMC) for the treatment 
of volumetric bone deficiencies in ten patients252. They also found a rationale 
for a clinical application of BMC/bone aspirate in the treatment of osseous 
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defects. The intraoperative harvest procedure is a safe method and does not 
significantly prolong the time of surgery. Dallari et al. evaluated the use of 
bone grafts supplemented with platelet gel or platelet gel and bone marrow 
stromal cells for the healing of high tibial osteotomy. During the osteotomy, 
lyophilized bone chips with platelet gel were implanted into eleven patients 
(Group A), lyophilized bone chips with platelet gel and bone marrow stromal 
cells were implanted in twelve patients (Group B), and lyophilized bone chips 
without gel were placed in ten patients as controls (Group C). Six weeks after 
surgery, computed tomography-guided biopsies of the grafted areas were 
performed and the specimens were analysed by histomorphometry. Clinical 
and radiographic evaluation was performed at six weeks, twelve weeks, six 
months, and one year after surgery. The histomorphometry after six weeks 
showed significantly increased osteoblasts and osteoid areas in the cell 
group and the group with platelet gel compared to the control group, as well 
as increased bone apposition on the chips which was the highest in the cell 
group. Moreover, the cell group showed significantly higher revascularization 
than the controls. Radiographs revealed a significantly higher rate of 
osseointegration in the cell group and the group with platelet gel than in the 
control at six weeks.  At the final evaluation at one year, the osseointegration 
was still better in the cell group and the group with platelet gel compared to 
the control group. However, all patients had complete clinical and functional 
evidence of healing.  
 
In 2009, Kim et al. published their results of a randomized, multi-centre 
clinical study to compare the effect and safety of autologous cultured 
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osteoblast (Ossron™) injection to treat fractures. Sixty-four patients with 
long-bone fractures were randomly divided into two groups, i.e. those who 
received autologous cultured osteoblast injection and those who received no 
additionally cell-treatment. The cells were obtained during the fracture 
surgery via bone marrow aspiration (3-5ml) in all patients of the experimental 
group. The cells were cultured in an osteogenic differentiation media and 
after 8 weeks about 1.2 x 107 cells/0.4ml in combination with 0.4ml of fibrin 
were injected into the fracture area using a radiation imaging instrument (C-
arm). The sum of the difference in the callus formation scores after four and 
eight weeks was used as the first efficacy variable. A modified callus 
formation score was used to evaluate the effectiveness of the injected cells. 
The average callus formation scores at the time of patient enrolment were 
1.4 and 2.1, respectively, in the experimental and control group patients. The 
final average callus formation scores of the experimental and control groups 
were 7.1 and 5.8, respectively, which was statistically significant (p = 0.03). 
But at one month, the data were not statistically significant (p = 0.196). The 
conclusion of this study was that autologous cultured osteoblasts can be 
used as an effective method for accelerating the rate of fracture healing. But, 
the study lacks of the more interesting long term outcomes after 6 months 
and 12 months, and therefore the results should be construed carefully.   
 
In the field of oral and maxillofacial surgery, Warnke et al. reported the 
successful transplantation of a customized, vascularised mandible 
replacement that had been exogenously engineered and subsequently 
cultured in vivo inside the patient's own 56-year-old body253. A titanium mesh 
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was chosen as an external scaffold, because degradable polylactite scaffolds 
had demonstrated a lack of contour stability in preceding animal studies. The 
custom-made titanium mesh was loaded with hydroxyapatite blocks that were 
coated with recombinant human Bone Morphogenetic Protein-7 (rhBMP-7) 
and bone marrow-derived mesenchymal stem cells. The patient's own body 
served as a living bioreactor as the prepared scaffold was implanted into his 
right latissimus dorsi muscle to allow for growth of heterotopic bone and for 
ingrowths of vessels from the thoracodorsal artery. After a cultivation period 
of 7 weeks the mandible replacement was transplanted (with the adjacent 
vessel pedicle) to repair a mandible defect resulting from resection of a 
tumour eight years previously. The patient regained full masticator function 
following this procedure allowing him to enjoy solids. Unfortunately, the 
patient died as a result of cardiac arrest 15 months after implantation of the 
mandible replacement. 
 
All of the proposed techniques may be applicable for the repair of bone 
defects, and could be a useful alternative to autologous bone grafts. The 
methods described appear to be safe, minimally invasive, and easy to 
perform, with great potential in clinical applications. Unfortunately, due to 
practical and ethical reasons, clinical situations often lack proper controls, 
making data interpretation difficult. This aspect is still to be solved if clear-cut 
decisions have to be made while debating on technology transfer from the 
bench to the clinic. 
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Author Year No.  of  
patients 




(average in cm) 
Rate of 
union 
Quarto et al.246  2001	   3	   Tibia,	  Ulna,	  Humerus	   EF	   BMSC	   5	   100%	  
Vacanti et al.248 2001	   1	   Phalanx	   -­‐-­‐	   PC	   2	   100%	  
Hernigou et al.251 2005	   60	   Tibia	   -­‐-­‐	   ABMG	   -­‐-­‐	   88.3%	  
Morishita et al.250 2006	   3	   Tibia	  Femur	   no	  Fixation	   MSC’s	   -­‐-­‐	   100%	  
Kitoh et al.254  2007	   11	   Tibia,	  Femur	   EF	   CD+PRP+BMSC	   8.95	   100%	  
Dallari et al.255  2007	   12	   Tibia	   PO	   BMSC	   -­‐-­‐	   100%	  
Kim et al.256  2009	   31	   Tibia,	  Femur,	  Humerus,	  
Ulna,	  Radius,	  Fibula	  
IMN	   Osteoblast	  
(Ossron™)	  
-­‐-­‐	   100%	  
Table 4: Clinical application and outcomes of the treatment of bone defects 
and bone non-unions with intramedullary nailing (IMN), plate osteosynthesis 
(PO), callus distraction „Ilizarov technique“ (CD)and external fixation (EF) in 
combination with bone marrow derived mesenchymal stem cells (BMSC), 
platelet- rich plasma (PRP), autologous bone-marrow grafting (ABMG) and 
periosteal cells (PC). 
 
2.5. Future Directions 
Treatment of non-unions or segmental bone defects must consider above all 
the healing response of the tissue treated, in addition to the inductive 
properties of the graft. In fact, if the capacity to produce new bone is 
compromised, the induction phase will not be successful. Advanced age, 
infections, compromised soft tissue and all the conditions that cause a 
reduction in the number of cells for the regeneration process will require a 
combined approach. The use of autografts, autologous cells from bone 
marrow or, perhaps in the future, from mesenchymal cell banks will be an 
indispensable element that would enhance further non-union treatment 
strategies. The tissue engineering approach to bone defect repair, although 
successful and highly promising in most of the cases where it has been 
attempted, still needs rigorous evaluation and optimization. The results 
presented in the reviewed articles are not comparable. Rates of different 
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types of non-unions, time between initial injury and final intervention, 
differences in the size of bone defects and diversities on the application of 
each biologically enhancing modality make comparisons and conclusions 
difficult. Properly conducted clinical trials that include sufficient numbers of 
patients are warranted before claims regarding the therapeutic efficacy of 
mesenchymal stem cells and different types of growth factors for the 
treatment of large bone defects. As shown in several animal studies, bone 
tissue engineering has the potential to become a real clinical alternative to 
autologous bone grafts. Nevertheless, several problems have to be solved 
before translation into a routine clinical application. In large defects, the 
homogenous blood supply, including nutrients and oxygen, is still an 
unsolved problem. Additional in vitro studies, as well as further animal 
studies, should be performed to select required factors and different 
properties of the scaffold to achieve the best and constant supply of cells with 
nutrients. Regarding the tissue engineering aspect of bone regeneration, the 
size of the defect plays another important role. Fractures and non-unions are 
smaller than large segmental bone defects, and other treatment strategies 
are required. It might be sufficient, to use growth factors like BMP-2 or BMP-
7 as local bone supplements to gain full bone regeneration.  
 
In large bone defects, scaffolds are necessary for the replacement of the 
structural integrity. These scaffolds must provide sufficient initial mechanical 
strength and stiffness to substitute for the loss of mechanical function of the 
diseased or damaged tissue. Yet, scaffolds may not necessarily be required 
to provide complete mechanical equivalence to healthy tissue, but stiffness 
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and strength should be sufficient to at least support and transmit forces to the 
host tissue site in this context. Continuous cell and tissue remodelling is 
important for achieving stable biomechanical conditions and vascularisation 
at the host site. Hence, the 3D scaffold/tissue construct should maintain 
sufficient structural integrity during the in vitro and/ or in vivo growth and 
remodelling process. The degree of remodelling depends on the tissue itself 
(e.g. skin 4-6 weeks, bone 4-6 months), and its host anatomy and 
physiology. In addition to these essentials of mechanics and geometry, a 
suitable construct will possess a 3D and highly porous interconnected pore 
network with surface properties which are optimized for the attachment, 
migration, proliferation and differentiation of cell types of interest and enable 
flow transport of nutrients and metabolic waste. Furthermore, they should be 
biocompatible and biodegradable with a controllable rate to compliment 
cell/tissue growth132.  
 
It cannot be emphasised strongly enough how essential it is to control and 
understand this degradation process to lead to successful tissue formation, 
remodelling, and maturation at the defect site. In the early days of tissue 
engineering it was believed that the scaffold should degrade and vanish as 
the tissue is growing. Currently, tissue ingrowth and maturation differs 
temporally from tissue to tissue and secondly tissue ingrowth does not 
equate to tissue maturation and remodelling, in other words a defect filled 
with immature tissue should not be considered “regenerated”.  Hence, many 
scaffold-based strategies have failed in the past as the scaffold degradation 
was more rapid than the tissue remodelling and/or maturation132.  
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Mesenchymal stem cells are becoming more and more popular as a cell 
source for a cell-based tissue engineering approach. These cells have shown 
their therapeutic capacity in several in vitro as well as in vivo studies for the 
regeneration of bone defects and non-unions. The supply of autologous 
mesenchymal stem cells is often limited. But their special immunological 
characteristics suggest that MSC’s could be used in non-autologous 
applications257,258. This offers a new opportunity for the availability of 
mesenchymal stem cells for regenerative medicine and a clinical application.  
 
Over the last few years, some research groups have focused their work on 
some additional cell sources. Osteoblasts isolated from axial bones and from 
orofacial bones show in some in vitro studies a higher osteogenic potential 
than mesenchymal stem cells. Further experiments are required regarding 
cell sources in combination with different scaffolds and growth factors. With a 
more established foundation of knowledge, researchers will be able to 
answer questions about whether cells for implantation should be 
undifferentiated or differentiated, and what the optimal cell source, 
proportion, and method of implantation will be to translate research findings 
into clinical practice. For the clinical application of different novel treatment 
strategies including the tissue engineering approach, a good clinical outcome 
with recovery of nearly normal function of the limb is most important for the 
patient. Prior to treatment of a patient with a bone defect or bone non-union, 
the different available options for treatment, even non-operative treatment, 
have to be balanced, and the best option should be taken in regard to the 
  50 
patient’s situation. Therefore, a close cooperation between researchers and 
clinicians is necessary to use the optimal combination of different treatment 
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Chapter III - Benchmarking autologous vs. 
allogenic mesenchymal progenitor cells for the 
reconstruction of critical-sized segmental tibial 
bone defects in aged sheep 
 
3.1. Introduction 
There are two major engineering approaches in the development of novel 
treatment concepts using scaffolds; cell-based and cell-free. The most 
suitable cell source for scaffold-based bone tissue engineering is still focus of 
much debate in the literature. The nature of regenerative medicine will be 
profoundly influenced by whether the cells used are allogeneic or patient- 
autologous. It is unlikely to be wholly one or the other that will dominate, 
however, at this early stage it is worth examining the issues, both from a 
scientific and translational point of view. 
  
A great advantage of natural patient-derived (autologous) cells is twofold; 
firstly the cells can be readily prepared either in the operation theatre or in a 
special lab attached to the hospital. Hence autologous therapy is something 
that clinician scientist can proceed in house, at least to early clinical trials, 
although they still need to meet regulatory requirements and secondly no 
host-versus-graft immunological reaction79. 
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For universal (allogeneic) cell material the pronounced advantage is that it is 
qualified of representing a commercial technology more comparable with that 
of pharmaceutical drug than autologous cells. This is because it is possible to 
envisage manufactured goods by scale-up with product characterization, 
which defines safety, applied to sizeable batches of cell-based products. In  
addition, in medical emergencies allogeneic cells have quite a lot of 
supplementary advantages. First, given reasonable cell stability during 
storage, there will be an immediately available supply in the operation 
theatre. A further value in non-elective treatments is that these therapies do 
not require a preliminary biopsy from a potentially severely ill person, thus 
avoiding an additional procedure and all the associated challenges including 
appropriate patient biopsy consent79. 
 
In bone tissue engineering cell-based strategies aim to improve 
osteoinduction by the incorporation of cells with a high osteogenic 
differentiation potential such as bone marrow derived mesenchymal 
progenitor cells (bMPCs). Gronthos et al.259 have defined these cells as 
multipotent progenitor cells, which have the potential to differentiate into a 
variety of mesenchymal tissues such as bone, cartilage, tendon, ligaments, 
muscle, fat and dermis80,81,82,83. They can be isolated from a variety of 
tissues233,234,235 using different separation techniques and can be 
differentiated into the appropriate phenotype under defined culture conditions 
and the action of specific growth factors or cytokines236. These cells have 
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shown their therapeutic potential in a number of in vivo studies for the 
regeneration of large bone defects and non-unions239,242,260-262. 
The supply of autologous MPCs is often limited and the preoperative 
preparations for their isolation, expansion and differentiation is time 
consuming and expensive. Hence, to acquire an adequate amount of cells for 
transplantation, the time period between cell isolation and cell transplantation 
is usually at least 4 – 6 weeks. Therefore, the major drawback of using an 
autologous cell source is two-pronged; limitations in cell numbers when 
utilising them immediately after extraction or the long time period and 
associated costs, which are necessary to expand the cells in vitro until a 
suitably high number is attained. However, the special immunological 
characteristics, which are evident with MPCs, suggest that MPCs could in 
fact be used successfully for non-autologous applications257,258. Allogenic cell 
transplantation is a common therapeutic option and is in routine clinical use 
in the field of oncology263,264. Translating the idea of allogenic cell-
transplantation from oncology to orthopaedics could offer a new opportunity 
for the availability of MPCs for regenerative medicine as an “off the shelf 
product”. Before translating these new treatment concepts into a clinical 
application in orthopaedic and trauma surgery, rigorous evaluation of the 
respective cell populations in an adequate preclinical animal model are 
essential76,77.  
Several animal models have been developed over the years to verify the 
practicality of different research approaches in bone regeneration. Among 
these, adult sheep offer the advantage of having a comparable body weight, 
a similar mineral composition of bone and similar metabolic and remodelling 
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rates to humans and furthermore, long bone dimensions suitable for the use 
of human implants and prostheses, which is not possible in smaller 
species65,265. Thus, our group has recently established a challenging ovine 
segmental bone defect model using relatively old animals, which show the 
secondary osteon remodelling characteristic of human bone. We move 
towards defining an appropriate cell source for bone tissue engineering to 
circumvent the aforementioned disadvantages associated with autologous 
cell transplantation in favour of allogenic MPC sources266.  
We hypothesize that allogenic MPCs have a similar osteogenic potential 
compared to autologous MPCs and can be used in a scaffold-cell based 
bone tissue engineering concept. Therefore, the aim of the current study was 
to assess and compare the regenerative potential of autologous versus 
allogenic MPCs in combination with a mPCL-TCP scaffold in a critical sized 
segmental bone defect in a sheep tibia.  
 
3.2. Material and Methods  
3.2.1. Scaffold fabrication and preparation  
Bioresorbable cylindrical scaffolds of medical grade poly-caprolactone (80%) 
and β-tricalcium phosphate (20%), (mPCL–TCP), (outer diameter: 20 mm, 
height: 30 mm, inner diameter: 8 mm) are used in this study. The scaffolds 
are produced by fused deposition modelling (FDM) and obtained from 
Osteopore International (Osteopore International, Singapore). The scaffolds 
have a porosity of 70% and a 0/90° lay down pattern (Fig. 3). This 
architectural layout is particularly suitable for load bearing tissue engineering 
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applications since the fully interconnected network of scaffold fibres can 
withstand early physiological and mechanical stress in a manner similar to 
cancellous bone. Moreover, the architectural pattern allows retaining of 
coagulating blood during the early phase of healing, and bone ingrowth at 
later stages. Prior to surgery, all scaffolds are surface treated for six hours 
with 1M NaOH and washed five times with PBS to render the scaffold more 
hydrophillic. Scaffold sterilization is achieved by incubation in 70% ethanol for 









                                      
                         5mm 
 
Figure 3: MicroCT image of a cylindric mPCL-TCP scaffold produced via 
fused deposition modelling for segmental bone defect repair. 
 
3.2.2. Animal study 
Thirty-two male sheep (40-50 kilogram, age 7-8 years) were used in this 
project (Table 5). An Animal Ethics Approval Certificate has been obtained. 
Animal surgery was performed at the QUT Medical Engineering Research 
Facility, The Prince Charles Hospital, Chermside. Owing to ethical reasons to 
lower the number of animals, the results of the experimental groups will 
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additionally be compared to the scaffold only group (negative control group) 
and the group with autologous bone graft (ABG), (positive control group) from 
the work of Dr. Johannes Reichert, who did these experiments for his thesis. 


















Total 8 8 8 8 
  
  Table 5: The research plan with details of the animal treatment groups. 
 
 
3.2.3. Preparation of platelet rich plasma  
To produce platelet rich plasma (PRP) 80ml of blood was collected from the 
jugular vein of each sheep and transferred into 3.5-ml monovettes 
supplemented with sodium citrate (3.8%) at a ratio of 9 volumes blood and 1 
volume sodium citrate according to Anitua et al.88 (Fig. 4 A). The citrated 
blood of 30 monovettes was transferred to eight 15 ml falcon tubes and 
centrifuged in a standard laboratory centrifuge for 20 min at 2,400 rpm (Fig. 4 
B/C). Subsequently, the yellow plasma of all tubes was transferred to one 
new 50-ml falcon tube and platelets pelleted in a second centrifugation step 
for 10 min at 3,600 rpm(Fig. 4 D)267. The pellet was resuspended in 2ml of 
plasma and the platelets counted in a hemocytometer. After the  preparation, 
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PRP was mixed with the cells (MPC), and the resulting suspension was 
loaded onto the sterilized scaffolds (Fig. 4 E/F). PRP was activated using 
Thrombin (5U/ml), and the scaffolds placed in the incubator for at least one 























Figure 4: Blood is collected from the jugular vein of the sheep (A), mixed (B), 
and transferred into eight 15 ml falcon tubes (C). After centrifugation with 
2400 rpm for 20min, the plasma is removed and centrifuged for a second 
time (D). The resulting pellet is resuspended in 2ml of plasma, and the cells 
in combination with PRP seeded onto the scaffolds (E/F). 
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3.2.4. Animal Surgery 
3.2.4.1. Anaesthesia and pre-operative treatment  
A jugular venous line is installed under aseptic conditions, and 15-20 ml of 
1% propofol injected to induce general anaesthesia. The animal is intubated 
with a 9-10 mm silicon endotracheal tube and connected to an automatic 
respirator (Campbell anaesthetic ventilator) for assisted ventilation with 2l 
O2/min. The general anesthesia is maintained with propofol (2%) at a rate of 
120-140 ml/min. For analgesia, Buprenorphine (0.1 mg per 10 kg body 
weight) is administered, for antibiotic prophylaxis gentamycine (5 mg/kg) and 
cephalothin (25 mg/kg). The animal's ECG, heart rate, oxygen saturation and 
end-tidal carbon dioxide levels are monitored and recorded continuously.  
 
3.2.4.2. Surgical Procedure 
All animals are placed in the right lateral position. The right hind limb is 
carefully shaved and thoroughly disinfected with 0.5% chlorhexidine solution 
red in 70 % ethanol. The animal torso and surroundings are covered with 
sterile sheets, the surgical area additionally with Opsite (Smith and Nephew). 
The right tibia is exposed by a longitudinal incision of approximately 12 cm 
length on the medial aspect of the limb (Fig. 5 A). A bone fixation plate (4.5 
mm broad DCP, 10 holes, Synthes) is adjusted to the morphology of the 
bone by bending (plate-bending press, Synthes) and applied to the medial 
tibia. The distal end of all plates is placed 2.5 cm proximal of the medial 
malleolus (Fig. 5 B). The screw holes are drilled and the plate is temporarily 
fixed with 2 screws adjacent to the anticipated defect (Fig. 5 C). The middle 
of the defect site is measured and marked with a raspatory. A distance of 1.5 
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cm each proximally and distally of the defect middle is measured and marked 
to define the osteotomy lines (Fig. 5 D). Next, the soft tissue inserting to the 
bone in the designated defect area is detached and a wet compress placed 
between bone and posterolateral soft tissue to avoid damage to proximate 
nerve and blood vessels during osteotomy (Fig. 5 E). Parallel osteotomies 
perpendicular to the bone’s longitudinal axis are performed with an 
oscillating saw (Stryker) under constant irrigation with saline solution to 
prevent heat induced osteonecrosis whilst the bone segment of 3 cm length 
is excised (Fig. 5 F). Care is taken to completely remove the periosteum 
within the defect area and 1 cm proximally and distally of the osteotomy lines 
(Fig. 5 G/H). The plate (DCP) is fixed on the proximal bone using 4 screws. 
Afterwards, the scaffold is gently placed into the defect and the distal part of 
the tibia is fixed to the plate using 3 screws (Fig. 5 I/K). Care is taken not to 
destroy or damage the scaffold but to place it, press fit, between the proximal 
and distal part of the tibia. The wound is closed in layers with a 2-0 Monocryl 
(Ethicon) and a 3-0 Novafil (Syneture) suture for the skin. The closed wound 
is sprayed with Opsite (Smith and Nephew), covered with pads and 
bandaged (Vetrap, 3M). After recovery from anaesthesia, animals are 

































Figure 5: To create a 3 cm segmental defect, a skin incision is made over 
the medial part of the tibia (A), the plate is placed 2.5 cm proximal of the 
mallelolus mediales (B) and temporarily fixed with two screws (C). The screw 
holes are drilled and the defect middle and osteotomy lines are marked (D). 
A wet compress is placed between the bone and the posterolateral soft 
tissue, to avoid damage to the nerve and blood vessels (E). The bone 
segment is removed after osteotomy (F). Care is taken to remove the 
periosteum (black arrow) (G), which is in the dorsal part very closed to the 
vessels and the nerve (black star) (H). After implanting the scaffold (I), the 
bone fragments are realigned and fixed with a plate and screws (K). 
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3.2.4.3. Euthanasia  
The animals were euthanized after 3 months by intravenous injection of 60 
mg/kg pentobarbital sodium (Lethobarb, Virbac, Australia). After euthanasia, 
both hind limbs were exarticulated at the knee-joint, the tibia dissected and 
the fixation plate removed.  
 
3.2.5. Experimental Groups 
- Group I  
The empty scaffold (mPCL-TCP) was placed into the defect and the wound 
closed in layers.  
 
- Group II 
Ovine mesenchymal progenitor cells (MPC) were obtained from Merino 
sheep undergoing experimental surgery. Bone marrow aspirates were 
obtained from the iliac crest under general anaesthesia (Fig. 6). Total bone 
marrow cells (5-15 x 106 cells/ml) were plated at a density of 10-20 x 106 
cells/cm2 in complete medium consisting of low glucose DMEM 
supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cells were subsequently plated at a density of 103 cells/cm2. 
Two weeks before implantation, the medium was changed to an osteogenic 
media (DMEM, 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin, 10 
µl/ml ß-glycerophosphate, 1 µl/ml ascorbic acid and 1 µl/ml dexamethasone) 
to induce osteogenic differentiation. For 3D cultures, 35 x 106 ovine MPC 
suspended in 250 µl of basal medium were mixed with PRP and then seeded 
onto each collagen type I coated mPCL-TCP scaffolds. PRP was activated 
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with thrombin and the cell scaffold constructs were implanted into the defect 











Figure 6: Bone marrow aspiration from the iliac crest under general 
anaesthesia.  
 
- Group III 
The cells (allogenic MPC) used in this group were obtained from merino 
sheep that were not included in this group (allogenic cells). The procedure of 
cell harvesting, cell culture and scaffold preparation is the same as explained 
in group II. 
 
- Group IV 
Autologous cancellous bone graft (ABG) was harvested from the left iliac 
crest. The surgical area was shaved and desinfected with 0.5% chlorhexidine 
red in 70% ethanol. A 5 cm incision was made following the iliac crest, the 
inserting musculature was carefully detached and the cortical bone of the 
lateral os ileum was fenestrated (2 x 2 cm) using a hammer and osteotome. 
Care was taken not to fracture the ala ossis ilii. The resulting lid was carefully 
  63 
removed with a raspatory and the cancellous bone harvested utilizing a bone 
curette. Then, the lid was reinserted, the musculature reattached with 2-0 
Vicryl sutures (Ethicon), and the wound closed in layers. The closed wound 
was sprayed with Opsite (Smith and Nephew). 
 
3.2.6. Blood analysis 
The allogenic group was monitored for six weeks after the procedure to 
assess any reaction to the impantation of the cells. Blood samples were 
taken from all animals of the allogenic group and of the autologous group as 
a control. Blood samples were taken on day 1,3,7,14,21 after the operation. 
At the same time the sheep were physically examined. A final physical 
examination was performed 6 weeks after surgery.  
 
3.2.7. Radiography analysis  
Throughout the study, x-rays were taken after 6 and 12 weeks, to determine 
the time of bridging of the defect in the different experimental groups. 
Conventional x-ray analysis (3.2 mAs; 65kV) was performed in two standard 
planes (anterior-posterior and medial-lateral). At euthanasia, the gross 
morphology and mobility at host-graft junctions was clinically assessed and 
the findings carefully documented and photographed.  
 
3.2.8. Computed tomography (clinicalCT) 
After sacrifice, a clinical CT scanner (Philips Brilliant CT 64 channels) was 
used to scan the experimental limbs. A dipotassium phosphate phantom was 
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used to calibrate measurements of mineral density. 3D reconstructions from 
the CT data were generated with AMIRA® 5.2.2 (Visage Imaging GmbH, 
Berlin, Germany) (Visage Imaging) with a threshold of 300 and qualitative 
analysis was performed to assess mineralization within the defect and 
bridging. For quantitative analysis, the CT datasets of operated and 
contralateral intact tibia of each animal were first cropped to image stacks 
with equal bounding box dimensions using AMIRA®. Next, cortical bone and 
callus tissue were segmented by choosing appropriate threshold values 
(lower threshold: 300) for the measured grey levels. A 3D surface was 
generated and saved as a binary file (STL binary Little Endian format). These 
.stl files were loaded into Rapidform2006 (Inus Technology, Seoul, Korea) 
and 4 corresponding reference points were selected on each intact and 
defect tibia and bound to the respective shell. Intact and defect tibia were 
registered to align their shells utilizing the previously defined common 
geometries between them. The reference point coordinates of the defect tibia 
were recorded prior to and after registration. The coordinates of the initial and 
final points were entered in an in-house MATLAB program (MATLAB 7.6.0, 
MathWorks, Inc., Natick, MA, USA) to determine the matrix for the required 
transformation. This transformation matrix was then used to align the image 
data stacks in AMIRA®. This alignment results in the intact and defect tibia 
having the same orientation and allows the definition of the three different 
regions of interest within the defect. Next, the amount of newly formed bone 
in these three different regions of interest within the 3 cm defect area was 
calculated using an in-house MATLAB program. Region 1 is the region of the 
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cortical bone, region 2 is the bone marrow region, and region 3 is the 









Figure 7: CT DICOM image of an intact ovine tibia (axial view) defining the 
three regions of interest. Region 1 is the region of the cortical bone, region 2 
is the bone marrow region, and region 3 is the external bone formation 
around the defect 
 
3.2.9. Biomechanical evaluation  
To determine the integration of the scaffolds into the bone and the recovery 
of the biomechanical function of the affected tibias, biomechanical testing 
was performed. After euthanasia, both tibias of each sheep were explanted 
and the fixation plate of the experimental leg was carefully removed. Both 
ends of the tibiae were embedded in 80 ml Paladur (Heraeus-Kulzer GmbH) 
and each bone was then mounted in an Instron 8874 biaxial testing machine 
(Fig. 8). By leaving as much soft tissue as possible attached, bone samples 
were prevented from drying out. Next, for the experimental and the intact tibia 
(control) a torsional test until failure was performed in a biaxial universal 
testing machine (Instron 8874, Instron, Norwood, USA). The torsion test was 
conducted with a compressive load of 0.05kN and at an angular velocity of 
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0.5 deg/s until the fracture point was reached (right tibiae counter clockwise, 
left tibiae clockwise). In order to avoid the possibility of damage to the 
specimens in the early stages of bone healing, no preconditioning of the 
samples was performed. The torsional moment (TM) and torsional stiffness 
(TS) values were calculated from the slope of the torque-angular 





















Figure 8: Potting of a sample tibia for biomechanical testing. First, the 
proximal part is embedded in Paladur with the tibial axis vertically aligned (A). 
The tibia is then rotated and the distal part is embedded (B). The torsion test 
is conducted counter clockwise for the right tibiae and clockwise for the left 
tibiae (C-D).  
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3.2.10. Computed tomography (microCT) 
After mechanical testing, both tibias were fixed in 10% neutral buffered 
formalin (NBF) and micro-CT scans of the defect and the control side were 
performed. On the defect side, a region of interest including the 30 mm 
defect gap and 5 mm of adjacent bone each proximally and distally was 
selected. A 1 cm large piece of bone from the contralateral side was scanned 
as a control. Samples were scanned (vivaCT 40, Scanco medical) with a 
voxel size of 36 µm. Samples were evaluated at a threshold of 210, a filter 
width of 0.8 and filter support of 1.0 and analysed for bone volume and bone 
mineral density within the defect using the software supplied by the 
manufacturer of the µCT. For bone volume, the regions of interest were 
determined as external callus formation (external), bone formation within the 
scaffold (scaffold) and bone formation in the inner part of the scaffold 











Figure 9: For bone volume evaluation, three regions of interest were 
determined as external callus formation (external, 3), bone formation within 
the scaffold (scaffold, 1) and bone formation in the inner part of the scaffold 
(endosteal, 2).  
 
  68 
3.2.11. Histological analysis  
After biomechanical testing and microCT analyses, tibial bone specimens 
were trimmed to 8 cm length. For histological analysis, the mid-defect regions 
were sectioned in the transverse and sagittal plane. Half of the samples were 
used for paraffin sectioning. After decalcification in 15% EDTA for 6-8 weeks, 
the samples were embedded in paraffin and 5 µm cross sections used for 
histological/histomorphometry (H&E and Masson’s Trichrome stains 
respectively) and immunohistological analysis. The other half of the samples 
were used for undecalcified embedding in methylmethacrylate. Longitudinal 
and cross sections were performed with a thickness of 6 µm and stained with 
Safranin Orange/von Kossa and Movat’s pentachrome to identify new bone 
formation.  
 
3.2.12. Statistical analysis  
Statistical analyses for the biomechanical results and for the ct-scans 
(clinicalCT and microCT) were carried out using a two-tailed Mann-Whitney-
U-test (SPSS 16.0, SPSS Inc.) and p-values are adjusted according to 
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3.3. Results  
3.3.1. Cell Isolation and Differentiation 
Mesenchymal progenitor cells were obtained from the sheep undergoing 
experimental surgery via bone marrow aspiration from the iliac crest under 
general anaesthesia (Fig. 10 A). Total bone marrow cells were plated at a 
density of 1-2 x 107 cells/cm2 in complete medium and cultured until they 
were confluent (Fig. 10 C). Two weeks before implantation, the medium was 
changed to an osteogenic media to induce osteogenic differentiation. Within 
a few days, the cells showed a clear response to the osteogenic induction 
media by a pronounced morphological change. The cell morphology changed 
from an elongated shape to a compact cobblestone-like appearance (Fig. 
11). The potential of bone marrow derived MPCs to secrete a mineralised 
extracellular matrix was analysed by alizarin red staining. After 2 weeks of 
induction, cultured MPCs had formed extensive amounts of alizarin red-


































Figure 10: Light microscopy images of the culture of mesenchymal stem 
cells (A) 3 days, (B) 7 days, and (C) after 14 days, (scale bar = 100 µm).  
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Figure 11: The cells typically have an elongated shape in regular media (A), 
this changed to a compact cobblestone-like appearance within days of being 













Figure 12: Alizarin red staining of mineral deposits for MPC cultures after 14 
days on 6-well plates. Under osteogenic conditions (osteogenic), MPC’s 
secrete an alizarin-red stained mineralized matrix. The control cultures 
(control) stained negative. 
 
3.3.2. Animal Surgery 
In all animals, no postoperative infections or other complications were 
observed. The chosen 4.5 mm broad DCP was proven to be biomechanically 
sufficient to prevent implant failure. All animals were in good health and 
survived the experimental period gaining weight in the months following 
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surgery. In particular, the animals of the allogenic group showed no clinical 
signs of implant rejection. 
3.3.3. Blood analyses 
Venous blood samples were taken preoperative and on day 1, 3, 7, 14, 21 
after the operation from all the animals of the allogenic group and some 
animals of the autologous group as a control value. The blood analyses 
showed no signs of graft rejection. Preoperatively, the result of the white cell 
count (WCC) in the allogenic group were slightly higher compared to the 
autologous group, and did not increase more than the autologous group after 














Figure 13: White cell count (WCC) of venous blood samples of animals of 
the autologous (dark blue) and allogenic (light blue) experimental groups. No 
significant differences were found between the groups.  
 
3.3.4. Radiographic analysis  
Immediately after surgery, after 6 and 12 weeks, conventional x-ray analyses 
in two standard planes (anterior-posterior and medial-lateral) were performed 
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to assess bone formation. After surgery, the correct position of the scaffold, 
the plate and the screws were confirmed. The x-ray analysis after 12 weeks 
showed no loosening of the implants or movement of the scaffolds in all 
experimental groups. External callus and bone formation within the defect 
was observed in all animals of the autologous and the allogenic cell group 
(Fig. 14 B/C). But a complete bridging of the defect was only observed in one 
animal of the allogenic group and two animals of the autologous group. The 
groups treated with mPCL-TCP scaffold (A) showed no radiographic signs of 
bone formation within the defect. The defect treated with autologous bone 
graft (ABG) showed clear radiographic signs of bone formation with defect 
















Figure 14: Representative x-ray images of the experimental groups after 3 
months. The groups treated with the scaffold only (A) showed no bone 
formation within the defect after 3 months. The defects reconstructed with 
mPCL-TCP scaffolds seeded with autologous MPC’s (B) and with allogenic 
MPC’s (C) show clear radiographic signs of a beginning defect bridging in 
both cell groups (white arrow) on the site of the vascular bundle (enhanced 
vascularity). The defect treated with autologous bone graft (ABG) showed the 
highest amount of bone formation in the defect with clear radiographic signs 
of defect bridging (D).  
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3.3.5. Computed tomography (clinicalCT) 
Qualitative CT analysis after 12 weeks showed bone formation within the 
defect in both experimental groups (Fig. 15). In two animals of the autologous 
cell group and in one animal of the allogenic cell group a defect bridging had 
occurred, which was on the posterolateral side. The results were additionally 
compared with the experimental groups of previous experiments of our 
group. Minor bone formation was seen in the mPCL-TPC scaffold group 
(negative control group), whereas a full defect bridging had occurred in all 
defects reconstructed with ABG (positive control group). No radiographic 
signs of inflammation (e.g. diffusely delimited soft tissue infiltrations, 
osteolysis, osteomyelitis, abscesses) were found. Scaffolds showed good 
osseointegration without any signs of resorption.  
Median values of total bone volume (BV) in the defect were higher in the 
allogenic cell group compared to the autologous cell group (Fig. 16). 
Furthermore, both cell groups showed a higher total bone volume compared 
to the scaffold only group. All the differences were not significant. In the 
cortical region (region 1) both cell groups showed a higher bone formation 
compared to the scaffold only group. Bone formation in the ABG group was 
calculated to be significantly higher when compared to the scaffold only 
group. Bone formation in region 2, the marrow region, was calculated to be 
significantly higher in the ABG group when compared to all other groups. In 
contrast to the total bone volume, the external bone formation (region 3) was 
higher in both cell groups and the scaffold only group than in the ABG group 
(Fig. 17). 
 










Figure 15: Representative 3D CT data reconstructions (AMIRA 5.2.2) after 
12 weeks of critical segmental bone defects, which were treated with an 
mPCL-TCP scaffold seeded with autologous MPC’s (A) and an mPCL-TCP 
scaffold seeded with allogenic MPC’s (B). A 3D reconstruction with a 
threshold of 300 combined with a 2D reconstruction using a lower threshold 
to show the soft tissue and the scaffold showed a similar bone formation 













Figure 16: Box plot demonstrating the median ± 1st and 3rd quartile. The 
figure illustrates the total bone volume (BV) after 12 weeks. Error bars 
represent minimum and maximum values. The cell groups showed more 
bone formation compared to the scaffold only group.  
 























Figure 17: Box plot (the median ± 1st and 3rd quartile) demonstrating the 
bone volume formed within the three regions of interest, the cortical region 
(region 1), the bone marrow region (region 2), and the external region (region 
3) after 12 weeks. Error bars represent minimum and maximum values. 
Asterisks indicate statistical significance. Bone formation in region 2, the 
marrow region, was calculated to be significantly higher in the ABG group 
when compare to all other groups. 
 
3.3.6. Biomechanical testing 
Biomechanical testing was performed on all the specimens from the cell 
groups and compared with the results from previous experiments of our 
group78 (Fig. 18-23). Biomechanical testing revealed an equal torsional 
stiffness (TS) for the autologous and the allogenic cell groups and slightly 
higher values for the torsional moment (TM) for the autologous group. Both 
cell groups showed a higher torsional moment, but a comparable torsional 
stiffness compared with the scaffold only group. The samples of the ABG 
group showed the highest values for torsional moment and torsional stiffness, 
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but they reached just about 15 to 20%, when compared to the contralateral 
non-operated side. No significant differences were found between all the 












Figure 18: The torsional stiffness of the operated tibiae were calculated from 
the slope of the torque-angular displacement curves. The ultimate torsional 













Figure 19: The torsional stiffness of the contralateral tibiae were calculated 
from the slope of the torque-angular displacement curves. The ultimate 
torsional moment was the peak value of the curve.  





















Figure 20: Results of the biomechanical testing (torsional moment) after 3 
months. Box plots demonstrating median values ± 1st and 3rd quartile of 





















Figure 21: Results of the biomechanical testing (torsional moment) after 3 
months. Box plots demonstrating median values ± 1st and 3rd quartile of 
torsional moment in relation to the contralateral tibia. Error bars represent 
maximum and minimum values. Asterisks indicate statistical significance. 























Figure 22: Results of the biomechanical testing (torsional stiffness) after 3 
months. Box plots demonstrating median values ± 1st and 3rd quartile of 






















Figure 23: Results of the biomechanical testing (torsional stiffness) after 3 
months. Box plots demonstrating median values ± 1st and 3rd quartile of 
torsional stiffness in relation to the contralateral tibia. Error bars represent 
maximum and minimum values. Asterisks indicate statistical significance. 
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3.3.7. Computed tomography (microCT) 
MicroCT analysis confirmed the trend of the results from the clinical CT scan 
regarding union rates and the amount of new bone formation. The 
differences in the absolute values were caused by the different scanning 
resolution of both methods. In the 3D reconstructions, both cell groups 
showed new bone formation mainly at the opposite site of the plate (Fig. 24 
A/B). The 2D reconstruction showed additionally bone formation within the 
scaffold (Fig. 24 C/D). In both cell groups, the mean values of newly formed 
bone were higher compared to the scaffold only group. Highest median 
values of newly formed bone were found for the ABG group, which were 
significantly higher when compared to the scaffold only group, but without 
significant differences compared to both cell groups (Fig. 25). In all samples, 
newly formed bone was still less compared to the amounts determined for 
the same anatomic level of the contralateral hind limbs (Fig. 26). The amount 
of new bone was evenly distributed throughout the proximal, middle and 
distal third of the defect although a tendency towards higher amounts in the 
proximal defect third was observed (Fig. 27). The mineral density of the 
newly formed, woven bone or tissue was found to be homogenous in the 
different experimental groups. Notably, tissue mineral density values were 
significantly lower than those determined for the compact bone of the 
















Figure 24: Representative 3D reconstructions and 2D sections of mircoCT 
scans of 3 cm tibial defects 12 weeks after surgery of the autologous cell 

















Figure 25: Box plot demonstrating median amounts of newly formed bone ± 
1st and 3rd quartile within the 3 cm defects 12 weeks after surgery. Error 















Figure 26: The blue box plots are demonstrating median amounts of newly 
formed bone ± 1st and 3rd quartile 12 weeks after surgery of the operated 
site, in contrast to the same anatomic level of the contralateral hind limbs. 
Error bars represent maximum and minimum values. Bars with asterisks 











Figure 27: Box plot demonstrating the distribution of newly formed bone in 
mm3 divided in three equal parts (proximal, middle, distal) of regenerated 
defects. A tendency towards higher amounts of bone in the proximal defect 
third was observed throughout the different experimental groups.  












Figure 28: Box plot demonstrating median values for tissue mineral density 
within the defects ± 1st and 3rd quartile 12 weeks after surgery. Tissue 
density did not differ significantly between the experimental groups. Tissue 
density in the defect zones was however only about 70% of that determined 
for the compact bone of the contralateral limb. Error bars represent maximum 
and minimum values. 
 
3.3.8. Histology/Immunohistochemistry 
The macroscopic overview of the implanted scaffolds before processing for 
histology showed a good integration of the scaffold to the host bone in all 
animals (Fig. 29 A). The mPCL-TCP scaffold was still in place and had not 
resorbed. Histological examinations of decalcified samples were performed 
after 12 weeks. Representative H&E staining of both cell groups 
demonstrated a good integration of the scaffold to the host bone on the 
proximal as well as the distal side (Fig. 29 B, C, F, G). Notably, new bone 
formation was seen in many pores within the mPCL-TCP scaffolds in both 
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cell groups (the scaffold itself is revealed in the histology slices as empty 
circular “holes”  and “bars” where the scaffold struts used to reside, due to 
the dissolution of the mPCL implant by xylene during processing) (Fig. 29 B-
G).   
Undecalcified sections (MMA resin) were stained with von Kossa/McNeal’s to 
identify new mineral deposition. Both cell groups showed mineral deposition 
(black stain) within the defect (Fig. 30 B, G). These results confirm our 
microCT and clinicalCT evaluation and demonstrate a limited amount of bone 
tissue growing into the whole scaffold area. Furthermore, the large overview 
pictures of the Goldner’s Trichrome staining demonstrate the presence of 
collagen fibres in the scaffold and surroundings (Fig. 30 A, F). New bone 
formation is traditionally accompanied by the expression of bone specific 
proteins within the extracellular matrix surrounding the osteoblasts, this may 
be detected using immunohistochemistry. As an early non-specific marker of 
osteoblastic differentiation during mineralisation, type I collagen showed a 
similar intensity in both cell groups (Fig. 30 D, I). Immunohistochemical 
staining for osteocalcin also demonstrated similar expression levels with a 
high expression of this late osteogenic marker localised around the scaffolds 
struts (labelled “s”) (Fig. 30 E, K). The staining to detect the BrdU labelled 























Figure 29: Macroscopic overview of the scaffold/cell constructs within the 
defect after explantation after 12 weeks (A). Representative H&E staining of 
both cell groups of the proximal (B, C) (longitudinal sections), middle (D, E) 
(transverse sections) and distal (F, G) (longitudinal sections) parts of the 
defect showed a good integration of the scaffold (S) as well as a good 
bonding of the regenerated bone to the host bone (HB), (B-G; bar=0.5cm). 
The solvents used during the preparation of the histological sections resulted 
in the mPCL–TCP scaffold material being dissolved during embedding. 
Hence mPCL–TCP struts (S) are represented in histological sections as 






































































Figure 30: Overview pictures of the undecalcified resin-embedded samples 
after 12 weeks, sectioned and stained with von Kossa/McNeal’s (B, G; 
bar=0,5cm) and Goldner’s Trichrome (A, F) demonstrated the mineralized 
tissue within collagen fibres (black arrows). Decalcified samples were stained 
with H&E (C, H), collagen type I antibody (D, I) and osteocalcin antibody (E, 
K); (bar in C-E, H-K=100µm). Representative stainings of both cell groups 
showed a good integration of the scaffold (scaffold strut labelled s) as well as 
a good bonding of the regenerated bone (NB) to the host bone (HB)(black 
arrows in E, H, I and K). The solvents used during the preparation of the 
histological sections resulted in the mPCL–TCP scaffold material being 
dissolved during embedding. Hence mPCL–TCP struts (S) are represented in 
histological sections as voids of similar geometry. 
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3.4. Discussion 
Given the demographic challenge of an ageing population, the development 
of strategies to exploit the potential of stem and progenitor cells to augment 
bone formation to replace or restore the function of traumatized, diseased, or 
degenerated bone is a major clinical and socioeconomic need.  
 
The use of allogenic cells for clinical therapy is already established and in 
routine use in other areas of medicine such as oncology and a large number 
of clinical trials are currently performed in cardiology268,269. These studies 
suggested that hMSCs could be used therapeuticly as allogeneic, “universal 
cells.” To support this suggestion, it has been further documented that 
culture-expanded hMSCs do not have MHC class I cell surface markers, but 
rather only MHC class II and no co-stimulator molecules270. Thus, hMSCs 
cannot be antigen-presenting cells and should be imperceptible to the host’s 
immune system. It is important to note that in all of the clinical usages of 
human adult marrow-derived, culture-expanded MSCs, whether autologous 
or allogeneic, no adverse events have been recorded271. 
 
The results of this study demonstrated the positive effect of allogenic bone 
marrow-derived mesenchymal progenitor cells (MPC’s) on scaffold-based 
bone regeneration. In addition to their osteogenic potential, it has been 
shown that MPCs are immunologically privileged making them highly 
appropriate for the use in allogenic cell transplantation concepts, and indeed 
we observed no immune response in a preclinical animal model. 
Furthermore, Niemeyer et al. demonstrated that MPC retain their 
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immunological properties after osteogenic induction in vitro272. The allogenic 
application of MPCs showed similar results for bone regeneration compared 
to the autologous cell group, with all the advantage of an allogenic cell 
source (easy to access and high abundance compared to autologous cells). 
Our results are in line with observations from Guo et al. who described that 
allogenic mesenchymal progenitor cells raised a minimal immunological 
reaction only in the early stages after implantation in a study in mini-pigs273. 
After the transplantation, the sheep were monitored by clinical examination 
and taking blood samples. We did not observe any general foreign body 
reaction or cell rejection or any different cellular reactions compared to the 
autologous group in the histological assessment throughout the defect, which 
demonstrated, once more, the low immunological activity of allogenic bone 
marrow derived cells. While the limited availability and the donor site 
morbidity of autologous bone grafts is often discussed and stated as a major 
disadvantage of this technique, the use of an allogenic cell source with 
comparable regeneration potential as a potential off-the-shelf-product would 
open new routine therapeutic potentials for regeneration of large bone 
defects274,275.  
Niemeyer et al. used human MPCs to assess bone regeneration in a critical 
sized defect of the sheep tibia and compared the regenerative potential with 
autologous ovine MPCs276. The autologous MPCs demonstrated better bone 
formation compared to the human MPCs and unloaded matrices in the 
histological and radiological evaluation. However, the bone regeneration was 
evaluated based on two dimensional imaging procedures and the study 
lacked any biomechanical testing, which would provide a greater depth of 
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understanding of the characteristics and functionality of the regenerated 
bone. Field et al. evaluated the efficacy of allogenic mesenchymal progenitor 
cells for the repair of an ovine tibial segmental defect262. They reported a 
higher osteogenic regeneration potential of the allogenic group compared to 
the scaffold only group with better biomechanical properties and more bone 
formation. But, studies by Field et al. and Niemeyer et al. used different 
fixation methods (double plate vs. intramedullary nail) and different 
experimental protocols, which renders direct comparison of these findings 
difficult. Using a medullary nail for example will result in blocking the 
medullary cavity of the tibia, which might reduce the regeneration potential in 
this area. Furthermore, different fixation methods result in different 
biomechanical impacts, such as more flexibility and a central loading (nail) 
compared to a much stiffer double plate fixation. Our biomechanical analysis 
of the DCP-plate fixation showed, under static loading conditions of up to 500 
N, a minimal displacement of the scaffold of less than 1%. Conclusively, the 
DCP results in a stable fixation. From an ethical as well as an economical 
point of view, it would be desirable to be able to directly compare the 
potential of different tissue engineering strategies to lower the costs and the 
number of animals and to realise the translation of novel concepts from 
research to clinical practice. Therefore, the bone tissue engineering 
community should advocate the combination of radiological, biomechanical, 
histological and immunhistochemical evaluations as necessary 
methodologies for an efficient and robust analysis of bone engineering 
strategies277.   
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As bone tissue engineering has become ever more prevalent over recent 
years, evaluating the different strategies with respect to potential clinical 
application in humans requires in vitro testing and small animal models and 
importantly, in the final stages, the use of standardised large animal models 
which are imperative for rigorous preclinical evaluation278. Thus, large 
preclinical animal models with comparable body weight, long bone 
dimensions, similar mineral composition, equivalent remodelling rates as well 
as established and standardised evaluation processes are essential to make 
sufficient predictions about the potential clinical success or failure of new 
bone tissue engineering strategies76,77. Over the last decade, the sheep has 
become a very important and useful model to address research problems 
and holds specific advantages compared to other large animal models (e.g. 
pig, dog) such as long bone dimensions, ease of handling, non aggression 
nature, and the ability to keep them in large numbers at relatively low costs. 
However, it is important to note that secondary bone remodelling is only seen 
in older sheep making them comparable to human bones279.  
Our group has established an ovine critical-sized segmental tibial defect 
model to address different bone tissue engineering approaches by testing 
combinations of growth factors, scaffolds and different cell types77,266. 
Compared to studies by other groups, this current model is a particularly 
challenging model using older sheep which are on the one hand more 
relevant to human bone but on the other hand have a lower general health 
status compared to younger animals. Some other groups only resect the 
periosteum on the proximal and the distal bone, however, we have shown in 
a preliminary study, that the periosteum on the dorsal side between the tibia 
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and the muscles which is closed to the vascular bundle (see back arrow Fig. 
4F) contains a significant regeneration potential based on the MPCs from the 
cambium layer266. To our knowledge, we are the first group who developed a 
large segmental tibial defect model, which also includes the removal of this 
part of the periosteum, which represents 30-40% of the whole volume of the 
periosteum within the defect. As a result of the complete removal of the 
periosteum and the age-related compromised regenerative capacity, it is not 
surprising that we revealed lower biomechanical stability (TM 10-15% and TS 
20-25% of contralateral tibia) after three months even in the ABG group 
compared to other research groups who even present significantly higher 
results in their control groups280,281. This demonstrates once again the 
importance of standardised large animal models with validated experimental 
protocols to compare outcomes of each different bone engineering approach. 
This is a condition sine qua non to move concepts from bench to bedside. 
The present study showed effectively that allogenic MPCs can be safely used 
in combination with a mPCL-TCP scaffold for bone regeneration in a critical 
sized bone defect in a sheep model. None of the animals of the study 
showed a rejection of the TECs or a foreign body reaction in form of a fibrous 
encapsulation. The allogenic and the autologous cell groups showed 
comparable results with respect to biomechanical properties and new bone 
formation. The biomechanical evaluation showed a small difference between 
the cell groups and the scaffold-only group, whereas the bone volume 
analysis using clinicalCT and microCT showed larger differences between 
these groups. This is likely due to the short time frame (three months) we 
chose for our experiment to terminate. We detected more bone volume in 
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both cell groups compared to the empty scaffold groups, which demonstrated 
that autologous as well as allogenic cell transplantation leads to enhanced 
bone formation in a critical sized segmental defect model. But within the 
three months time period, the bone regeneration was still in its early progress 
phase and most of the defects were not completely bridged which resulted in 
low biomechanical test results. Most other studies using a critical sized 
segmental tibial defect in a large animal had longer time frames for their 
experiments, which logically resulted in more bone formation and higher 
biomechanical stability262. As we were specifically interested in considering 
the immune response and the safety of delivering allogenic MPCs at this 
stage of our research we intentionally chose an early time point. 
A common practice to improve the biological competence of osteoconductive 
scaffolds is via incorporation of osteogenic stimuli such as bone 
morphogenetic proteins (BMP) and/or vascular endothelial growth factor 
(VEGF) and platelet derived growth factor (PDGF). Platelet rich plasma 
(PRP) consists of several growth factors including significant amounts of 
VEGF and PDGF and has been in clinical use for many years in the dental 
surgery field. However the benefits of PRP are still ambiguous regarding 
large bone defect regeneration in orthopaedics, whereas the positive effect of 
BMPs for bone regeneration has been shown extensively in several small 
and large animal models as well as in the clinic89,93-96.  
Because of the similarity to clinically used fibrin glue, PRP converts from a 
liquid state into a fibrin hydrogel in the solid state after being activated by 
thrombin and therefore it is used in several studies as a highly biocompatible 
cell-loading vehicle97. We could demonstrate that the scaffold-PRP construct 
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used in our study for large bone defects didn’t have significant effects 
regarding bone regeneration when compared to the scaffold only group 
(unpublished data). But it can be used as a very effective cell delivery vehicle 
in a scaffold design with a channel-like architecture with large pores and 
large pore interconnections which allow full vascularization in a 3 cm 
segmental bone defect. 
The evaluation of the bone volume using both clinical- and micro-CT 
scanning showed slight differences in the raw data (absolute values) due to 
the different resolutions as well as the different phantoms used for 
calibration; however the trend was the same. The experimental groups all 
showed a comparable tendency with respect to the contralateral tibia of the 
animals (Fig. 7 F). Keeping in mind the concept of translational research 
which might result in a later clinical application, the assessment of the 
correlation between clinicalCT scanning and microCT scanning becomes 
important, especially for future interpretation of clinicalCT scanning results 
from large bone defects in humans, as these may be directly related to the 
CT-results of the large animal studies. Beside the CT-scanning, which is 
essential for the 3D-reconstruction overview and analysis of the bone 
volumes, the histological evaluation plays an important role for a detailed 
evaluation on a cell-based level. Therefore, both evaluation methods (CT-
scanning and histology) are absolutely required to perform a reliable study to 
analyse different tissue engineering approaches for bone regeneration.  
The use of cell-based tissue engineering strategies is often compromised 
due to a low survival rate off the implanted cells. To prove the effect of the 
transplanted cells, different labelling methods are available to demonstrate 
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the survival of the transplanted cells at the end of the experiment282. Among 
these, BrdU-labelling is a straightforward method of cell labelling showing 
good results in small animal models. However, despite the potential shown 
using small animal models, we were not able to detect any BrdU-labelled 
cells in the large bone defect model283. This may be due to labelling the cells 
in passage 1 and using the cells of passage 3-4 for the in vivo experiments, 
because of the high amount of cells required for the experiment, hence the 
proliferation of the cells may have led to a loss of signal. Li et al. reported a 
decreasing of the labelling signal of BrdU over time, describing that the 
percentage of BrdU-positive cells decreased from 94% in passage 0 down to 
18% in passage 2282. Therefore, for the use in large segmental bone defects 
such as our sheep model, another labelling method would be more 
appropriate to proof the survival of the cells284,285.  
Furthermore, a detailed and critical understanding of using allogenic cells for 
bone tissue engineering would be desirable, but can’t be easily achieved 
from a histological perspective when using ovine cells, because of a lack of 
specific ovine antibodies. These precise questions could be answered by 
using human cells in a xenogenic transplantation setting, but as Niemeyer et 
al. demonstrated, human MPCs led to reduced bone formation in a ovine 
defect model compared to the use of allogenic cells276.  
 
3.5. Conclusion 
Although MPCs can differentiate into various phenotypes of mature cells, 
their intrinsic capacity to secrete cytokines and growth factors at sites of 
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tissue injury and inflammation contribute significantly to their therapeutic 
capacity. We assume that the production of these trophic mediators is 
defined by their in vivo location, niche, and severity of injury. The present 
study showed promising data using an allogenic compared to autologous cell 
source for regeneration of critical sized segmental bone defects in a large 
animal model. The use of allogenic or autologous cells combined with an 
mPCL-TCP scaffold showed no differences in their bone regeneration 
potential as demonstrated by radiological, histological and biomechanical 
results. We furthermore detected no adverse immunological response. In the 
future, the successful translation of allogenic cell transplantation into clinical 
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Chapter IV – Assessment of the regenerative 
potential of allogenic osteoblasts versus 
allogenic mesenchymal progenitor cells in the 
reconstruction of ovine critical sized segmental 
tibial bone defects  
 
4.1. Introduction 
Mesenchymal progenitor cells (MPCs) and osteoblast cells (OB) have been 
considered in cell-based tissue engineering strategies. Osteoblast cells can 
be isolated from different bones of the axial skeleton261. Looking to the 
embryological development of the bones, there are differences between the 
bones of the axial skeleton and the orofacial bones286.   
In orofacial surgery, autologous bone grafts used to stimulate new bone 
formation at sites of orofacial osseous defects are commonly obtained from 
several donor sites including orofacial, axial and appendicular bones. 
Bridging orofacial defects with grafts obtained from an orofacial donor sites 
are usually more successful than those from non-orofacial sites, indicating 
anatomic skeletal site-specific differences affecting graft integration287,288. 
This clinical observation, along with the fact that many bone abnormalities 
(such as cherubism289 and hyperparathyroid jaw tumor syndrome290) are 
limited to craniofacial bones, suggests that there are differences in bone 
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metabolism in orofacial and axial bones. These differences should be 
dictated by site-specificity of embryological progenitor cells and osteogenic 
properties of resident multipotent bone marrow stromal cells. The 
embryological development of the complex array of bones and cartilage in 
the craniofacial skeleton are different from those occurring in other body 
sites291.  
The orofacial bones are formed exclusively by neural crest cells, while axial 
bones are formed by mesoderm292. Neither chondrocytes nor osteocytes, 
however, are unique to neural crest cells; both skeletal cell types also arise 
from the mesodermal cells, which form the axial, appendicular and rib 
skeleton. Neural crest cells are marked by expression of a number of genes, 
including members of the MSX, slug/snail, Zic, Pax-3/7, and the Distalless 
gene family. The neural crest, and the subsequent development of the 
craniofacial skeleton, represents an important evolutionary innovation. These 
clinical, laboratory and developmental differences imply the existence of site-
specific properties of progenitor cells in bone marrow. Therefore, the cells 
isolated from these bones have different origins and ways of bone formation. 
Osteoblasts, isolated from orofacial bones form bone via intramembranous 
bone formation, whereas osteoblasts, isolated from axial bones form bone 
















Figure 31: Embryological development of the human skeleton. The orofacial 
bones are formed by ectoderm (blue), whereas the axial bones are formed by 
mesoderm (orange)(Figure from Wolpert et al.)278. 
During further in vitro experiments, our group detected significant differences 
in the osteogenic potential (production of extracellular matrix, bone volume, 
osteogenic differentiation) of osteoblasts from orofacial bones (mOB), 
osteoblasts from axial bones (tOB) and mesenchymal progenitor cells 
(MPC’s)294. We could demonstrate, that mesenchymal progenitor cells show 
a higher osteogenic potential in vitro compared to differentited cells 
(osteoblasts). Surprisingly, the in vivo experiments show a higher osteogenic 
potential of osteoblasts compared to mesenchymal progenitor cells in an 
ectopic setting, when transplanted subcutaneously in mice279.  
Cell-based strategies in tissue engineering approaches for bone tissue 
regeneration include implantation of cell-seeded three-dimensional scaffolds 
in the defect. These cells should have a high osteogenic regenerative 
potential. The supply of autologous mesenchymal progenitor cells and 
osteoblasts is often limited and the preoperative procedure for isolation, 
augmentation and differentiation is time consuming. But their special 
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immunological characteristics suggest that MPC’s could be used in non-
autologous applications257,258. Allogenic cell transplantation is a common 
therapeutic option and is in routine clinical use in the field of oncology263,264. 
In further in vitro experiments by our group, we found a similar expression of 
surface markers between mesenchymal stem cells and osteoblasts. Hence, a 
non-autologous use of both cell types should be possible278. Translating the 
idea of allogenic cell-transplantation from oncology to orthopaedics could 
offer a new opportunity for the availability of mesenchymal stem cells for 
regenerative medicine and a clinical application in orthopaedic and trauma 
surgery.  
The combination of different cells, biomaterials, and different kinds of growth 
factors and a combination thereof is a complex process with interdependent 
sets of variables. Therefore, the different developments must be monitored 
and tested consequently in vitro and in vivo before translating new treatment 
concepts into clinical practice.  
Based on the results of previous experiments, we hypothesized that 
osteoblasts (differentiated cells) show a higher osteogenic potential than 
mesenchymal progenitor cells in a scaffold-cell based bone tissue 
engineering concept for regeneration of a critical sized segmental defect in a 
large animal model. The aim of the current study was to assess and compare 
the regenerative potential of allogenic bone marrow mesenchymal progenitor 
cells (allogenic MPC’s) with allogenic osteoblasts isolated from axial bones 
(allogenic tOB’s – mesenchymal origin) and from orofacial bones (allogenic 
mOB’s – neurocrestal origin) in combination with a mPCL-TCP scaffold in a 
critically sized segmental bone defect in sheep tibiae.  
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4.2. Material and Methods 
4.2.1. Scaffold fabrication and preparation  
The scaffolds used in this study were the same as used in the previous 
studies. For detailed information about the scaffold fabrication and 
preparation please see chapter III, part 3.2. 
 
4.2.2. Animal study 
Thirty-two male sheep (40-50 kilogram, age 7-8 years) were used in this 
project (Table 6). An Animal Ethics Approval Certificate has been obtained. 
Animal surgery was performed at the QUT Medical Engineering Research 
Facility, The Prince Charles Hospital, Chermside. There were 8 animals in 
each group and all were euthanized after 6 months. 
 
The research 













mPCL-TCP  + 
allogenic tOB 
Total 8 8 8 8 
Table 6: The research plan with details of the animal treatment groups. The 
time duration of this experiment was 6 months.  
 
4.2.3. Preparation of platelet rich plasma  
The method to produce platelet rich plasma (PRP) was described in detail 
in the previous chapter. For detailed information please see chapter III, 
part 3.2.3.  
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4.2.4. Animal Surgery 
The anaesthetic procedures, the pre-operative treatment and the surgical 
procedures were already described in chapter III. For detailed information 
please see chapter III, part 3.2.4.  
 
4.2.5. Experimental Groups 
- Group I  
The empty scaffold (mPCL-TCP) was loaded with a mixture of 250 µl of basal 
medium and 1ml of PRP and then seeded onto each collagen type I coated 
mPCL-TCP scaffolds. PRP was activated with thrombin and the cell scaffold 
constructs were implanted into the defect site and the wound closed in layers 
around the autograft. 
 
- Group II 
Allogenic ovine mesenchymal progenitor cells (allogenic MPC) were obtained 
from Merino sheep that were not included in this study (allogenic cells). Bone 
marrow aspirates were obtained from the iliac crest under general 
anaesthesia. Total bone marrow cells (5-15 x 106 cells/ml) were plated at a 
density of 10-20 x 106 cells/cm2 in complete medium consisting of low 
glucose DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 
µg/ml streptomycin. Cells were subsequently plated at a density of 103 
cells/cm2. Two weeks before implantation, the medium was changed to an 
osteogenic media (DMEM, 10% FBS, 100 U/ml penicillin and 100 µg/ml 
  102 
streptomycin, 10 µl/ml ß-glycerophosphate, 1 µl/ml ascorbic acid and 1 µl/ml 
dexamethasone) to induce osteogenic differentiation. For 3D cultures, 35 x 
106 ovine MPC suspended in 250 µl of basal medium were mixed with 1ml of 
PRP and then seeded onto each collagen type I coated mPCL-TCP 
scaffolds. PRP was activated with thrombin and the cell scaffold constructs 
were implanted into the defect site and the wound closed in layers around the 
autograft.  
 
- Group III 
Alogenic ovine mandibular osteoblast (mOB) explants were obtained from 
Merino sheep that were not included in this study (allogenic cells). Compact 
bone samples were collected under sterile conditions from the mandibular 
under general anaesthesia with a special trephine drill (∅ 5mm), minced, 
washed with PBS and vortexed a minimum of 5 times. Bone samples were 
incubated with 10 ml 0.25% trypsin/EDTA for 3 min at 37°C, 5% CO2. After 
trypsin inactivation with 10 ml low glucose Dulbecco's Modified Eagle Media 
(DMEM) containing 10% fetal bovine serum (FBS), samples were washed 
once again with PBS and transferred to 175 cm2 tissue culture flasks. 
Samples were topped-up with 15 ml of DMEM containing 10% FBS and 1% 
penicillin/streptomycin. Outgrowth of osteoblasts was observed after 5-7 
days. Cells were expanded to the second or third passage for following 
experiments. Two weeks before implantation, the medium was changed to an 
osteogenic media (DMEM, 10% FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin, 10 µl/ml ß-glycerophosphate, 1 µl/ml ascorbic acid and 1 µl/ml 
dexamethasone) to induce osteogenic differentiation. For 3D cultures, 35 x 
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106 ovine mOB suspended in 250 µl of basal medium were mixed with 1ml of 
PRP and then seeded onto each collagen type I coated mPCL-TCP 
scaffolds. PRP was activated with thrombin and the cell scaffold constructs 
were implanted into the defect site and the wound closed in layers around the 
autograft.  
 
- Group IV 
Allogenic ovine tibial osteoblast (tOB) explants were obtained from Merino 
sheep that were not included in this study (allogenic cells). Compact bone 
samples were collected under sterile conditions from the tibia under general 
anaesthesia with a special trephine drill (∅ 5mm), minced, washed with PBS 
and vortexed a minimum of 5 times. Bone samples were incubated with 10 
ml 0.25% trypsin/EDTA for 3 min at 37°C, 5% CO2. After trypsin inactivation 
with 10 ml low glucose Dulbecco's Modified Eagle Media (DMEM) containing 
10% fetal bovine serum (FBS), samples were washed once again with PBS 
and transferred to 175 cm2 tissue culture flasks. Samples were topped-up 
with 15 ml of DMEM containing 10% FBS and 1% penicillin/streptomycin. 
Outgrowth of osteoblasts was observed after 5-7 days. Cells were expanded 
to the second or third passage for following experiments. Two weeks before 
implantation, the medium was changed to an osteogenic media (DMEM, 10% 
FBS, 100 U/ml penicillin and 100 µg/ml streptomycin, 10 µl/ml ß-
glycerophosphate, 1 µl/ml ascorbic acid and 1 µl/ml dexamethasone) to 
induce osteogenic differentiation. For 3D cultures, 35 x 106 ovine tOB 
suspended in 250 µl of basal medium were mixed with 1 ml of PRP and then 
seeded onto each collagen type I coated mPCL-TCP scaffolds. PRP was 
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activated with thrombin and the cell scaffold constructs were implanted into 
the defect site and the wound closed in layers around the autograft.  
 
4.2.6. Blood analysis 
All allogenic groups were monitored for six weeks after the procedure to 
assess any reaction to the implantation of the cells. Blood samples were 
taken from all animals of the allogenic group and from the animals of the 
scaffold only group as a control. Blood samples were taken on day 
1,3,7,14,21 after the operation. At the same time the sheep were physically 
examined. A final physical examination was performed 6 weeks after surgery.  
 
4.2.7. Radiography analysis  
Throughout the study, x-rays were taken at 3 and 6 months, to determine the 
bridging time of the defect in the different experimental groups. Conventional 
x-ray analysis (3.2 mAs; 65kV) was performed in two standard planes 
(anterior-posterior and medial-lateral). At euthanasia, the gross morphology 
and mobility at host-graft junctions was clinically assessed and the findings 
carefully documented and photographed.  
 
4.2.8. Biomechanical evaluation  
To determine the integration of the scaffolds into the bone and the recovery 
of the biomechanical function of the affected tibias, biomechanical testing 
was performed after 6 months. The detailed procedure of biomechanical 
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testing was already described in chapter III. For detailed information please 
see chapter III, part 3.2.9. 
 
4.2.9. Computed tomography (microCT) 
After mechanical testing, both tibias were fixed in 10% neutral buffered 
formalin (NBF) and micro-CT scans of the defect and the control side were 
performed. The detailed procedure of the microCT analysis was already 
described in chapter III. For detailed information please see chapter III, part 
3.2.10. 
 
4.2.10. Histological analysis  
After biomechanical testing and microCT analyses, tibial bone specimens 
were trimmed to 8 cm length and used for histological analysis. The detailed 
procedure of histological analysis was already described in chapter III. For 
detailed information please see chapter III, part 3.2.11. 
 
4.2.11. Statistical analysis  
Statistical analyses for the biomechanical results and for the ct-scans 
(microCT) were carried out using a two-tailed Mann-Whitney-U-test (SPSS 
16.0, SPSS Inc.) and p-values are adjusted according to Bonferroni-Holm. 
Results were considered significant for p-values <0.05. 
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4.3. Results  
4.3.1. Cell Isolation and Differentiation 
Osteoblasts (allogenic mOB and allogenic tOB) were obtained from the tibia 
and the mandible of sheep not included in this study. Compact bone samples 
were cultured in 15 ml of DMEM containing 10% FBS and 1% 
penicillin/streptomycin. Outgrowth of osteoblasts was observed after 5-7 days 
(Fig. 32). Cells were expanded to the second or third passage for following 
experiments.  
Mesenchymal progenitor cells (allogenic MPC) were obtained from the sheep 
not included in this study via bone marrow aspiration from the iliac crest 
under general anaesthesia. Total bone marrow cells were plated at a density 
of 1-2 x 107 cells/cm2 in complete medium and cultured until they were 
confluent. 
Two weeks before implantation, the medium was changed in all groups to an 
osteogenic media to induce osteogenic differentiation. Within a few days, the 
cells showed a clear response to the osteogenic induction media by a 
pronounced morphological change. The cell morphology changed from an 
elongated shape to a compact cobblestone-like appearance (Fig. 33). The 
potential of bone marrow derived MPCs and osteoblasts (mOB and tOB) to 
secrete a mineralised extracellular matrix was analysed by alizarin red 
staining. After 2 weeks of induction, all the cells had formed extensive 
amounts of alizarin red-positive mineral deposits throughout the adherent 
layers (Fig. 34). 
 






















Figure 32: Culture of osteoblasts in a culture flask after 1 day (A), 7 days (B), 
and after 14 days (C), (scale bar = 20 µm). Outgrowth of osteoblasts was 












Figure 33: The cells typically have an elongated shape in regular media (A), 
this changed to a compact cobblestone-like appearance within days of being 












Figure 34: Alizarin red staining for MPC, mOB and tOB cultures after 14 
days on 6-well plates. Under osteogenic conditions (osteogenic), all the cells 
secrete an alizarin-red stained mineralized matrix. The control cultures 
(control) stained negative. 
 
4.3.2. Animal Surgery 
In all animals, no postoperative infections or other complications were 
observed. The chosen 4.5 mm broad DCP was proven to be biomechanically 
sufficient to prevent implant failure. All animals were in good health and 
survived the experimental period gaining weight in the months following 
          MPC       mOB              tOB 
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surgery. In particular, the animals of the allogenic groups showed no clinical 
signs of implant rejection. 
 
4.3.3. Blood analyses 
Venous blood samples were taken preoperative and on days 1, 3, 7, 14, 21 
after the operation from all the animals of the allogenic group and of the 
autologous group as a control value. The blood samples were analysed to 
investigate the changing white cell count (WCC) after transplantation. The 
blood analyses of all animals showed no signs of graft rejection.  
 
4.3.4. Radiographic analysis  
Immediately after surgery and at 3 and 6 months post-operative, 
conventional x-ray analyses in two standard planes (anterior-posterior and 
medial-lateral) were performed to assess bone formation. After surgery, the 
correct position of the scaffold, the plate and the screws was confirmed. After 
3 months, some bone formation was observed starting from the dorsal part of 
the tibia where the defect is covered by the large muscle of the lower leg. 
The x-ray analysis after 6 months showed no loosening of the implants or 
movement of the scaffolds. External callus and bone formation within the 
defect was observed in all animals of the cell groups (Fig. 35 B-D). But no 
animal of the cell groups showed a complete bridging of the defect. The 
animals of group I (scaffold and PRP group) showed less bone formation in 
the defect compared to the cell groups.  
 








Figure 35: Representative x-ray images after 6 months of a defect 
reconstructed with a mPCL-TCP scaffold and PRP (A), a mPCL-TCP scaffold 
seeded with allogenic MPCs (B), a mPCL-TCP scaffold seeded with allogenic 
mOB (C) and a mPCL-TCP scaffold seeded with allogenic tOBs (D). The 
images show radiographic signs of bone formation within the defect in all cell 
groups. 
 
4.3.5. Biomechanical testing 
Biomechanical testing was performed on all specimens after 6 months. 
Biomechanical testing revealed an equal torsional stiffness (TS) for both 
osteoblast groups and the PRP group and slightly higher values for the MPC 
group (Fig. 36). The allogenic MPC group showed a higher torsional moment 
compared to the other cell groups and the PRP group (Fig. 37). For torsional 
stiffness and torsional moment the group with allogenic MPC showed the 
highest results and the PRP group the lowest results. But, no significant 



























Figure 36: Results of the biomechanical testing after 6 months. Box plots 
demonstrating median values ± 1st and 3rd quartile of torsional stiffness in all 






















Figure 37: Results of the biomechanical testing after 6 months. Box plots 
demonstrating median values ± 1st and 3rd quartile of torsional moment of 
the experimental groups. Error bars represent maximum and minimum 
values.  
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4.3.6. Computed tomography (microCT) 
MicroCT analysis confirmed the trend of the results from the conventional x-
ray analysis regarding union rates and the amount of new bone formation. In 
the 3D reconstructions, all cell groups showed small amounts of new bone 
formation in the defect, mainly at the opposite site of the plate (Fig. 38). The 
mean values of newly formed bone in the MPC group was higher compared 
to the osteoblast groups and the PRP group (Fig. 39). The two osteoblast 
groups showed the lowest median values of newly formed bone. In all 
samples, newly formed bone was still less compared to the amounts 
determined for the same anatomic level of the contralateral hind limbs.  
The new bone was distributed throughout the external, scaffold and 
endosteal area of the defect with the highest amount of newly formed bone in 








Figure 38: Representative 3D reconstructions of mircoCT scans of 3 cm 
tibial defects 6 months after surgery of the PRP-Group (A), the allogenic 






















Figure 39: Results of the microCT scanning after 6 months. Box plot 
demonstrating median amounts of newly formed bone ± 1st and 3rd quartile 
within the 3 cm defects 6 months after surgery. Error bars represent 
























Figure 40: Results of the microCT scanning after 6 months. The amount of 
bone volume within the defect was distributed to the area outside the scaffold 
(external), the area within the scaffold (scaffold) and the inner part of the 
scaffold (endosteal). Box plots are demonstrating median amounts of newly 
formed bone ± 1st and 3rd quartile 6 months after surgery of the operated 
site. Error bars represent maximum and minimum values.  
 
4.3.7. Histology/Immunohistochemistry 
The macroscopic overview of the implanted scaffolds before processing for 
histology showed good integration of the scaffold with the host bone in all 
animals of all experimental groups. The mPCL-TCP scaffold was still in place 
and had not been resorbed. Histological examinations of decalcified samples 
were performed after 12 weeks. Representative H&E staining of all 
experimental groups demonstrated a good integration of the scaffold to the 
host bone on the proximal as well as the distal side (Fig. 41 A, C, E, G). 
Notably, new bone formation was seen in many pores within the mPCL-TCP 
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scaffolds in all cell groups as well as the PRP group (the scaffold itself is 
revealed in the histology slices as empty circular “holes” and “bars” where the 
scaffold struts used to reside, due to the dissolution of the mPCL implant by 
xylene during processing) (Fig. 41 B, D, F, H).   
These results confirm our microCT evaluation and demonstrate a limited 
amount of bone tissue growing into the whole scaffold area in all the cell 










Figure 41: Representative H&E staining of all experimental groups after 6 
months. The proximal parts of the defect showed a good integration of the 
scaffold as well as a good bonding of the regenerated bone to the host bone 
(A, C, E, G; bar=0.5cm). The solvents used during the preparation of the 
histological sections resulted in the mPCL–TCP scaffold material being 
dissolved during embedding. Hence mPCL–TCP struts are represented in 
histological sections as empty “holes” of similar geometry. All experimental 




Bone regeneration and fracture healing in the field of orofacial surgery is 
indistinguishable to the axial skeleton. On both injury sites, the regeneration 
  116 
process goes through the same stages, however several in vitro and in vivo 
experiments showed differences in the repair mechanism of these cells. 
Leucht et al. showed that cells isolated from orofacial bones respond to local 
cues, adopt their Hox status of their new locale, and robustly contribute to the 
formation of bony regeneration295. In contrast, cells isolated from the axial 
skeleton maintain their Hox status when transplanted to an orofacial bone 
defect with a resulting disruption in bone regeneration. Furthermore, Akintoye 
et al. found in their experiments the existence of skeletal site properties of 
orofacial cells and axial cells based on their different embryological origins296.  
 
Cells used in our experiments were isolated from orofacial bones (mOB), 
from axial bones (tOB) and from the iliac crest (MPC). While finding clear 
differences in the osteogenic potential of osteoblasts and mesenchymal 
progenitor cells in further in vitro and in vivo experiments, we were not able to 
detect any differences in their bone regenerative potential in a critical sized 
tibial bone defect in a large animal model.  
 
The use of allogenic cells for clinical therapy is already established and in 
routine use in other areas of medicine and shows several advantages 
compared to the use of autologous cells 268,269.  In further in vitro experiments 
by our group, we found a similar expression of surface markers between 
mesenchymal stem cells and osteoblasts. Both cell populations were 
negative for the haematopoietic surface markers CD 45 and CD 31 and 
positive for CD 29 and CD 44283.  
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Hence, a non-autologous use of all cell types was performed to have all the 
positive effects of allogenic cell transplantation. The results of our study 
demonstrate, that allogenic cell transplantation of mesenchymal progenitor 
cells and differentiated cells (mOB and tOB) is a safe method without 
showing any signs of immunological reaction.  
We were able to demonstrate clear advantages in the use of differentiated 
cells for bone regeneration in a small animal model. The results of the small 
animal model study could not be confirmed in our large animal study. We 
were unable to see any differences in the regenerative potential of 
mesenchymal progenitor cells compared to the application of differentiated 
cells (osteoblast; mB and tOB) regarding the bone volume within the defect 
or the biomechanical properties. All the cell based tissue engineering 
approaches in our study showed similar results compared to the cell-free 
approaches (Scaffold and PRP). No beneficial effect of the cells could be 
demonstrated.  
This demonstrates once again the importance of standardised large animal 
models with validated experimental protocols to compare outcomes of each 
different bone engineering approach. Results gained from in vitro 
experiments or small animal models can’t be transferred to the clinical 
setting. New tissue engineering approaches need to be tested in large animal 
models to generate advanced information about the procedures and to make 
the decision to move to a clinical study.  
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4.5. Conclusion 
The present study showed that the use of allogenic differentiated cells in 
orthopaedics for bone regeneration is a safe method for a cell based tissue-
engineering approach. We detected no adverse immunological response. 
But, we were not able to show a positive effect of the cells on bone 
regeneration in a large animal model compared to the cell-free approach. 
Therefore, the cell-based tissue engineering approaches for large bone 
defect regeneration still needs further optimisation before translating these 
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Chapter V – New concepts in bone tissue 
engineering - Delayed Injection of allogenic 
mesenchymal progenitor cells for the 
reconstruction of large bone defects 
 
5.1. Introduction 
Cell based tissue engineering approaches are common concepts for bone 
regeneration in the area of regenerative medicine. Several experts 
demonstrate promising results in vitro as well as in small animal models.  
Autologous and allogenic mesenchymal progenitor cells (MPCs) have been 
injected into tissue sites or infused into the blood stream and have been 
observed to congregate to tissue sites of injury involving broken or inflamed 
blood vessels such as an acute myocardial infarct, stroke, spinal cord injury, 
lung- and pulmonary disease, burns and wound healing. Experiments from 
different groups indicate that BMSCs secrete numerous cytokines and 
chemokines well known to be important to stimulate and achieve wound 
healing, such as vascular endothelial growth factor alpha (VEGF alpha), 
epidermal growth factor-alpha (EGF alpha), insulin growth factor-1 (IGF1), 
keratinocyte growth factor (KGF), angiopoietin-1 (Ang1), stromal derived 
factor-1 (SDF1), macrophage inflammatory protein-1 alpha and beta (MIP1 
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alpha and beta), and erythropoietin in greater amounts than dermal 
fibroblasts297. 
 
Caplan et al. recently reported, that MPCs are clinically active at different 
tissue sites, that MPCs are pericytes and can be isolated from any 
vascularized tissue, and that MPCs secrete large quantities of a variety of 
bioactive molecules as part of their local trophic and immunomodulatory 
activities271.  
Despite successful results in clinical trials in other areas of medicine, the 
translation of cell based tissue engineering concepts into clinical practice is 
still experimental in the area of trauma and orthopaedic surgery. The 
functional role of MPCs in the regeneration of different tissues is not fully 
understood and often discussed controversially. Kon et al. reported, that the 
regenerative effects of mesenchymal stem cells are due to their structural 
contribution to tissue repair and to their immunomodulatory and anti-
inflammatory activity, through direct cell-cell interaction or secretion of 
various factors298. 
 
In the histological analyses of our samples in previous experiments we found 
most of the transplanted cells to be necrotic. This might be due to the initial 
inflammatory phase, due to low nutrition supply and local hypoxia 
postoperative.  
Based on our results, we hypothesised that the technique for cell delivery 
needed to be modified. Therefore, we modified the experimental setup of the 
cell delivery procedure. We decided to implant the scaffold without cells, and 
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postponed the cell delivery until the inflammatory phase had passed (3-4 
weeks after scaffold implantation). Afterwards, the cell suspension was 
injected percutaneously into the prior implanted scaffold.  
We hypothesized that the technique of delayed cell injection of allogenic 
stem cells would lead to a higher cell survival rate and therefore to increased 
bone formation, which would be comparable to the application of autologous 
bone grafts (ABG).  
The aim of this study was to assess and compare the regenerative potential 
of allogenic bone marrow mesenchymal progenitor cells (allogenic MPC’s) in 
combination with a mPCL scaffold with the application of autologous bone 
grafts (ABG) in a critically sized segmental bone defect in sheep tibiae.  
 
5.2. Material and Method 
5.2.1. Scaffold fabrication and preparation  
Bioresorbable cylindrical scaffolds of medical grade poly-caprolactone 
(mPCL), (outer diameter: 16 mm, height: 30 mm, inner diameter: 8 mm) were 
used in this study. The scaffolds are produced by fused deposition modelling 
(FDM). The scaffolds have a porosity of 70% and a 0/90° lay down pattern 
(Fig. 42). This architectural layout was particularly suitable for load bearing 
tissue engineering applications since the fully interconnected network of 
scaffold fibres can withstand early physiological and mechanical stress in a 
manner similar to cancellous bone. Moreover, the architectural pattern 
allowed the retainment of coagulating blood during the early phase of 
healing, and bone ingrowth at later stages. Prior to surgery, all scaffolds were 
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surface treated for six hours with 1M NaOH and washed five times with PBS 
to render the scaffold more hydrophillic. Scaffold sterilization was achieved 
by incubation in 70% ethanol for 5 min and UV irradiation for 30 min.  
To enhance osteoinduction, mPCL scaffolds were coated with a layer of 
calcium phosphate (CaP). The coating process consisted of three steps: 
surface activation with alkaline treatment (Sodium hydroxide (NaOH)); 
treatment with simulated Body Fluid 10x (SBF10x) to deposit the CaP; and 
post-treatment with NaOH. For 1 L of solution, reagents were dissolved in 
ddH20 in the following order: 58.430g NaCl, 0.373g KCl, 3.675g CaCl2.2H2O 
and 1.016g MgCl2.6H2O. The next reagent (1.420g of Na2HPO4) was 
dissolved separately in 20 mL of ddH20 and added drop by drop into the 
main solution while maintaining the pH level at 4 by adding Hydrochloric acid 
(HCl) 32% in order to avoid precipitation of calcium cations and phosphate 
anions. The tubes were first cleaned by immersion in 70% ethanol solution 
under vacuum for 15 min for the purpose of removing entrapped air bubbles, 
then the structures were immersed into pre-heated (37 °C) NaOH 2M and a 5 
min vacuum treatment was performed at room temperature. For the rest of 
the activation steps, the scaffolds were placed at 37 °C for 30 min to 
accelerate the etching process. The scaffolds were then rinsed with ddH2O 
until the pH level dropped to approximately 7. Meanwhile, NaHCO3 was 
added to the SBF10x solution until a pH of 6 was reached. This activated 
SBF solution was filtered (0.2 µm filter) and another 5 min vacuum treatment 
at room temperature was performed to ensure that the solution fully 
penetrated the tubes. The samples were thereafter placed at 37 °C for 
another 30 min. The solution was replaced with freshly activated and filtered 
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SBF and placed again at 37 °C for 30 min. The tubes were rinsed in ddH2O 
and then immersed in pre-heated NaOH 0.5 M for 30 min at 37 °C. Finally 
the tubes were rinsed with ddH2O and the pH level was adjusted to 
approximately 7 and then dried overnight in a dessicator. 
Prior to cell loading, the scaffolds were modified by making 3 large punch 
holes on the back side of the scaffold (diameter 4mm) and 4 smaller holes on 
the front side (diameter 3mm) (Fig. 42). The holes on the back were placed 
directly over the neuro-vascular bundle in the dorsal part of the bone defect, 
to allow the ingrowth of new blood vessels (Fig. 43 C/D). The 4 holes in the 
front part were used for the delayed cell injection into the scaffold after 4 









Figure 42: The new scaffold design of the mPCL-CaP scaffolds. The 4 holes 
on the front side were used for the delayed cell injection, whereas the 3 holes 















Figure 43: The 4 holes on the front side were used for the delayed cell 
injection (A) and were placed next to the plate, where as the 3 holes on the 
back side should support the ingrowth of new blood vessels into the scaffold 
(B).  
 
5.2.2. Animal study 
Sixteen male sheep (40-50 kilogram, age 7-8 years) were used in this project 
(Table 7). An Animal Ethics Approval Certificate had been obtained. Animal 
surgery was performed at the QUT Medical Engineering Research Facility, 
The Prince Charles Hospital, Chermside. Owing to ethical reasons to lower 
the number of animals, the results of the experimental groups will additionally 
be compared to the autologous bone graft group (ABG), (positive control 
group) from the work of Dr. Johannes Reichert, who included these 
experiments in his thesis. There were 8 animals in each group and all were 
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The research plan for 
this study is 
structured as follows: 





Total 8 8 
Table 7: The research plan with details of the animal treatment groups. The 
time duration of this experiment was 12 months.  
 
5.2.3. Animal Surgery 
The anaesthetic procedures, the pre-operative treatment and the surgical 
procedures were described in chapter III. For detailed information please see 
chapter III, part 3.2.4.  
 
5.2.4. Experimental Groups 
- Group I 
All the scaffolds (mPCL-CaP) in this group were implanted into the defect site 
and the wound closed in layers. Delayed cell injection was performed four 
weeks after implantation of the scaffolds (see part 5.2.5. cell delivery). Prior 
to injection, the allogenic ovine mesenchymal progenitor cells were obtained 
from Merino sheep that were not included in this study (allogenic cells). Bone 
marrow aspirates were obtained from the iliac crest under general 
anaesthesia. Total bone marrow cells (5-15 x 106 cells/ml) were plated at a 
density of 10-20 x 106 cells/cm2 in complete medium consisting of low 
glucose DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 
µg/ml streptomycin. Cells were subsequently plated at a density of 103 
cells/cm2. Two weeks before injection, the medium was changed to an 
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osteogenic media (DMEM, 10% FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin, 10 µl/ml ß-glycerophosphate, 1 µl/ml ascorbic acid and 1 µl/ml 
dexamethasone) to induce osteogenic differentiation.  
 
- Group II 
Autologous cancellous bone graft (ABG) was harvested from the left iliac 
crest. The surgical area was shaved and desinfected with 0.5% chlorhexidine 
red in 70% ethanol. A 5 cm incision was made following the iliac crest, the 
inserting musculature was carefully detached and the cortical bone of the 
lateral os ileum was fenestrated (2 x 2 cm) using a hammer and osteotome. 
Care was taken not to fracture the ala ossis ilii. The resulting lid was carefully 
removed with a raspatory and the cancellous bone harvested utilizing a bone 
curette. Then, the lid was reinserted, the musculature was reattached with 2-
0 Vicryl sutures (Ethicon), and the wound closed in layers. The closed wound 
was sprayed with Opsite (Smith and Nephew). 
 
5.2.5. Cell delivery 
Four weeks after implantation of the scaffolds, the allogenic MPCs were 
injected percutaneously into the scaffold. For this procedure, 100 x 106 cells 
were detached from the cell culture flasks using a cell scraper so not to 
destroy the extracellular matrix. The resulting cell sheets were transferred to 
large petri dishes filled with standard media (Fig. 44 A). The cell sheets were 
dissected using a sharp scalpel blade to get a smooth solution of the cells 
(Fig. 44 B). Finally the cell solution (4 ml) was equally transferred to four 5ml 
syringes under sterile conditions (Fig. 44 C-E). Cell injection to the bone 
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defects was performed under general anaesthesia and sterile conditions in 
the operating room.  
The right hind limb was carefully shaved and thoroughly disinfected with 
0.5% chlorhexidine solution red in 70 % ethanol. The animal torso and 
surroundings were covered with sterile sheets. The DCP plate was localized 
through the skin and another plate was placed from outside to identify the 
exact position of the plate holes (Fig. 45 A). A sharp needle (14 gauge) was 
placed through the proximal hole of the scaffold. After that, three other 













Figure 44: Cells for the injection were detached using a cell scraper and put 
into large petri dishes with standard media (A). The cell sheets were 
dissected using a sharp scalpel blade (B) and the transferred to four 5ml 
syringe under sterile conditions (D/E). 
 











Figure 45: The plates were localized through the skin and another plate was 
placed from outside to identify the exact position of the plate holes (A). Four 
needles were placed into the holes of the scaffold (B), and the cell 
suspensions were injected into the defect (C/D).  
 
The cell suspension (1 ml) from every prepared syringe was injected into the 
defect and the previously implanted scaffold starting at the proximal end of 
the defect (Fig. 45 C/D; Fig. 46). The wound was sprayed with Opsite (Smith 
and Nephew), covered with pads and bandaged (Vetrap, 3M). After recovery 





























Figure 46: Schematic description of the cell injection process. The syringe 
was placed in the hole of the scaffold and half of the cell solution was 
injected into the anterior part of the scaffold (A/B). The needle was then put 
through the middle wall of the scaffold and the rest of the cell solution was 
injected into the posterior part of the scaffold (C).  
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5.2.6. Radiography analysis  
Throughout the study, x-rays were taken after 3, 6 and 12 months, to 
determine the time of bridging of the defect in the different experimental 
groups. Conventional x-ray analysis (3.2 mAs; 65kV) was performed in two 
standard planes (anterior-posterior and medial-lateral). At euthanasia, the 
gross morphology and mobility at host-graft junctions was clinically assessed 
and the findings carefully documented and photographed.  
 
5.2.7. Biomechanical evaluation  
To determine the integration of the scaffolds into the bone and the recovery 
of the biomechanical function of the affected tibias, biomechanical testing 
was performed. The detailed procedure of biomechanical testing was 
described in chapter III. For detailed information please see chapter III, part 
3.2.9. 
 
5.2.8. Computed tomography (microCT) 
After mechanical testing, both tibias were fixed in 10% neutral buffered 
formalin (NBF) and micro-CT scans of the defect and the control site were 
performed. The detailed procedure of the microCT analysis was described in 
chapter III. For detailed information please see chapter III, part 3.2.10. The 
microCT analyses of the specimens in this study are still in progress.  
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5.2.9. Histological analysis  
After biomechanical testing and microCT analyses, tibial bone specimens 
were trimmed to 8 cm length and used for histological analysis. The detailed 
procedure for histological analysis was described in chapter III. For detailed 
information please see chapter III, part 3.2.11. Due to the associated time 
frame needed for histological analyses of large bone specimens (6 – 12 
months, decalcification and embedding) the histological analyses of the 
specimens from this study are still in progress.  
 
5.2.10. Statistical analysis  
Statistical analyses for the biomechanical results and for the ct-scans 
(microCT) were carried out using a two-tailed Mann-Whitney-U-test (SPSS 
16.0, SPSS Inc.) and p-values are adjusted according to Bonferroni-Holm. 
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5.3. Results  
5.3.1. Cell Isolation and Differentiation 
Mesenchymal progenitor cells (allogenic MPC) were obtained from Merino 
sheep not included in this study via bone marrow aspiration from the iliac 
crest under general anaesthesia. Total bone marrow cells were plated at a 
density of 1-2 x 107 cells/cm2 in complete medium and cultured until they 
were confluent. 
Two weeks before implantation, the medium was changed in all groups to an 
osteogenic media to induce osteogenic differentiation. Within a few days, the 
cells showed a clear response to the osteogenic induction media by a 
pronounced morphological. The cell morphology changed from an elongated 
shape to a compact cobblestone-like appearance. The potential of bone 
marrow derived MPCs to secrete a mineralised extracellular matrix was 
analysed by alizarin red staining. After 2 weeks of induction, all the cells had 
formed extensive amounts of alizarin red-positive mineral deposits 
throughout the adherent layers (see Fig. 33/34, chapter 4). 
 
5.3.2. Animal Surgery 
In all animals, no postoperative infections or other complications were 
observed. The chosen 4.5 mm broad DCP was proven to be biomechanically 
sufficient to prevent implant failure. After 12 months, bone overgrowth was 
observed on nearly all plates. All animals were in good health and survived 
the experimental period, gaining weight in the months following surgery. In 
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particular, the animals of the allogenic group showed no clinical signs of 
implant rejection. 
 
5.3.3. Radiographic analysis  
Immediately after surgery and after 3, 6 and 12 months, conventional x-ray 
analyses in two standard planes (anterior-posterior and medial-lateral) were 
performed to assess bone formation. After surgery, the correct position of the 
scaffold, the plate and the screws were confirmed. After 3 months, bone 
formation was observed in the ABG group and the cell group starting from 
the dorsal part of the tibia where the defect is covered by the large muscle of 
the lower leg. The x-ray analysis after 6 months showed no loosening of the 
implants or movement of the scaffolds. Increasing bone formation was 
observed in the ABG group and the cell group. After 12 months, no implant 
loosening was observed in any animals. Complete bridging of the defects in 






















Figure 47: Representative x-ray images after 12 month of a defect 
reconstructed with a mPCL-CaP scaffold and allogenic MPCs (delayed 
injection) (A), and a defect reconstructed with the application of autologous 
bone grafts (ABG) (B). The images show radiographic signs of bone 
formation within the defect in the cell group as well as the ABG group.  
 
 
5.3.4. Biomechanical testing 
Biomechanical testing was performed on all specimens after 12 months. 
Biomechanical testing revealed a higher torsional stiffness (TS) and a higher 
torsional moment (TM) for the cell group compared to the scaffold only group. 
The results were not statistically significant. The ABG group showed the 
highest results for both, torsional moment and torsional stiffness, with 
significantly higher results compared to the scaffold only group and no 
significantly higher results compared to the cell group (Fig. 48/49).  
 
 











Figure 48: Biomechanical analyses (torsional moment) after 12 months. Box 
plots demonstrating median values ± 1st and 3rd quartile of torsional stiffness 
in all experimental groups. Error bars represent maximum and minimum 











Figure 49: Biomechanical analyses (torsional stiffness) after 12 months. Box 
plots demonstrating median values ± 1st and 3rd quartile of torsional stiffness 
in all experimental groups. Error bars represent maximum and minimum 
values. Asterisks indicate statistical significance (p<0.05). 
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5.3.5. Computed tomography (microCT) 
MicroCT analysis confirmed the trend of the results from the conventional x-
ray analysis regarding union rates and the amount of new bone formation.  
In the 3D reconstructions, the groups showed large amounts of new bone 
formation in the defect with a complete bridging of the defect (Fig. 50). The 
mean values of newly formed bone in the MPC group was slightly higher 







Figure 50: Representative 3D reconstructions of mircoCT scans of 3 cm 
tibial defects 12 months after surgery of the allogenic MPC group (A) and the 





















Figure 51: Results of the microCT scanning after 12 months. Box plot 
demonstrating median amounts of newly formed bone ± 1st and 3rd quartile 
within the 3 cm defects 12 months after surgery. Error bars represent 
maximum and minimum values.  
 
5.4. Discussion 
Cell-based therapies are promising strategies in regenerative medicine. The 
future of these cell-based strategies will be influenced by the cell source 
used, either allogenic or autologous cells and the donor site of the cells. 
Mason and Dunhill assessed the advantages and disadvantages of 
autologous and allogenic human cells for regenerative medicine79.  There are 
a number of issues that need to be considered comparing the efficiency and 
efficacy when comparing allogeneic and autologous cells (Table 8/9) and 
more specifically for scaffold-cell based bone engineering.  
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The treatment of large segmental bone defects requires a large number of 
cells with a high osteogenic differentiation potential. If using an autologous 
cell source, the cost and the time to get the required cells is high. Therefore 
the use of an allogeneic cell source which can be used as an “off-the shelf 
product” is preferable to use a high number of cells for the treatment of bone 
defects within an acceptable time frame, if using these concepts in traumatic 
bone defects.  The major disadvantage of using allogeneic cell sources is the 
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Advantages 
• Allogeneic 
– Producing cells for many patients is more efficient 
– Scale-up can go much further 
– Quality control (QC) can be applied to larger lots 
– Existing attachment cell technology for production scale is useful 
– Material of high consistency 
– Allows high patient throughput 
– Cells are always available 
– Can address emergency indications 
– Represents a good commercial opportunity for cell suppliers/contract   
   manufacturing organizations (CMOs) 
– No patient biopsy needed 
– Less clinical time and resources 
– Avoids needing biopsy consent from severely ill patients 
– Commercial product orientated 
 
• Autologous 
– Avoids immune rejection 
– Does not require costly immunosuppression and its associated  
   complications 
– May be easier to proceed with, for example, no requirement for cell line   
  development 
– Reduced start-up costs 
– Avoids embryonic sources 
– Simpler regulations 
– Avoids nondonor virus and prion concerns 
– May avoid cell abnormalities given less expansion for individual patient’s  
   requirement 
– Potential for ‘point-of-care’ processing 
– Could enable independent clinical technology 
– Favored for bioaesthetic applications 




















Table 8: Potential advantages of allogenic and autologous therapeutic cells 



















– Immune rejection may be a major issue 
– Risk of cell abnormalities, particularly with many cycles of in vitro replication 
– Teratoma formation risk is a concern 
– Provision and consenting of donated cells requires significant time and resources 
– Development investment is high 
 
• Autologous 
– Variability of source material 
– Difficult to generate large numbers of cells from either somatic or adult stem cells 
– Inability to deal with emergencies 
– Patient throughput will be relatively low 
– Difficult to address large numbers of patients at reasonable costs 
– Minimal economies of scale 
– Biopsy procedure is not without risk to patients 













Table 9: Potential disadvantages of allogenic and autologous therapeutic 
cells in regenerative medicine (Table taken from Mason et al.79) 
 
Despite successful results of cell based bone tissue engineering approaches 
in vitro and in vivo, the transfer of these novel concepts into routine clinical 
practise has not been realized298,299.  
In bone regeneration research, the application of tissue engineering 
constructs loaded with cells is often transplanted into a bone defect, 
immediately after the defect was created. Thus, the nutrient and oxygen 
supply in the defect area is very low and the inflammation reaction is in 
progress. Therefore, the transplantation of mesenchymal progenitor cells into 
these bone defect areas often leads to a low survival rate of the cells, 
resulting in lower bone regeneration.  
The regeneration of bone defects starts with an inflammation reaction, 
followed by the regeneration phase (soft callus phase). The duration of the 
initial inflammation phase depends on the size of the defect and ends usually 
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after about 2 - 3 weeks. During the inflammation reaction we can find 
macrophages and platelets in the defect area, whereas during the soft callus 
phase this changes to endothelial cells, mesenchymal progenitor cells and 
chondrocytes300. Hence, the normal appearance of the mesenchymal 
progenitor cells is after the inflammation reaction. Furthermore an ingrowth of 
new blood vessels into the defect area has been detected in the soft callus 
phase, which resulted in a higher nutrient and oxygen supply at this time 
point. Based on these ideas, our novel concept of delayed injection of 
mesenchymal progenitor cells into a created large bone defect after 3 – 4 
weeks was developed. The better nutrient and oxygen supply at this time 
point should lead to a higher survival rate of the transplanted cells in the 
defect area.  
So far, our results demonstrate that the concept of delayed cell injection of 
allogenic mesenchymal progenitor cells leads to bone regeneration with 
complete bridging of a critically sized segmental defect in a large animal 
model. The delayed application of allogenic cells is a safe procedure, which 
didn’t show any clinical signs of immune reaction in the animals. We still were 
not able to find a validated cell labelling method in our large preclinical animal 
model, to prove the survival rate of the transplanted cells. Therefore, we can’t 
correlate the results regarding bone regeneration in our experimental cell 
groups to the cells.  
In tissue engineering, confluent cultured cells are usually harvested by 
enzymatic digestion before seeding onto a scaffold. The use of enzymatic 
digestion in cell culture is a standard procedure and well accepted, but this 
method separates the cells from the extracellular matrix (ECM) produced 
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after osteogenic differentiation. This extracellular matrix is rich in growth 
factors and has a strong osteogenic potential. The Okano group developed 
the use of cell sheet technologies to allow the cells to recover within their 
own matrix after transplantation301. As we used the cell sheet technology in 
our study as well, we are not able to distinguish between the osteogenic 
regeneration potential of our transplanted cells vs. the transplanted cell 
sheets (ECM). Further analyses have to be made in the future to clearly 
demonstrate the effect of the transplanted cells.  
Nevertheless, the concept of delayed injection of cells for tissue engineering 
approaches seems to be a promising technique in bone regeneration and 
might lead to better results in cell-based tissue engineering approaches.  
The experimental cell groups have yet to be completely analysed, including 
histological analyses to get detailed information about the bone regeneration 












  143 
Overall Discussion and Conclusions 
In regenerative medicine, mesenchymal progenitor cells have emerged as a 
promising cell source with a great potential for cell-based therapies. It has 
been shown in several studies that these cells can be isolated from a variety 
of tissues and can differentiate into several cell lineages like bone, cartilage, 
tendon, nerve and muscle.  
To analyse potential novel bone tissue engineering strategies for a later 
clinical application in humans, rigorous in vitro testing, small animal models 
and (importantly in the final stages) the use of standardised large animal 
models are necessary. Thus, large preclinical animal models with 
comparable body weight, long bone dimensions, similar mineral composition, 
and equivalent remodelling rates as well as established and standardised 
evaluation processes are essential to make sufficient predictions about the 
potential clinical success or failure of new bone tissue engineering strategies.  
 
Over the last decade, the sheep has become a very important and useful 
preclinical model to address research problems and holds specific 
advantages compared to other large animal models (e.g. pig, dog) such as 
long bone dimensions, ease of handling, non aggressive nature, and the 
ability to keep them in large numbers at relatively low costs. 
Our group has established an ovine critical-sized segmental tibial defect 
model to address different bone tissue engineering approaches by testing 
combinations of growth factors, scaffolds and different cell types.  
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Mesenchymal progenitor cells are a common cell source used in cell-based 
bone tissue engineering approaches. It has been shown in several small 
animal models, that these cells can be used for allogenic cell transplantation.  
The supply of autologous MPCs is often limited and the preparations for their 
isolation, expansion and differentiation is time consuming and expensive. 
Therefore, the use of an allogenic cell source with comparable regenerative 
potential as a potential off-the-shelf product would open new avenues of 
therapeutic intervention for the regeneration of large bone defects. 
It has been shown, due to their special immunological characteristics, that 
MPCs could be used successfully for allogenic cell-based bone tissue 
engineering approaches257,258. 
Our results of the first study (chapter III) demonstrated the positive effect of 
allogeneic bone marrow-derived mesenchymal progenitor cells (MPC’s) on 
bone regeneration and the clinically safe and easy delivery of these cells into 
a biodegradable composite scaffold. From our previous studies, knowing that 
we had developed the most challenging large segmental bone defect model, 
we didn’t expect much bone formation after 3 months. However, we were 
specifically interested in the safe delivery of the allogenic cells. Because of 
this we chose this early time point for the first study.  We were able to detect 
a strong trend of more bone formation within the defect in both cell groups 
(allogenic and autologous MPC) compared to the scaffold only group without 
significant differences. But it was not clear if the positive effect on the bone 
formation was due to the cells or the cell delivery vehicle in form of PRP that 
we were using.  
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Therefore, we decided for the second study to include a group treated with 
scaffolds and PRP to determine the differences between the cells and the 
PRP. As we didn’t detect significant differences between the cell groups and 
the scaffold only group, we decided to include another cell source 
(osteoblasts) in our study, which is often used in bone tissue engineering. 
Furthermore, the time point was increased to 6 months in the second study to 
achieve a higher bone formation within our defect.  
Based on previous experiments in our group, it was hypothesized for the 
second study, that differentiated cells (osteoblasts) have a higher osteogenic 
potential compared to mesenchymal progenitor cells.  
Our results of the second study demonstrated no differences in the 
osteogenic potential of osteoblast compared to mesenchymal progenitor 
cells. Furthermore, we couldn’t detect significant differences between the 
scaffold-PRP group compared to the cell groups. This means, we were not 
able to prove a beneficial effect of the cells for bone regeneration in our 
experiments so far. The second study showed again a trend of more bone 
formation and higher biomechanical values for the allogenic MPC group, 
compared to the osteoblast groups and the scaffold-PRP group. 
Furthermore, the second study showed again a safe delivery of different 
allogenic cell sources for bone tissue engineering without any clinical signs of 
an immune reaction even after 6 months. 
Taking the results of study I and study II, the concept of our cell-based tissue 
engineering approach was discussed and then restructured. Both studies 
showed a trend of more bone formation in our MPC groups, compared to the 
  146 
other cell groups (osteoblasts), with respect to the x-ray analyses as well as 
the microCT analyses.   
Furthermore, the easier accessibility and higher proliferation rate of 
mesenchymal progenitor cells makes them more favourable for novel tissue 
engineering concepts. Because of this we used only MPCs for our last study. 
As we could show the safe delivery of allogenic cells for bone tissue 
engineering in our previous studies, we chose a later time point (12 months) 
for the third study in order to obtain more information about the bone 
regeneration from a functional and hence clinical point of view.  
 
One of the unique issues for any scaffold-cell based concept is the 
interactions between the host and the transplanted cells of the implanted 
construct. At the implant site, the tissue engineered construct (TEC) would be 
subjected to inflammatory mediators and signaling molecules such as 
cytokines, growth factors, and extracellular matrix enzymes and proteins 
which is different than the native environment of the cells inside the scaffold. 
Depending on the cell type in the TEC, these mediators could evoke variable 
responses such as activation, differentiation, proliferation, or migration. 
Additionally, cells near or on the scaffold surface would be subjected to an 
environment of low pH, ROS, and degradative enzymes which are specific to 
the foreign body reaction. Conclusively, TEC’s must maintain its properties 
and functions, and regenerate tissue in the midst of a highly “compromised” 
environment. In order for the TEC’s to perform optimally, specific modulation 
of the foreign body reaction would be required, however as shown by our 
results this is an impossible task in a large segmental bone defect. 
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The delayed cell injection concept in our last study was developed, based on 
the fact, that after the inflammation reaction slows down, the nutrient and 
oxygen supply and the vascularity is higher compared to after the defect 
creation, which should lead to a less compromised environment and hence  
to a higher cell survival rate and consequently better bone regeneration.  
 
This premise lead to the novel concept of delayed injection of allogeneic 
mesenchymal progenitor cells into a created large bone defect after 3 – 4 
weeks was performed in our last study (study III, chapter V).  
 
The delayed injection of allogenic mesenchymal progenitor cells leaded to 
complete bridging of critically sized bone defects with massive bone 
regeneration. The amount of bone formation was comparable to the ABG 
group when compared using x-ray analyses. X-ray analyses of the last study 
were performed after 3, 6 and 12 months. Comparing the x-ray results of the 
first study after 3 months (allogenic MPC group and scaffold only group) with 
the x-ray results of the last study (delayed cell injection of allogenic MPC) we 
could clearly detect differences with more bone formation in the group with 

















Figure 50: Representative x-ray images, after 3 months, of a defect 
reconstructed with a mPCL-TCP scaffold (A) and a mPCL-TCP scaffold 
seeded with allogenic MPCs (B) (from study I). The x-ray analyses of study I 
was compared to the x-ray analyses of the cell group with allogenic MPC 
from study III (delayed cell injection) (C) and the ABG group of study I (D). 
The images show clear radiographic signs of bone formation within the defect 
in the cell group with delayed cell injection (C) as well as the ABG group (D). 
Notably, there are clear radiographic differences between the cell group of 
study I (B) and the delayed cell injection group of study III (C) with more bone 
formation in the delayed injection group (C).  
 
Defining the mechanisms of MSC therapeutic efficacy may require elaborate 
technology associated with delivery, imaging, and targeting, which has the 
potential of identifying appropriate delivery mechanisms and the ability to 
localize hMPCs. Despite the promising results of the delayed cell injection 
concept so far, all analyses of this experiment (histological evaluation) have 
to be finished for the final interpretation of the results and the concept. For 
example, we were still not able to prove the viability of the transplanted cells 
in our defect.  Therefore, to quantify the effect of the transplanted cells, a 
reliable and validated cell labelling method for large animal models should be 
used in future experiments.  
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For further improvement of the delayed cell injection concept and to detect 
the optimal time point for cell delivery, novel treatment strategies such as the 
use of contrast-enhanced ultrasound might be used to analyse the perfusion 
and the blood supply of the bone defect302. The application of biocompatible 
contrast agents might allow the longitudinal monitoring of the development of 
the vascularity. Thus, the optimal time point for cell delivery could be 
determined to achieve a higher cell survival rate and hence the potential for 
more bone regeneration.  
 
Issues in Understanding scaffold cell mechanism of action in vivo 
Issue Differences Approaches 
Classification Define phenotypes and 
functions. 
Negative selection, flow cytometry, in 
vivo modeling. 
Efficacy Define the success of cells 
within a study. 
Reproducible effects in vitro, in vivo, and 
clinically. 
Potency How much is enough for cells 
activity? 




Does systemic versus 
localized administration make 
a difference? 
Direct comparison of localized versus 
systemic administration in the same 
model system with the same 
preparation. 
Dosage How many and how many 
times do cells need to be 
administered for 
effectiveness? 




Fat tissue, amniotic, bone 
marrow. 
Different sources may have different 





Define success of output related to 
disease of interest. 
Cell tracking Transformation potential, area 
of impact, local or distance 
orchestration through the 
lymphatics 
Issues related to tracking for host 
response and changes in cell 
phenotype. 
Table 10: Issues in Understanding scaffold cell mechanism of action in vivo 
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In summary, mesenchymal cells both precursors and differentiated exhibit 
extensive diversity in differentiation, production of trophic mediators, and 
interaction with the host environment. Clinical studies are ongoing in a variety 
of indications to determine if the unique functions of hMPCs may have a 
therapeutic impact on bone regeneration. The issues are that scaffold-cell-
based concepts are in their infancy compared to scaffold-BMP based 
technology, with ongoing studies to define the unique identification of cells in 
a scaffold, their efficacy in vivo, dosage, route of administration, and the 
duration of their potency. Applications of scaffold-cell-based concepts in large 
segmental bone defects should be embraced at both the bench and bedside 
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Abstract 
Mesenchymal progenitor cells (MPCs) represent an attractive cell population 
for bone tissue engineering. Their special immunological characteristics 
suggest that MPCs may be used in an allogenic application. The objective of 
this study was to compare the regenerative potential of autologous vs. 
allogenic MPCs in an ovine critical-sized segmental defect model. Ovine 
MPCs were isolated from bone marrow aspirates, expanded and cultured 
with osteogenic media for two weeks before implantation. Cells were seeded 
onto medical grade polycaprolactone-tricalcium phosphate scaffolds (mPCL-
TCP) in combination with platelet rich plasma. Autologous and allogenic 
transplantation was performed by using the cell-seeded scaffolds, unloaded 
scaffolds and the application of autologous bone grafts served as control 
groups (n=6). Bone healing was assessed twelve weeks after surgery by 
radiology, micro computed tomography, biomechanical testing and histology. 
No local or systemic rejection was observed after transplantation of allogenic 
cells. Radiology, biomechanical testing and histology revealed no significant 
difference in bone formation between the autologous and allogenic group. 
Both cell groups showed more bone formation than the scaffold alone, 
whereas the biomechanical data showed no significant differences between 
the cell-groups and the unloaded scaffolds. The results of the study suggest 
that scaffold based bone tissue engineering using allogenic cells offers the 
potential for an off the shelf product, which would be desired from a health 
economic point of view, because such new tissue engineering concepts 
would drastically lower the therapeutical costs. Therefore, the results of this 
study serve as an important baseline for the translation of the assessed 
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Introduction 
There are two major engineering approaches in the development of novel 
treatment concepts using scaffolds; cell-based and cell-free. The most 
suitable cell source for scaffold-based bone tissue engineering is still focus of 
much debate in the literature. There is no denying the potential of including a 
cell population within a tissue engineered construct (TEC) which is able to 
regenerate the host site; however, the best approach is yet to be determined. 
Some cell-based strategies aim to improve osteoinduction by the 
incorporation of cells with a high osteogenic differentiation potential such as 
bone marrow derived mesenchymal progenitor cells (bMPCs). Gronthos et 
al.1 have defined these cells as multipotent progenitor cells, which have the 
potential to differentiate into a variety of mesenchymal tissues such as bone, 
cartilage, tendon, ligaments, muscle, fat and dermis.2,3,4,5 They can be 
isolated from a variety of tissues6,7, 8 using different separation techniques 
and can be differentiated into the appropriate phenotype under defined 
culture conditions and the action of specific growth factors or cytokines.9 
These cells have shown their therapeutic potential in a number of in vivo 
studies for the regeneration of large bone defects and non-unions.10-14 
The supply of autologous MPCs is often limited and the preoperative 
preparations for their isolation, expansion and differentiation is time 
consuming and expensive. Hence, to acquire an adequate amount of cells for 
transplantation, the time period between cell isolation and cell transplantation 
is usually at least 4 – 6 weeks. Therefore, the major drawback of using an 
autologous cell source is two-pronged; limitations in cell numbers when 
utilising them immediately after extraction or the long time period and 
associated costs, which are necessary to expand the cells in vitro until a 
suitably high number is attained. However, the special immunological 
characteristics, which are evident with MPCs, suggest that MPCs could in 
fact be used successfully for non-autologous applications.15, 16 Allogenic cell 
transplantation is a common therapeutical option and is in routine clinical use 
in the field of oncology.17, 18 Translating the idea of allogenic cell-
transplantation from oncology to orthopaedics could offer a new opportunity 
for the availability of MPCs for regenerative medicine as an “off the shelf 
product”. Before translating these new treatment concepts into a clinical 
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application in orthopaedic and trauma surgery, rigorous evaluation of the 
respective cell populations in an adequate preclinical animal model are 
essential.19, 20  
Several animal models have been developed over the years to verify the 
practicality of different research approaches in bone regeneration. Among 
these, adult sheep offer the advantage of having a comparable body weight, 
a similar mineral composition of bone and similar metabolic and remodelling 
rates to humans and furthermore, long bone dimensions suitable for the use 
of human implants and prostheses, which is not possible in smaller 
species.21, 22 Thus, our group has recently established a challenging ovine 
segmental bone defect model using relatively old animals, which show the 
secondary osteon remodelling characteristic of human bone. We move 
towards defining an appropriate cell source for bone tissue engineering to 
circumvent the aforementioned disadvantages associated with autologous 
cell transplantation in favour of allogenic MPC sources.23  
We hypothesize that allogenic MPCs have a similar osteogenic potential 
compared to autologous MPCs and can be used in a scaffold-cell based 
bone tissue engineering concept. Therefore, the aim of the current study was 
to assess and compare the regenerative potential of autologous versus 
allogenic MPCs in combination with a mPCL-TCP scaffold in a critical sized 
segmental bone defect in a sheep tibia.  
 
Material and Methods  
Scaffold fabrication and preparation  
Bioresorbable cylindrical scaffolds of medical grade poly-caprolactone (80 
wt%) and β-tricalcium phosphate (20wt%), (mPCL–TCP), (outer diameter: 20 
mm, height: 30 mm, inner diameter: 8 mm) were produced by fused 
deposition modelling (FDM) (Osteopore International, Singapore; 
www.osteopore.com.sg). The structural parameters of the scaffolds were 
tailored by computer-aided design and included a 70% porosity with 100% 
pore interconnectivity within a pore size of 350-500 µm. Filaments of 
approximately 300 µm in diameter were deposited following a 0/90° pattern 
with a separation of approximately 1200 µm (Fig. 1 F). The scaffolds had an 
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compressive stiffness of 446.5 N/mm. This architectural layout is particularly 
suitable for load bearing tissue engineering applications since the fully 
interconnected network of scaffold fibres can withstand early physiological 
and mechanical stress in a manner similar to cancellous bone.24, 25 Moreover, 
the architectural pattern allows retention of coagulating blood clots during the 
early phase of healing, and bone in-growth at later stages. Prior to surgery, 
all scaffolds were surface treated for six hours with 1M sodium hydroxide 
(NaOH) and washed five times with phosphate-buffered saline (PBS) to 
render the scaffold more hydrophilic. Scaffold sterilization was achieved by 
incubation in 70% ethanol for 5 min followed by complete evaporation and 
UV irradiation for 30 min. 
 
Biomechanical testing of scaffold and internal fixation 
To investigate the mechanical behaviour of the implant-bone-scaffold 
construct, biomechanical testing was performed in vitro. A fixation plate (10 
hole Dynamic Compression Plate, Synthes) was affixed to a cylindrical bone 
analogue cut to a length of 240 mm (fibre-filled epoxy cylinder with a 20 mm 
outer diameter, 3 mm wall thickness, Pacific Research Laboratories, 
Washington, USA). A 3 cm defect was created in the bone analogue and a 
mPCL-TCP scaffold inserted into the defect. The ends of the construct were 
embedded in Paladur (Heraeus-Kulzer, Hanau, Germany) and the construct 
mounted in a biaxial materials testing machine (Instron 8874, MA, USA) 
using a custom-made jig.26 The test area was enclosed and heated to 37 
degrees using a patient heater. The specimen was subjected to 5 cycles with 
the last cycle used for analysis. The custom-made jig was used to simulate 
three load cases; confined axial compression (500 N), axial torsion (7 Nm) 
and medial-lateral bending (10 Nm). To determine the interfragmentary 
movements (IFMs) at the centre of the defect, optical marker rigid bodies 
(Orthopaedic Research Pins, Northen Digital Inc, Ontario, Canada) were 
affixed to the proximal and distal fragments of the bone-analogue. The 
displacements of the rigid bodies were captured via a motion capture system 
(Optotrak Certus, Northen Digital Inc, Ontario, Canada) and the IFMs 
calculated using matrix algebra. The test was then repeated with the scaffold 
removed from the construct. 
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Cell harvesting  
Ovine mesenchymal progenitor cells (MPCs) were obtained from 6-7 years 
old Merino sheep undergoing experimental surgery. Bone marrow aspirates 
were obtained from the iliac crest under general anaesthesia (Fig. 1 A). Total 
bone marrow cells (5-15 x 106 cells/ml) were plated at a density of 10-20 x 
106 cells/cm2 in complete medium consisting of low glucose DMEM 
supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cells were subsequently plated at a density of 103 cells/cm2 
(Fig. 1 B). We have demonstrated previously that MPCs express the 
respective phenotypic profile typical for different mesenchymal cell 
populations and show a multilineage differentiation potential.27 Two weeks 
before implantation, the medium was changed to an osteogenic media 
(DMEM, 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin, 10 µl/ml 
ß-glycerophosphate, 1 µl/ml ascorbic acid and 1 µl/ml dexamethasone) to 
induce osteogenic differentiation (Fig. 1 C). For 3D cultures, 35 x 106 ovine 
MPCs suspended in 500 µl of basal medium were mixed with platelet rich 
plasma (PRP) (described in subsequent section) and then seeded onto each 
mPCL-TCP scaffold (Fig. 1 G). PRP was activated with thrombin (5 U/ml), 
and the scaffolds were incubated at 37°C for at least one hour before 
implantation into the defect. 
 
Cell labelling with Bromodeoxyuridine 
Cells from one animal per experimental group were labelled with 
Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU). Cells for labelling were 
seeded at a density of 3000/cm2 in DMEM/10% FBS and allowed to attach 
overnight. The day after seeding, BrdU labelling was achieved by incubating 
ovine MPCs with the BrdU labelling reagent (Invitrogen) at a concentration of 
1:100 in DMEM/10% FBS for 6 h. BrdU is a synthetic nucleoside that is an 
analogue of thymidine. It can be incorporated into newly synthesized DNA of 
replicating cells substituting for thymidine during DNA replication thus 
labelling the respective cells. Specific antibodies may then be used to 
visualize the incorporated chemical.  
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Preparation of platelet rich plasma  
To produce platelet rich plasma (PRP), 80ml of blood was collected from the 
jugular vein of each sheep and transferred into 3.5 ml monovettes 
supplemented with sodium citrate (3.8%) at a ratio of 9 volumes blood and 1 
volume sodium citrate according to Anitua et al.28 The citrated blood was 
transferred to falcon tubes and centrifuged in a standard laboratory centrifuge 
for 20 min at 2,400 rpm (Fig. 1 D/E). Subsequently, the yellow plasma layer 
from all tubes was transferred to a fresh falcon tube and the platelets were 
pelleted in a second centrifugation step for 10 min at 3,600 rpm.29 The pellet 
was resuspended in 1.2 ml of plasma and the platelets counted in a 
Neugebauer counting chamber. After preparation, the PRP and cell 
















Fig. 1: Bone marrow aspirations (10 ml) from the iliac crest were performed under general 
anaesthesia (A). MPCs were typically elongated in shape after a culturing period of 10-14 
days in expansion media (B) (scale bar=100µm). Cell shape changed to a more compact 
cobblestone-like appearance within days after being exposed to osteogenic media (C) (scale 
bar=100µm). The insert in (C) shows alizarin red staining of MPC cultures after 14 days on 
6-well plates. Under osteogenic conditions MPCs secreted a mineralized matrix, whereas the 
control cultures didn’t reveal any staining. To prepare PRP, blood was collected from the 
jugular vein of the sheep, mixed, and transferred into falcon tubes (D). After centrifugation at 
2,400 rpm for 20 min, the plasma was removed and centrifuged a second time (E). The 
resulting pellet was resuspended in 1.2 ml of plasma, and the cells in combination with PRP 
were seeded onto the scaffolds (G). A microCT image of the cylindrical mPCL-TCP scaffold 
produced via fused deposition modelling for segmental bone defect repair is depicted in (F) 
(scale bar=5mm).  
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Experimental groups/Surgical procedure 
Twenty-four merino sheep (weight 45±2 kg, aged 6-7 years) were operated 
upon as approved by the University Animal Ethics Committee of the 
Queensland University of Technology, Brisbane, Australia (Ethics No.: 
0900000906). The experimental groups comprised two cell groups (allogenic 
and autologous cells), a scaffold only group, which served as a negative 
control, and an autologous bone graft (ABG) group, which served as a 
positive control. For surgical procedures, all animals were placed in the right 
lateral position. The right tibia was exposed by a longitudinal incision of 
approximately 12 cm length on the medial aspect of the limb (Fig. 2 A). A 
broad dynamic compression plate (DCP, 4.5 mm, 10 holes, Synthes) was 
adjusted to the morphology of the bone by bending (plate-bending press, 
Synthes) and applied to the medial tibia. The distal end of all plates were 
placed 2.5 cm proximal of the medial malleolus (Fig. 2 B). The screw holes 
were drilled and the plate was temporarily fixed with 2 screws adjacent to the 
anticipated defect (Fig. 2 C). The middle of the defect site was measured and 
marked with a raspatory. A distance of 1.5 cm each proximally and distally of 
the defect centre was measured and marked to define the osteotomy lines 
(Fig. 2 D).30  
Next, the soft tissue inserting to the bone in the designated defect area was 
detached to avoid damage to the proximate nerve and blood vessels during 
the osteotomy. Parallel osteotomies perpendicular to the bone’s longitudinal 
axis were performed with an oscillating saw (Stryker) under constant 
irrigation with saline solution to prevent heat-induced osteonecrosis whilst the 
bone segment of 3 cm length was excised (Fig. 2 E/G). Care was taken to 
completely remove the periosteum within the defect area and additionally 1 
cm proximally and distally of the osteotomy lines (Fig. 2 F, arrow). The plate 
(DCP) was fixed on the proximal bone using 4 screws. Afterwards, the 
scaffold was gently placed into the defect and the distal part of the tibia was 
fixed to the plate using 3 screws (Fig. 2 H/I). One DCP hole was used to 
place the scaffold under low pressure into the defect. The wound was closed 
in two layers with a 2-0 Monocryl (Ethicon) and a 3-0 Novafil (Syneture) 
suture for the skin. The closed wound was sprayed with Opsite (Smith and 
Nephew), covered with pads and bandaged (Vetrap, 3M).30 After recovery 
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from anaesthesia, animals were allowed unrestricted weight bearing. After 12 
weeks, the animals were euthanized by intravenous injection of 60 mg/kg 
pentobarbital sodium (Lethabarb, Virbac, Australia).  
 
Group I Group II Group III Group IV 
mPCL/TCP, 
autologous 








n=6 n=6 n=6 n=6 
Table 1: The four experimental groups of the study. 
Every group consisted of 6 animals. Group III was 
treated with a scaffold only (negative control) 



















Fig. 2: To create a 3 cm segmental defect, a skin incision was made over the medial part of 
the tibia (A), the plate was placed 2.5 cm proximal of the medial malleolus (B) and 
temporarily fixed with two screws (C). The screw holes were drilled and the defect middle 
and osteotomy lines were marked (black arrow, D). The bone segment was removed after 
creating a 3cm defect with an oscillating saw (black arrow, E; G). Care was taken to 
completely remove the periosteum (black arrow, F), which was closely located to to the 
vessels and the nerve in the dorsal part..After implanting the scaffold (*) (H), the bone 
fragments were realigned and fixed with a plate and screws (I). 
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Post-operative monitoring 
The experimental group with allogenic cell transplantation was monitored for 
six weeks after the surgical procedure to assess any evidence of an immune 
reaction to the implantation of the cells. Blood samples were taken from all 
animals on day 1, 3, 7, 14 and 21 after the operation from the allogenic group 
and from selected animals from the autologous group as a control to identify 
any possible immune reactions (white blood cell count). At the same time the 
sheep were physically examined. A final physical examination was performed 




Immediately after surgery, and after six and twelve weeks, conventional x-
rays were taken to determine the time of bridging of the defect in the different 
experimental groups. Conventional x-ray analysis (3.2 mAs; 65kV) was 
performed in two standard planes (anterior-posterior and medial-lateral).  
 
Computed tomography (CT) 
ClinicalCT 
CT analysis was performed as described previously.31 Briefly, a clinical CT 
scanner (Philips Brilliant CT 64 channels) was used to scan the experimental 
limbs. A dipotassium phosphate phantom was used to calibrate 
measurements of mineral density. 3D reconstructions from the CT data were 
generated with AMIRA® 5.2.2 (Visage Imaging GmbH, Berlin, Germany) 
(Visage Imaging) with a threshold of 300 and qualitative analysis was 
performed to assess mineralization within the defect and bridging. For 
quantitative analysis, the CT datasets of the operated tibia of each animal 
were edited by using the programs AMIRA® and Rapidform2006 (Inus 
Technology, Seoul, Korea). The amount of newly formed bone within the 3 
cm defect area was calculated using an in-house MATLAB program 
(MATLAB 7.6.0, MathWorks, Inc., Natick, MA, USA).  
 
Microcomputed tomography (microCT) 
MicroCT analyses were performed as described previously.31 Briefly, 
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samples were scanned (µCT 40, Scanco, Brüttisellen, Switzerland) with a 
voxel size of 36 µm. The x-ray tube was operated at 55kV and 145 µA. 
Samples were evaluated at a threshold of 210, a filter width of 0.8 and filter 
support of 1.0 and analysed for bone volume and bone mineral density within 
the defect using the software supplied by the manufacturer. For the bone 
volume calculations, the regions of interest were determined as external 
callus formation (external), bone formation within the scaffold (scaffold) and 
bone formation in the inner part of the scaffold (endosteal).  
 
Biomechanical testing 
Biomechanical testing was performed as described previously.31 Briefly, both 
tibiae of each sheep were explanted and the fixation plate of the 
experimental leg was carefully removed. Both ends of the tibiae were 
embedded in 80 ml of Polymethylmethacrylate (PMMA) (Paladur, Heraeus 
Kulzer, Germany) and each bone was then mounted in an Instron 8874 
biaxial testing machine. By leaving as much soft tissue as possible attached, 
bone samples were prevented from drying out. Next, for the experimental 
and the intact tibia (control) a torsional test until failure was performed in a 
biaxial universal testing machine (Instron 8874, Instron, Norwood, USA). The 
torsion test was conducted with a compressive load of 0.05kN and at an 
angular velocity of 0.5 deg/s until the fracture point was reached (right tibiae 
counter clockwise, left tibiae clockwise). In order to avoid the possibility of 
damage to the specimens in the early stages of bone healing, no 
preconditioning of the samples was performed. The torsional moment (TM) 
and torsional stiffness (TS) values were calculated from the slope of the 
torque-angular displacement curves and normalized against the values of the 
intact contralateral tibiae. 
 
Histology/Immunohistochemistry 
After biomechanical testing and microCT analyses, tibial bone specimens 
were trimmed to 6 cm length and fixed in 10% neutral buffered formalin for 1 
week. For histological analysis, the mid-defect regions were sectioned in the 
transverse and sagittal plane. The sagittal sectioned samples were used for 
paraffin embedding. To process the samples for paraffin embedding, bone 
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samples were decalcified in 15% EDTA for 6-8 weeks at 4 °C. The samples 
were then serially dehydrated in ethanol in a tissue processor (Excelsior ES, 
Thermo Scientific, Franklin, MA, USA), and embedded in paraffin. Samples 
(5 µm) were sectioned using a microtome (Leica RM 2265). The slides were 
then deparaffinised with xylene and rehydrated before staining with 
haematoxylin and eosin (Sigma Aldrich) and mounting with Eukitt mountant 
(Fluka Biochemica, Milwaukee, WI, USA). The remaining samples were used 
for undecalcified embedding in methylmethacrylate resin (Technovit 9100 
NEU, Heraeus Kulzer, Wehrheim, Germany). Longitudinal sections were 
performed with a thickness of 6 µm and stained with von Kossa/McNeal’s 
Tetrachrome to identify new bone formation and Goldner’s Trichrome to 
identify cellular details. For immunohistochemistry, paraffin sections were 
deparaffinised with xylene and rehydrated with serial concentrations of 
ethanol. Subsequently, sections were rinsed in distilled water and placed in 
0.2 M Tris-HCl buffer (pH 7.4). Endogenous peroxidase activity was blocked 
by incubating the sections in 3% H2O2 in Tris-HCl for 20 min. This was 
followed by three washes with Tris buffer (pH 7.4) for 2 min each. Sections 
were incubated with Proteinase K (DAKO, Botany, Australia) for 20 min and 
subsequently incubated with 2% bovine serum albumin (BSA) (Sigma, 
Sydney, Australia) in DAKO antibody diluent (DAKO) in a humidified chamber 
at room temperature for 60 min to block non-specific binding sites. 
Afterwards, immunohistochemical staining was performed using primary 
antibodies specific to the osteogenic markers: type I collagen (Abcam, 
Cambridge, UK) and osteocalcin (Abcam, Cambridge, UK). The sections 
were incubated with the specific antibody in humidified chambers at 4°C over 
night. Sections were then washed three times for 2 min with Tris buffer (pH 
7.4) and incubated with peroxidase labelled dextran polymer conjugated to 
goat anti-mouse and anti-rabbit immunoglobulins (DAKO EnVision+ Dual 
Link System Peroxidase, DAKO) at room temperature in humidified 
chambers for 60 min. Colour was developed using a liquid 3,3-
diaminobenzidine (DAB) based system (DAKO). Kaiser’s glycerol gelatin 
(DAKO) was used for coverslip mounting.  
For detection of BrdU labelled cells, a Zymed® streptavidin-biotin based 
system for BrdU staining (Invitrogen) was used on paraffin sections 
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according to the manufacturer’s protocol.  
 
Statistical analysis 
Statistical analyses for the biomechanical results and for the computed 
tomography scans (clinicalCT and microCT) were carried out using a two-
tailed Mann-Whitney-U-test (SPSS 17.0, SPSS Inc.) and p-values are 
adjusted according to Bonferroni-Holm. 
 
Results 
No postoperative infections or other complications were observed in any of 
the animals. All animals were in good health and survived the experimental 
period gaining weight in the months following surgery. Notably, the animals of 
the allogenic group showed no clinical signs of immune response.  
 
Biomechanical testing of scaffold construct (prior to implantation) 
Under an axial compression load of 500 N the interfragmentary movement in 
the defect was 0.27 mm giving an interfragmentary strain (IFS = IFM/gap-
size) of less than 1%. There was minimal difference in the IFM (0.21 mm) 
under compression with the scaffold removed. Subjected to torsion (7 Nm) 
the construct underwent a relative rotation of the bone fragments of 7.4 deg. 
Medial-lateral bending induced by an axial load of 100 N at an offset of 10 cm 
resulted in a shortening of the defect axially by 4.0 mm (IFS 13%) with a 
bending angle of 1.9 deg. 
 
Monitoring of immune response 
Venous blood samples were taken preoperatively and on day 1, 3, 7, 14 and 
21 after the operation from all the animals of the allogenic group and some 
animals of the autologous group (control). The blood tests showed no signs 
of graft rejection. Preoperatively, the results of the white cell count (WCC) in 
the allogenic group were slightly higher compared to the autologous group, 























Fig. 3: White cell count (WCC) of venous blood samples of 
animals from the autologous (blue colum) and allogenic (red 
colum) experimental groups. No significant differences were 
found between the groups.  
 
Radiographic analysis 
Immediately after surgery, and after 6 and 12 weeks, conventional x-ray 
analyses in two standard planes (anterior-posterior and medial-lateral) were 
performed to assess bone formation. After surgery, the correct position of the 
scaffold, the plate and the screws were confirmed (Fig. 4 A). After 6 weeks, 
some initial bone formation was observed starting from the dorsal part of the 
tibia where the defect was covered by the large muscle of the lower leg (Fig. 
4 B). The x-ray analysis after 12 weeks showed no loosening of the implants 
or movement of the scaffolds. External callus and bone formation within the 
defect was observed in all animals of the autologous and the allogenic cell 
group (Fig. 4 C/D). A complete bridging of the defect was only observed in 
one animal of the allogenic group and two animals of the autologous group. 
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Fig. 4: Representative x-ray images directly after surgery (A), after 6 weeks (B) and after 12 
weeks (C) of defects reconstructed with mPCL-TCP scaffolds seeded with autologous 
MPC’s (A-C) and with allogenic MPC’s (D). The images show clear radiographic signs of a 
beginning defect bridging in both cell groups (white arrow) on the site of the vascular bundle 
(enhanced vascularity).  
 
Computed tomography (CT) 
ClinicalCT 
Qualitative CT analysis after 12 weeks showed bone formation within the 
defect in both experimental cell groups (Fig. 5 A, B). Minor bone formation 
was seen in the mPCL-TPC scaffold group (negative control group), whereas 
a full defect bridging had occurred in all defects reconstructed with ABG 
(positive control group). No radiographic signs of inflammation (e.g. diffusely 
delimited soft tissue infiltrations, osteolysis, osteomyelitis, abscesses) were 
found. Scaffolds showed good osseointegration without any signs of 
resorption. Median values of total bone volume (BV) in the defect were higher 
in the allogenic cell group compared to the autologous cell group. 
Furthermore, both cell groups showed a higher total bone volume compared 
to the scaffold only group (Fig. 5 G). However, the differences were not 
statistically significant.  
 
MicroCT 
MicroCT analysis confirmed the trends observed with the clinical CT scans 
regarding union rates and the amount of new bone formation (Fig. 5 C, D). In 
both cell groups, the mean values of newly formed bone were higher 
compared to the scaffold only group (Fig. 5 E). Highest median values of 
newly formed bone were found for the ABG group, which were significantly 
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higher compared to the scaffold only group, but were not significantly 
different to both cell groups (Fig. 5 E). However, even in the ABG group, 
newly formed bone still only reached levels equating to 50% of that 
determined for the same anatomic level of the contralateral hind limbs 
(control) (Fig. 5 E). The amount of new bone was distributed equally 
throughout the external, scaffold and endosteal area of the defect (Fig. 5 F). 
A tendency towards a higher volume of bone formation in the allogenic cell 
group compared to the autologous cell group and the scaffold only group was 
observed (Fig. 5 F). The tissue mineral density of the regenerated bone 
showed similar results in all experimental groups of approximately 60 – 80% 

































Fig. 5: Representative 3D clinicalCT data reconstructions (AMIRA 5.2.2) of critical 
segmental bone defects showed a similar bone formation within the defect in the autologous 
cell group (A) and the allogenic cell group (B). The 3D reconstructions of the clinicalCT 
scans were performed with a threshold of 300 and combined with a 2D reconstruction using 
a lower threshold to show the soft tissue and the scaffold. Box plots demonstrating the 
median ± 1st and 3rd quartile. Error bars represent minimum and maximum values. MicroCT 
3D reconstructions showed just a small amount of bone formation within the defect in the 
autologous cell group (C) (bar=5mm) as well as the allogenic cell group (D) (bar=5mm). The 
drill holes in the host bone, through which the screws inserted to attach the DCP plate may 
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be observed in (C) and (D),(white asterisk). The microCT results depict the median amounts 
of newly formed bone within the 3 cm defects as a percentage of the contralateral control 
side (E). The amount of bone volume was distributed into external part (1), scaffold area (2) 
and the endosteal area (3). Both cell groups showed a slightly higher amount of bone 
formation within the scaffold area compared to the scaffold only group (F). The total bone 
volume (BV) after 12 weeks, as measured by clinicalCT and microCT, showed slight 
differences in the absolute values due to the different resolution of both scanning methods 
(G). The tissue mineral density of the regenerated bone in all experimental groups was 
approximately 60 – 80% of the contralateral tibia (H). 
 
Biomechanical testing 
Biomechanical testing was performed on all operated groups (right tibiae) as 
well as the non-operated left tibiae, which served as a control (Fig. 6 A). 
Biomechanical testing revealed an equal torsional stiffness (TS) for the 
autologous and the allogenic cell groups (Fig. 6 B) and slightly higher values 
for the torsional moment (TM) for the autologous group (Fig. 6 C). Both cell 
groups showed a higher torsional moment, but a comparable torsional 
stiffness compared with the scaffold only group. The samples of the ABG 
group showed the highest values for torsional moment and torsional stiffness, 
however they only reached approximately 15 to 20% of that obtained from 
the contralateral non-operated side (control). No significant differences were 









Fig. 6: For biomechanical testing, both ends of the tibia were embedded in 
Polymethylmethacrylate with the tibial axis vertically aligned (A). Box plots demonstrating 
median values ± 1st and 3rd quartile of torsional stiffness (B) and torsional moment (C) in 
relation to the contralateral tibia. Error bars represent maximum and minimum values. Both 
cell groups showed a higher torsional moment, but a comparable torsional stiffness 
compared with the scaffold only group. The samples of the ABG group showed the highest 
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3.4. Histology/Immunohistochemistry 
The macroscopical overview of the implanted scaffolds before processing for 
histology showed a good integration of the scaffold to the host bone in all 
animals (Fig. 7 A). The mPCL-TCP scaffold was still in place and had not 
resorbed. Histological examinations of decalcified samples were performed 
after 12 weeks. Representative H&E staining of both cell groups 
demonstrated a good integration of the scaffold to the host bone on the 
proximal as well as the distal side (Fig. 7 B, C, F, G). Notably, new bone 
formation was seen in many pores within the mPCL-TCP scaffolds in both 
cell groups (the scaffold itself is revealed in the histology slices as empty 
circular “holes”  and “bars” where the scaffold struts used to reside, due to 
the dissolution of the mPCL implant by xylene during processing) (Fig. 7 B-
G).   
Undecalcified sections (MMA resin) were stained with von Kossa/McNeal’s to 
identify new mineral deposition. Both cell groups showed mineral deposition 
(black stain) within the defect (Fig. 8 B, G). These results confirm our 
microCT and clinicalCT evaluation and demonstrate a limited amount of bone 
tissue growing into the whole scaffold area. Furthermore, the large overview 
pictures of the Goldner’s Trichrome staining demonstrate the presence of 
collagen fibres in the scaffold and surroundings (Fig. 8 A, F). New bone 
formation is traditionally accompanied by the expression of bone specific 
proteins within the extracellular matrix surrounding the osteoblasts, this may 
be detected using immunohistochemistry. As an early non-specific marker of 
osteoblastic differentiation during mineralisation, type I collagen showed a 
similar intensity in both cell groups (Fig. 8 D, I). Immunohistochemical 
staining for osteocalcin also demonstrated similar expression levels with a 
high expression of this late osteogenic marker localised around the scaffolds 
struts (labelled “s”) (Fig. 8 E, K). The staining to detect the BrdU labelled cells 


















Fig. 7: Macroscopical overview of the scaffold/cell constructs within the defect after 
explantation (A). Representative H&E staining of both cell groups of the proximal (B, C) 
(longitudinal sections), middle (D, E) (transverse sections) and distal (F, G) (longitudinal 
sections) parts of the defect showed a good integration of the scaffold (S) as well as a good 
bonding of the regenerated bone to the host bone (HB), (B-G; bar=0.5cm). The solvents 
used during the preparation of the histological sections resulted in the mPCL–TCP scaffold 
material being dissolved during embedding. Hence mPCL–TCP struts (S) are represented in 





























Fig. 8: Overview pictures of the undecalcified resin-embedded samples, sectioned and 
stained with von Kossa/McNeal’s (B, G; bar=0,5cm) and Goldner’s Trichrome (A, F) 
demonstrated the mineralized tissue within collagen fibres (black arrows). Decalcified 
samples were stained with H&E (C, H), collagen type I antibody (D, I) and osteocalcin 
antibody (E, K); (bar in C-E, H-K=100µm). Representative stainings of both cell groups 
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showed a good integration of the scaffold (scaffold strut labelled s) as well as a good 
bonding of the regenerated bone (NB) to the host bone (HB)(black arrows in E, H, I and K). 
The solvents used during the preparation of the histological sections resulted in the mPCL–
TCP scaffold material being dissolved during embedding. Hence mPCL–TCP struts (S) are 




The use of allogenic cells for clinical therapy is already established and in 
routine use in other areas of medicine such as oncology and a large number 
of clinical trials are currently performed in cardiology.32, 33 Our results 
demonstrated the positive effect of allogenic bone marrow-derived 
mesenchymal progenitor cells (MPC’s) on scaffold-based bone regeneration. 
In addition to their osteogenic potential, it has been shown that MPCs are 
immunologically privileged making them highly appropriate for the use in 
allogenic cell transplantation concepts, and indeed we observed no immune 
response in a preclinical animal model. The allogenic application of MPCs 
showed similar results for bone regeneration compared to the autologous cell 
group, with all the advantage of an allogenic cell source (easy to access and 
high abundance compared to autologous cells). Our results are in line with 
observations from Guo et al. who described that allogenic mesenchymal 
progenitor cells raised a minimal immunological reaction only in the early 
stages after implantation in a study in mini-pigs.34 After the transplantation, 
the sheep were monitored by clinical examination and taking blood samples. 
We did not observe any general foreign body reaction or cell rejection or any 
different cellular reactions compared to the autologous group in the 
histological assessment throughout the defect, which demonstrated, once 
more, the low immunological activity of allogenic bone marrow derived cells. 
While the limited availability and the donor site morbidity of autologous bone 
grafts is often discussed and stated as a major disadvantage of this 
technique, the use of an allogenic cell source with comparable regeneration 
potential as a potential off-the-shelf-product would open new routine 
therapeutic potentials for regeneration of large bone defects.35, 36  
Niemeyer et al. used human MPCs to assess bone regeneration in a critical 
sized defect of the sheep tibia and compared the regenerative potential with 
autologous ovine MPCs.15 The autologous MPCs demonstrated better bone 
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formation compared to the human MPCs and unloaded matrices in the 
histological and radiological evaluation. However, the bone regeneration was 
evaluated based on two dimensional imaging procedures and the study 
lacked any biomechanical testing, which would provide a greater depth of 
understanding of the characteristics and functionality of the regenerated 
bone. Field et al. evaluated the efficacy of allogenic mesenchymal progenitor 
cells for the repair of an ovine tibial segmental defect.14 They reported a 
higher osteogenic regeneration potential of the allogenic group compared to 
the scaffold only group with better biomechanical properties and more bone 
formation. But, studies by Field et al. and Niemeyer et al. used different 
fixation methods (double plate vs. intramedullary nail) and different 
experimental protocols, which renders direct comparison of these findings 
difficult. Using a medullary nail for example will result in blocking the 
medullary cavity of the tibia, which might reduce the regeneration potential in 
this area. Furthermore, different fixation methods result in different 
biomechanical impacts, such as more flexibility and a central loading (nail) 
compared to a much stiffer double plate fixation. Our biomechanical analysis 
of the DCP-plate fixation showed, under static loading conditions of up to 500 
N, a minimal displacement of the scaffold of less than 1 %. Conclusively, the 
DCP results in a stable fixation. From an ethical as well as an economical 
point of view, it would be desirable to be able to directly compare the 
potential of different tissue engineering strategies to lower the costs and the 
number of animals and to realise the translation of novel concepts from 
research to clinical practice. Therefore, the bone tissue engineering 
community should advocate the combination of radiological, biomechanical, 
histological and immunhistochemical evaluations as necessary 
methodologies for an efficient and robust analysis of bone engineering 
strategies.37   
As bone tissue engineering has become ever more prevalent over recent 
years, evaluating the different strategies with respect to potential clinical 
application in humans requires in vitro testing and small animal models and 
importantly, in the final stages, the use of standardised large animal models 
which are imperative for rigorous preclinical evaluation.38 Thus, large 
preclinical animal models with comparable body weight, long bone 
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dimensions, similar mineral composition, equivalent remodelling rates as well 
as established and standardised evaluation processes are essential to make 
sufficient predictions about the potential clinical success or failure of new 
bone tissue engineering strategies.19, 20 Over the last decade, the sheep has 
become a very important and useful model to address research problems 
and holds specific advantages compared to other large animal models (e.g. 
pig, dog) such as long bone dimensions, ease of handling, non aggression 
nature, and the ability to keep them in large numbers at relatively low costs. 
However, it is important to note that secondary bone remodelling is only seen 
in older sheep making them comparable to human bones.39 Our group has 
established an ovine critical-sized segmental tibial defect model to address 
different bone tissue engineering approaches by testing combinations of 
growth factors, scaffolds and different cell types.20, 23 Compared to studies by 
other groups, this current model is a particularly challenging model using 
older sheep which are on the one hand more relevant to human bone but on 
the other hand have a lower general health status compared to younger 
animals. Some other groups only resect the periosteum on the proximal and 
the distal bone, however, we have shown in a preliminary study, that the 
periosteum on the dorsal side between the tibia and the muscles which is 
closed to the vascular bundle (see back arrow Fig. 2F) contains a significant 
regeneration potential based on the MPCs from the cambium layer.23 To our 
knowledge, we are the first group who developed a large segmental tibial 
defect model, which also includes the removal of this part of the periosteum, 
which represents 30-40% of the whole volume of the periosteum within the 
defect. As a result of the complete removal of the periosteum and the age-
related compromised regenerative capacity, it is not surprising that we 
revealed lower biomechanical stability (TM 10-15% and TS 20-25% of 
contralateral tibia) after three month even in the ABG group compared to 
other research groups who even present significantly higher results in their 
control groups.40, 41 This demonstrates once again the importance of 
standardised large animal models with validated experimental protocols to 
compare outcomes of each different bone engineering approach. This is a 
condition sine qua non to move concepts from bench to bedside. 
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The present study showed effectively that allogenic MPCs can be safely used 
in combination with a mPCL-TCP scaffold for bone regeneration in a critical 
sized bone defect in a sheep model. None of the animals of the study 
showed a rejection of the TECs or a foreign body reaction in form of a fibrous 
encapsulation. The allogenic and the autologous cell groups showed 
comparable results with respect to biomechanical properties and new bone 
formation. The biomechanical evaluation showed a small difference between 
the cell groups and the scaffold-only group, whereas the bone volume 
analysis using clinicalCT and microCT showed larger differences between 
these groups. This is likely due to the short time frame (three months) we 
chose for our experiment to terminate. We detected more bone volume in 
both cell groups compared to the empty scaffold groups, which demonstrated 
that autologous as well as allogenic cell transplantation leads to enhanced 
bone formation in a critical sized segmental defect model. But within the 
three month time period, the bone regeneration was still in its early progress 
phase and most of the defects were not completely bridged which resulted in 
low biomechanical test results. Most other studies using a critical sized 
segmental tibial defect in a large animal had longer time frames for their 
experiments, which logically resulted in more bone formation and higher 
biomechanical stability.14 As we were specifically interested in considering 
the immune response and the safety of delivering allogenic MPCs at this 
stage of our research  we intentionally chose an early time point. 
A common practice to improve the biological competence of osteoconductive 
scaffolds is via incorporation of osteogenic stimuli such as bone 
morphogenetic proteins (BMP) and/or vascular endothelial growth factor 
(VEGF) and platelet derived growth factor (PDGF). Platelet rich plasma 
(PRP) consists of several growth factors including significant amounts of 
VEGF and PDGF and has been in clinical use for many years in the dental 
surgery field. However the benefits of PRP are still ambiguous regarding 
large bone defect regeneration in orthopaedics, whereas the positive effect of 
BMPs for bone regeneration has been shown extensively in several small 
and large animal models as well as in the clinic.42-46 Because of the similarity 
to clinically used fibrin glue, PRP converts from a liquid state into a fibrin 
hydrogel in the solid state after being activated by thrombin and therefore it is 
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used in several studies as a highly biocompatible cell-loading vehicle.47 We 
could demonstrate that the scaffold-PRP construct used in our study for large 
bone defects didn’t have significant effects regarding bone regeneration 
when compared to the scaffold only group (unpublished data). But it can be 
used as a very effective cell delivery vehicle in a scaffold design with a 
channel-like architecture with large pores and large pore interconnections 
which allow full vascularization in a 3 cm segmental bone defect. 
The evaluation of the bone volume using both clinical- and micro-CT 
scanning showed slight differences in the raw data (absolute values) due to 
the different resolutions as well as the different phantoms used for 
calibration; however the trend was the same. The experimental groups all 
showed a comparable tendency with respect to the contralateral tibia of the 
animals (Fig. 5 F). Keeping in mind the concept of translational research 
which might result in a later clinical application, the assessment of the 
correlation between clinicalCT scanning and microCT scanning becomes 
important, especially for future interpretation of clinicalCT scanning results 
from large bone defects in humans, as these may be directly related to the 
CT-results of the large animal studies. Beside the CT-scanning, which is 
essential for the 3D-reconstruction overview and analysis of the bone 
volumes, the histological evaluation plays an important role for a detailed 
evaluation on a cell-based level. Therefore, both evaluation methods (CT-
scanning and histology) are absolutely required to perform a reliable study to 
analyse different tissue engineering approaches for bone regeneration.  
The use of cell-based tissue engineering strategies is often compromised 
due to a low survival rate off the implanted cells. To prove the effect of the 
transplanted cells, different labelling methods are available to demonstrate 
the survival of the transplanted cells at the end of the experiment.48 Among 
these, BrdU-labelling is a straightforward method of cell labelling showing 
good results in small animal models. However, despite the potential shown 
using small animal models, we were not able to detect any BrdU-labelled 
cells in the large bone defect model.27 This may be due labelling the cells in 
passage 1 and using the cells of passage 3-4 for the in vivo experiments, 
because of the high amount of cells required for the experiment, hence the 
proliferation of the cells may have led to a loss of signal. Li et al. reported a 
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decreasing of the labelling signal of BrdU over time, describing that the 
percentage of BrdU-positive cells decreased from 94% in passage 0 down to 
18% in passage 2.48 Therefore, for the use in large segmental bone defects 
such as our sheep model, another labelling method would be more 
appropriate.49, 50  
Furthermore, a detailed and critical understanding of using allogenic cells for 
bone tissue engineering would be desirable, but can’t be easily achieved 
from a histological perspective when using ovine cells, because of a lack of 
specific ovine antibodies. These precise questions could be answered by 
using human cells in a xenogenic transplantation setting, but as Niemeyer et 
al. demonstrated, human MPCs led to reduced bone formation in a ovine 
defect model compared to the use of allogenic cells.15  
The present study showed promising data using an allogenic compared to 
autologous cell source for regeneration of critical sized segmental bone 
defects in a large animal model. The use of allogenic or autologous cells 
combined with a mPCL-TCP scaffold showed no differences in their bone 
regeneration potential as demonstrated by radiological, histological and 
biomechanical results. We furthermore detected no adverse immunological 
response. In the future, the successful translation of allogenic cell 
transplantation into clinical practice could provide beneficial treatment 
alternatives for challenging bone defects.  
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